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ABSTRACT
Pyruvate kinase M2 (PKM2) has been studied for decades on its role in cancer metabolism. Recently, PKM2 is highlighted again for its new function: promoting gene transcription by acting as a protein kinase. Moreover, the PKM2 levels in patient circulation have been used as a diagnostic marker for
many types of cancers. However, it remains unclear whether PKM2 in blood circulation has any physiological or pathological function. In my dissertation, I demonstrate that PKM2 released from cancer cells
facilitates tumor growth by promoting tumor angiogenesis. Our experiments show that PKM2 promotes
endothelial cell proliferation, migration and survival. Only the dimeric PKM2, not the tetrameric PKM2
possesses the activity in angiogenesis promotion. Our results further indicate that PKM2 regulates angiogenesis by integrin αvβ3 activation and integrin redistribution. I also found that PKM2 enhances drug
resistance of cancer cells expressing integrin αvβ3.
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CHAPTER 1
1.1

GENERAL BACKGROUND

Cancer Metabolism and Warburg effect
Cancer progression requires high division rate. To accommodate themselves to this change, can-

cer cells produce more metabolic intermediates to synthesize cell components such as nucleotides, cell
skeletons and other bio-macromolecules. Normal cells utilize glucose to produce three-carbonintermediate Acetyl-CoA, which is transported to mitochondria for further metabolism, TCA cycle and
oxidative phosphorylation. Major ATP producing sources are citric acid cycle (Three Carbon Acid cycle or
TCA cycle) and oxidative phosphorylation. This occurs in normal cells with sufficient oxygen supply.
However, cancer cells modify these metabolic pathways. Cancer cells elevate glucose and glutamine uptakes and produce ATP from glycolysis instead of TCA cycle and oxidative phosphorylation in mitochondria. Pyruvate produced by glycolysis is further metabolized to lactate in cytoplasm. Cancer cells produce ATP via glycolysis even when oxygen supply is sufficient (Hsu and Sabatini 2008). This pathological
phenomenon was termed as Warburg effect, named after Nobel Laureate Dr. Otto Heinrich Warburg.
Warburg effect is one of the manifest characteristics of cancer cells (Warburg 1956). Glycolysis only produces two moles of ATP per mole of glucose used, while TCA cycle produces 34 molecules of ATP. Why
do cancer cells rely on glycolysis, a so inefficient pathway to produce energy? The most popular and acceptable explanation is that: cancer cells require huge amount of metabolic intermediates such as amino
acids, nucleic acid and lipids to synthesize proteins, DNA/RNA and cell membrane for cancer rapid cell
division (Soga 2013). Glycolytic intermediates provide the sources for synthesis of these biomacromolecules. For instance, Fructose-6-phosphate can be used to synthesize nucleic acid via Pentose
Phosphate Pathway (PPP); 3-phosphoglycerate is used to synthesize amino acid such as Glycine, Cysteine and Sphingolipids. Pyruvate kinase catalyzes the last reaction in glycolysis. Therefore, if pyruvate ki-
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nase is impaired, all intermediates from glycolysis are retained for macromolecule biosynthesis. Another
explanation for Warburg effect is that glycolysis is much faster than TCA cycle in producing ATPs. But
this requires cancer cells to provide more glucose for glycolysis. The direct evidence for this is that cancer cells uptake more glucose than normal cells do. (Cairns, Harris et al. 2011). Warburg effect is caused
by many metabolism alterations. For instance, cancer cells express Pyruvate Kinase M2 instead of Pyruvate Kinase M1 by alternative splicing; c-Myc and HIF-1 were reported to induce the expression of
GLUT, a glucose transporter, on the cell membrane to facilitate glucose uptake; constitutive activation of
signaling pathways in cancer cells manipulates metabolic enzymes and regulates their enzymatic activities. In conclusion, cancer cells modify metabolic pathways to support their rapid cell division.
1.2
1.2.1

Pyruvate kinase
Pyruvate kinase transcription and expression
Glycolysis is a critical metabolic pathway to convert glucose to pyruvate, which occurs in the cy-

tosol. The last and rate-limiting step of glycolysis is catalyzed by an enzyme called pyruvate kinase to
convert PEP and ADP to pyruvate and ATP. Pyruvate kinase family contains four isoenzymes in mammals: M2, M1, L and R types. PKL is expressed in liver, while PKR in red blood cells. PKM1 is expressed in
most other cell types in adult tissues, mainly in muscle. PKM2 and PKM1 are both gene products of M
gene (Noguchi, Inoue et al. 1986). M gene contains 12 exons and 11 introns. Alternative splicing leads to
a 23 amino acid variation between PKM1 and PKM2 (between residues 378-434). Similarly, PKLR gene
encodes both PKL and PKR. PKM2 is expressed in fetal tissues, and gradually replaced by other three
isotypes during fetus maturation. It was noted for decades that PKM2 is expressed not only in embryonic cells but also in other highly proliferating cell types, such as cancer cells and immortal cell lines,
MCF10A cells for example (Christofk, Vander Heiden et al. 2008). C-Myc has been reported to induce the
conversion of PKM1 to PKM2 (David, Chen et al. 2010). PKM2 plays a crucial role in cancer proliferation
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and tumor progression. It was also reported that cancer cells can be converted to ‘normal-like’ or benign
cells and that Warburg effect is partially reversed by knockdown of PKM2 and re-expression of PKM1 in
cancer cells.
1.2.2

Pyruvate kinase structure
Since they are encoded by the same genes with one exon difference, human PKM1 and PKM2

share 96% identity in their amino acid sequences (Fig 1-1). Pyruvate kinases in different species are very
conservative at the enzymatic active site, especially Glu271 and Asp295 residues (Larsen, Laughlin et al.
1994). Therefore, the major difference is from their quaternary structure. PKM1 forms homo-tetramers
and each monomer is composed of four domains (N, A, B, C), while PKM2 has two quaternary conformations: dimers and tetramers. PKM2 tetrameric conformation possesses high binding affinity to its
substrate phosphoenolpyruvate (PEP), but dimeric PKM2 has low affinity to PEP (Christofk, Vander
Heiden et al. 2008) (Fig 1-2). The interfaces between each monomer can be defined as A-A’ (strong interaction interface) and C-C’ interface (weak interaction interface). The differences between the amino
acid sequences of PKM1 and PKM2 locate in C-C’ interface and in FBP binding site (Dombrauckas,
Santarsiero et al. 2005) (Fig 1-3).
PKM2 forms both homodimer and homotetramer conformations and the equilibrium of dimer
and tetramer is regulated by numerous allosteric cofactors. Fructose 1, 6-Bisphosphate (FBP) has been
reported to allosterically regulate PKM2 enzymatic activity (Ashizawa, McPhie et al. 1991). FBP binding
site is located at a loop region from residue 402 to 407 and binding of FBP orientates the loop to an ordered structure (Jurica, Mesecar et al. 1998). In the absence of FBP, C domains from two subunits expel
each other; upon the binding to PKM2, FBP induces a huge conformational change of C domains at the
interface and exposes charged residues to form salt bridges interaction. The binding of FBP to PKM2 results in the interaction of two dimers by C domains to form tetrameric PKM2 and increase of PKM2 en-
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zymatic activity. Besides FBP, metabolic intermediates such as amino acids L-Alanine, L-Leucine and LProline are also able to regulate PKM2 enzymatic activity. On the contrary to FBP, these factors inhibit
PEP binding to PKM2 and suppress PKM2 activity physiologically (Mazurek, Boschek et al. 1997).
Besides the physiological regulations, cancer cells regulate PKM2 dimer/tetramer in different
ways. Oncoprotein pp60v-src (Presek, Reinacher et al. 1988) and E7 of the human papilloma virus
(Mazurek, Zwerschke et al. 2001) phosphorylates PKM2 and stabilizes dimeric PKM2. However, the detailed mechanism remains unclear in their studies. Recently, a number of studies have highlighted novel
mechanisms of regulation of enzymatic activity of PKM2. PKM2 was also converted to dimer conformation by binding to certain synthesized phosphotyrosine peptides screened from a peptide library
(Christofk, Vander Heiden et al. 2008). This peptide however does not belong to any existing protein as
they discussed in their study, however, it is possible that peptide with similar sequence but not identical
sequence could bind to PKM2. Other studies have confirmed this result that PKM2 binds to certain kinases in the cells. PKM2 is phosphorylated at tyrosine 105 residue by Fibroblast Growth Factor Receptor
(FGFR) after ligand binding and phosphorylated PKM2 is induced to dimer conformation (Hitosugi, Kang
et al. 2009). All the studies indicated that PKM2 is converted to dimers by different pathways in various
types of cancers. We also reported that 399R mutated to Glutamic acid residue (E) in PKM2 mimics dimer conformation of PKM2. This mutation breaks down the salt bridge interactions between two dimers.
1.2.3

PKM2 localization
Glycolysis takes place in perinulear region in cytosol. Pyruvate produced by glycolysis is trans-

ported to mitochondria and further oxidized to CO2 by in TCA and produce more ATPs. Pyruvate kinase is
associated with glycolytic enzyme complex with other glycolytic enzymes located in cytosol; therefore,
the major PKM2 pool is cytosol.
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However, non-canonical localizations of PKM2 have been reported in recent studies. Firstly,
PKM2 translocates to nucleus. First report is that Interleukin-3 induces PKM2 nuclear localization which
regulates cell proliferation (Hoshino, Hirst et al. 2007). Our lab also revealed that dimeric PKM2 has
more nuclear localization than tetrameric PKM2 has (Gao, Wang et al. 2012). Our results indicated that
mutation of residue Lysine 399 to Glutamic acid (R399E) converts recombinant PKM2 (rPKM2) from tetramer to dimer. Dimer rPKM2 translocates to nucleus to phosphorylate STAT3. Phosphorylated STAT3
further activates MEK5 gene transcription to promote cancer cell proliferation. PKM2 nuclear translocation might be regulated by ERK2. The detailed mechanism is studied by Yang and colleagues that activated ERK2 phosphoryaltes Pyruvate kinase M2 at Serine 37 residue. PIN1 recruites importin α5 binding
to phosphorylated PKM2 and leads to PKM2 nuclear translocation (Yang and Lu 2013).
Furthermore, PKM2 is detected in body fluids from cancer patients. PKM2 has been used as a
cancer biomarker especially for colorectal cancer, gastric cancer and lung cancer diagnosis. PKM2 is detected by diagnosis kit (ELISA, Enzyme-Linked ImmunoSorbent Assay kit) in patients’ blood sera or feces
samples (Kumar, Tapuria et al. 2007). In vitro, PKM2 is released from colorectal carcinoma cell line
colo205 and SW480 to culture medium (Wu, Chen et al. 2008). However, it remains unresolved how
PKM2 is secreted and whether circulation PKM2 possesses any function. Many researchers have attempted to investigate the potential physiological or pathological functions of PKM2. Shin et al. found
that PKM2 released by cancer cells is related with 5-fluorouracil resistance in colon cancer cell lines
(Shin, Yoo et al. 2009). 5-fluorouracil resistance cell line secretes more PKM2 to the culture medium
than 5-fluorouracil non-resistance cell line does.
PKM2 in cell culture medium is possibly released from exosomes or microvesicles (Meckes,
Gunawardena et al. 2013). Exosomes and microvesicles are small vascular compartments and secreted
by many cell types such as B lymphocytes, dendritic cells and cancer cells. The physiological roles of these microvesicles are not fully understood and exosomes are speculated to function in intercellular com-
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munication or cell-matrix modification. Pyruvate kinase was reported to be present in exosomes and
microvesicles identified by Mass spectrum. PKM2 was also reported to be included in neutrophil granules, which suggested another potential pathway of PKM2 secretion in immune cells (Lominadze, Powell
et al. 2005). Our unpublished data also supported that PKM2 is secreted by neutrophils. In summary,
non-canonical localizations of PKM2 are related to its novel biological functions from the enzymatic activity.
1.2.4

PKM2 biological functions
Pyruvate kinase catalyzes the last step of glycolysis to convert PEP to pyruvate and generate one

mole of ATP. The active site locates in a pocket between the interface of A and B domains. Mg2+, K+ and
H2O molecules are required for PKM2 catalytic activity (Larsen, Benning et al. 1998). When oxygen is
supplied, glucose is metabolized through glycolysis and followed by TCA cycle in mitochondria. Glucose
is converted to pyruvate and lactate when oxygen in the cell environment is low. Cancer cells, however,
produce lactate even with sufficient oxygen supply (Mazurek, Boschek et al. 1997). Metabolic enzymes
form a protein complex termed as glycolytic enzyme complex, containing enolase, lactate dehydrogenase, pyruvate kinase and other glycolysis enzymes (Mazurek, Michel et al. 1997). Once PKM2 forms dimers, the quaternary structure changes and the binding affinity to its substrate PEP decreases. Meanwhile, dimeric PKM2 dissociates from the glycolyitc enzyme complex. Due to these changes, metabolic
intermediates in glycolysis are accumulated and utilized to synthesize amino acids, nucleotides and
phospholipids for cancer cells (Mazurek, Boschek et al. 2005). PKM2 enzymatic activity is fully manipulated in cancer cells. Firstly, switch of PKM1 to PKM2 expression is one of strategies that cancer cells use
to meet the demand for their high proliferation rate. As mentioned above, phosphorylation of PKM2 at
several residues was reported to enhance PKM2 dimer formation and promote tumorigenesis.
Anastasiou and co-workers found that reactive oxygen species (ROS) also inhibits PKM2 enzymatic activ-
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ity (Anastasiou, Poulogiannis et al. 2011). The metabolic pathways, manipulated by cancer cells, downregulate PKM2 enzymatic activity and support cancer cells to achieve Warburg effect. .
1.2.4.1

Pyruvate kinase M2 acts as a gene transcription activator

Early in 2008, Lee et al. reported that PKM2 interacts with transcription factor Oct-4 in vitro. This
PKM2 and Oct-4 interaction was analyzed by affinity purification and mass spectrometry (Lee, Kim et al.
2008). The authors speculated that the interaction plays a role in regulation of gene transcription.
Moreover, hypoxia inducible factor 1 (HIF-1) is well-known to be responsible for oncogene transcription
activation. PKM2 has also been shown to enhance HIF-1α transcription activity by binding with prolyl
hydroxylase 3 (PHD3) (Luo, Hu et al. 2011). The interaction is critical for regulation of HIF-1α transcription activity, thus it was proposed that PKM2 coordinates with HIF-1α in manipulating hypoxia response
in cancer cells. PKM2 also plays an important role in β-catenin transactivation in tumor proliferation and
malignancy. In quiescent cells, β-catenin forms complex with Axin, APC and GS3K. Β-catenin is phosphorylated by GS3K and degraded through proteasome. Once cells are activated by Wnt ligand, βcatenin dissociates from the complex and translocates to nucleus to activated tumorigenesis-relatedgene activation. PKM2 binds Y333 phosphorylated β-catenin and co-activates β-catenin downstream
gene transcription (Yang, Xia et al. 2011). Our lab also reported that PKM2 regulates MEK5 gene transcription resulting in promoting cancer cell proliferation (Gao, Wang et al. 2012). It remains unclear that
how PKM2 binds to those gene transcription factors. We proposed that PKM2 acts as a protein kinase to
phosphorylate STAT3.
1.2.4.2

PKM2 is also a protein kinase
Small molecules PEP and ADP are the substrates of PKM2. The enzymatic active sites are only

able to accommodate small molecules. However, proteins were also found as the substrates of PKM2.
The first reported substrate is Histone H1 in Morris hepatoma 7777 tumor cell. Lysine residue in Histone
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H1 is phosphorylated by utilizing PEP as phosphate donor (Ignacak and Stachurska 2003). Multifunctional protein prothymosin alpha (ProTα) is another target, which is phosphorylated by PKM2 (Diaz-Jullien,
Moreira et al. 2011). Furthermore, Dr. Zhimin Lu’s group recently reported that PKM2 phosphorylated
Histone H3 and this modification led to gene transcription and further promoted tumor growth. Our lab
data also demonstrated that PKM2 phosphorylates STAT3. Transcription factor STAT3 is phosphorylated
at Y705 by PKM2 using PEP as phosphate donor. Phosphorylated STAT3 leads to the enhanced tumor
cell proliferation. However, PKM1 lacks this protein kinase activity (Gao, Wang et al. 2012). FBP regulates PKM2 protein kinase activity by promoting tetramer formation. It is likely that PKM2 protein kinase
activity requires the conformational change because PKM2 crystal structure indicated that the enzymatic activity pocket does not provide enough space for protein substrates. Dimerization might induce conformational change to expose the enzymatic pocket to improve accessibility for protein substrates.
1.2.4.3

Extracellular PKM2

PKM2 in patients’ serum and stool samples was used as a biomarker in some inflammatory diseases as well as malignant tumors (Staib, Hoffmann et al. 2006; Aloysius, Zaitoun et al. 2009). PKM2 is a
potential fecal marker in Crohn’s disease patients (Day, Judd et al. 2012). However, it was also reported
that PKM2 level in inflammatory bowel disease (IBD) patients serum is not as high as in various cancer
patients (Meng, Zhu et al. 2012). Colorectal cancer has elevated PKM2 concentration in blood serum (57 times higher than normal individuals); two-fold increase of serum PKM2 is in adenoma compared to
health population. PKM2 secreted by cancer cells was reported to correlate with 5-fluorouracil resistance in colon cancer cell lines (Shin, Yoo et al. 2009). PKM2 in the culture medium is up-regulated in
the cancer cell line with 5-fluorouracil resistance compared to the cell line without 5-FU resistance.
However, the mechanism needs to be further studied. Similarly, another glycolytic enzyme:
phosphoglycerate kinase 1 (PGK-1) is secreted to the extracellular region (Daly, Wind et al. 2004) and
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regulates angiogenesis (Lay, Jiang et al. 2000). In our study, we found that PKM2 enhances angiogenesis
by promoting endothelial cell migration, adhesion and survival via interaction with integrin αvβ3.
1.2.5

PKM2 inhibitor and activator in cancer therapy
Since PKM2 is universally expressed in various types of cancers, researchers tried to develop small

compounds to inhibit PKM2 and induce cell apoptosis (Vander Heiden, Christofk et al. 2010). However,
cancer cell induces tetrameric PKM2 to form dimers either through binding phosphorylated peptide or
through being phosphorylated by tyrosine kinase. Decrease in enzymatic activity of pyruvate kinase favors the accumulation of metabolic intermediates in cancer cells. Therefore, PKM2 inhibitor may not be
successful due to this end. More recently studies focused on reversing the process by promote PKM2
enzymatic activity. Substitution of PKM2 by PKM1 decreases tumor sizes in mice model (Christofk,
Vander Heiden et al. 2008). PKM2 allosteric co-activator, FBP acts as an activator to promote PKM2 tetramer formation. However, it was demonstrated that FBP has no effect on the PKM2 phosphorylated
by FGFR in cancer cells (Hitosugi, Kang et al. 2009). Anastasiou and colleagues synthesized compounds
which specifically recognize PKM2 and convert dimeric PKM2 to tetrameric PKM2. These compounds
were termed as PKM2 activators (Anastasiou, Yu et al. 2012). PKM2 enzymatic activity was up-regulated
by PKM2 activators and these activators have been shown to inhibit mice tumorigenesis.
1.3

Angiogenesis
The closed blood circulation system is unique in vertebrates. Blood vessel growth is a vital physio-

logical process in embryonic development and wound healing. Blood vessels are formed by tube forming
endothelial cells, called endothelium. Endothelium is surrounded and covered by smooth muscle cell
layer. Elastic tissues and connective tissues provide support and protection to the blood vessel from
stress and physical damage (Adair and Montani 2010). Blood vessels without vessel wall or with thin wall
exist at the blood vessel frontier and those vessels are termed as capillaries or microvessels. Blood ves-
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sels are formed by two stages: vasculogenesis and angiogenesis. Vasculogenesis is the process that
blood vessels start growth from scratch. It is related to the differentiation of blood vessel precursor cells
such as angioblasts (Patan 2004). It has been well-studied that blood vessel precursor cells differentiate
into endothelial cells in response to growth factor or extracellular matrix, such as bFGF and VEGF
(Kazemi, Wenzel et al. 2002); while angiogenesis is the process that blood vessels or capillaries grow or
extend from the existing vessels. Angiogenesis involves endothelial cell proliferation, migration, survival
and tube-like structure formation.
1.3.1

Angiogenesis and its regulation
Angiogenesis is tightly regulated in the body. Loss of the control of angiogenesis is related to a

series of pathological conditions. Insufficient angiogenesis leads to Alzheimer’s disease, diabetes, chronic wound healing and etc. On the contrary, excessive angiogenesis also impairs the physiological orders
and is involved in more than 20 diseases including cancer. Cancer is one of the most important disorders
highly related to angiogenesis (Griffioen and Molema 2000). Angiogenesis balance is maintained by two
protein families: angiogenic activators and inhibitors (Mundel and Kalluri 2007) (Fig 1-4). Both
angiogenic activators and inhibitors collaborate to regulate physiological angiogenesis. Angiogenesis
activator family contains various growth factors (such as fibroblast growth factor, placental growth factor and vascular endothelial growth factor), angiopoietin 1, interleukin 8 and etc. Angiogenesis inhibitor
family consists of a group of proteins or peptides which specifically inhibit angiogenesis, such as
endostatin, interferon and thrombospondin 1 (Zetter 2008). The high proliferation rate of cancer cells
requires enhanced nutrients transportation. Initial tumor growth depends on diffused oxygen and nutrients from adjacent stroma cells; while larger tumors need blood vessels to support their further growth
(Folkman, Long et al. 1963). In clinical cases, tumor size is limited to 1-2mm in diameter without angiogenesis support (Folkman, Watson et al. 1989).
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1.3.2
1.3.2.1

Angiogenesis and cancer therapy
VEGF-dependent and VEGF-independent angiogenesis

Vascular endothelial growth factor (VEGF) is the most important angiogenesis activator, which
strongly stimulates vasculogenesis and angiogenesis. VEGF was identified in early 90s (Senger, Galli et al.
1983) and belongs to platelet derived growth factors VEGF/PDGF superfamily (Trelles, Leon et al. 2002).
VEGF has at least 5 members: VEGF-A, B, C, D, E (Shibuya 2008). VEGF is a homodimeric glycosylated
protein and contains two intermonomer disulfide bonds and three intramonomer disulfide bonds. VEGF
has 5 isotypes: VEGF121, 145, 165, 189 and 206. All those isotypes are encoded by VEGF gene and produced by alternative splicing. VEGF has two subcellular forms: secreted VEGF and membrane-bound
VEGF (Salvador, Li et al. 2008). VEGF is secreted by many types of cells, such as endothelial, fibroblasts
and activated immune cells. VEGF is also expressed and secreted by cancer cells themselves or by cancer
cell infiltrated stroma cells.
VEGF induced cellular response is mainly via VEGF receptors (VEGFRs). VEGFR is a tyrosine kinase
receptor, which contains an extracellular domain, a transmembrane domain and a cytoplasmic tail.
VEGFR family has 3 members, VEGFR-1 (flt-1), VEGFR-2 (flk-1 or KDR) and VEGFR-3 (flt-4). VEGFR-1 mainly is the receptor for VEGF-A and VEGF-B; VEGFR-2 is receptor for VEGF-A, C, D and E; VEGFR-3 is for
VEGF-C and D. VEGFR-1 and VEGFR-2 is responsible for vasculogenesis and angiogenesis signaling transduction; while VEGFR-3 is conducting the signaling pathways related to lymph-angiogenesis (Hicklin and
Ellis 2005). Binding VEGF to their receptors dimerizes VEGFR VEGFR c-terminal undergoes
autophosphorylation. Phosphorylation of tyrosine residues leads to the activation of various signal
pathways such as Ras, PLC, p38 and PI3K. Those downstream kinases regulate cell functions related to
cell proliferation, survival and migration.
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It is necessary to understand angiogenesis mechanism better in order to treat or diagnose cancer
and other diseases with deregulated angiogenesis. Besides VEGF-dependent angiogenesis, VEGFRindependent angiogenesis is equally crucial. Other growth factors than vascular endothelial growth factor also regulate angiogenesis. It was reported that platelet-derived growth factor (PDGF) regulates angiogenesis through PDGF receptor by promoting endothelial cell proliferation and tube formation
(Battegay, Rupp et al. 1994). EGF was also reported to modulate angiogenesis by increasing endothelial
cell migration (Mehta and Besner 2007). Moreover, Angiopoietin regulates angiogenesis through Tie
receptors. Angiopoietin family has four members: Ang-1, Ang-2, Ang-3 and Ang-4. Among all the members, Ang-1, Ang-3 and Ang-4 bind Tie2 receptor, while Ang-2 binds Tie1 receptor. After binding to receptors, Ang dimerizes Tie receptor and then autophosphorylates the intracellular domain of the receptor. Receptor activation phosphorylates their downstream signaling cascades, mainly through PI3K/Akt
signaling pathway and STAT to regulate gene transduction of cell survival and cell proliferation
(Mochizuki, Nakamura et al. 2002).
1.3.2.2

Angiogenesis inhibitor

Increase in VEGF secretion and/or VEGF receptor expression induces angiogenesis in cancer. Tumor
vessels are different from vessels in normal tissues (Shojaei 2012). -Tumor blood vessels are not as organized as the normal vessels due to the defective vascular structure in cancer. Repressing angiogenesis
is one of the important ways for cancer therapy. Different strategies have been explored for angiogenesis related cancer therapy.
1. Targeting VEGF. VEGF antibody was developed to specifically target VEGF and decreased the serum level of VEGF. Bevacizumab (Avastin) is the most successful case and was approved for clinical use
in 2004 by U.S. Food and Drug Administration (FDA). Bevacizumab is also the first FDA approved biological drug for tumor angiogenesis. Furthermore, Bevacizumab has been used for conjugated with radio-
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therapy chemicals or cocktailed with chemotherapy drugs to bring more benefits to cancer patients
(Bhuvaneswari, Yuen et al. 2007; Jayson 2011).
2. VEGFR inhibitors. Two distinct inhibitors for VEGFR were exploited to inhibit angiogenesis. The
first type of VEGFR inhibitor is anti-VEGFR antibody, which were developed to inhibit VEGF ligand binding to its receptor. DC101, an anti-VEGFR2 monoclonal antibody potentially inhibits prostate tumor
growth and metastasis (Sweeney, Karashima et al. 2002). DC101 has also been shown to be used to enhance paclitaxel or radiology treatment (Inoue, Slaton et al. 2000; Verhoeff, Stalpers et al. 2009). Antibodies anti-VEGFR extracellular domain also induce cancer cell apoptosis (Sweeney, Karashima et al.
2002). The second type inhibitor is small compounds. Virtual Screening and computational modeling
were used to design and screen the compounds for inhibiting VEGFR dimerization (Elgamacy, Shalaby et
al. 2011).
3. VEGFR signaling pathway inhibitors. VEGF receptor is one of the receptor tyrosine kinase family
members. Therefore, the most common strategy to inhibit angiogenesis is to repress VEGFR signal
transduction. Plentiful tyrosine kinase inhibitors (TKIs) are developed and utilized to treat different tumor types. Pazopanib is an FDA-approved medication for treatment of advanced renal cell carcinoma
(Sloan and Scheinfeld 2008). Pazopanib is a synthetic chemical compound which specifically targets and
inhibits tyrosine kinase sites of VEGFR and platelet-derived growth factor receptor (PDGFR).
Generally, VEGF-VEGF receptor induced angiogenesis has been well studied. However, inhibition of
angiogenesis through VEGF-VEGFR pathway is not sufficient to treat cancer. Some important drawbacks
cannot be ignored. Firstly, VEGF-VEGFR is not the only signaling pathway to regulate angiogenesis
(Shibuya 2008). Secondly, inhibition of VEGFR pathway causes disease-related side-effects such as dysfunction or failure of major organs: heart, liver and renal system (Chen and Cleck 2009); repression on
the wound healing; and hypertension (Bhargava 2009). The last but not the least, most VEGFR inhibitors
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themselves cannot inhibit tumor growth and it is required to combine VEGF with other anti-cancer drugs
for better clinical outcomes.
1.4

Integrins
Eukaryotic cells are constantly communicating with their microenvironment through both cell-

matrix adhesion and cell-cell adhesion. Numerous molecules are involved in cell adhesion. Integrin family is one of the most important proteins involved in cell adhesion and migration. Specific integrin expression pattern is correlated to endothelial cell proliferation, spreading, migration and invasion. Integrins
activate intracellular signaling pathways after interacting with extracellular ligands such as extracellular
matrix proteins (ECM).
1.4.1

Cell adhesion
Cells interact with surrounding cells to form tissue layers or to transfer nutrient and cellular sig-

nals. Four major cell-cell adhesion complexes exist in epithelial and endothelial cells: tight junction,
adherens junction, gap junction and desmosome.
Tight junction functions at anchoring adjacent cell together tightly and prohibiting fluids to diffuse through the gaps between epithelial/endothelial cells. Tight junction also maintains the polarity of
epithelia or endothelia layer. Tight junction is composed of a series of transmembrane proteins such as
claudin, occludin and tetraspanins. The interaction between these proteins from adjacent cells provides
the molecular bases for tight junction (Gonzalez-Mariscal, Betanzos et al. 2003).
Adherens junction is mainly for holding epithelial and endothelial cells together and supporting
the cell architecture. Cadherin and catenin family proteins are responsible for adherens junction formation. E-cadherin and N- cadherin are calcium binding transmembrane proteins and interact with cadherin molecules from adjacent cells. After two cadherin molecules interact, α- and β-catenins are activated to bind to actin filaments to sustain the cells architecture (Niessen 2007).
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Gap junction is involved in cytoplasm component exchange. Gap junction is a hexamer formed
by connexin family proteins. Gap junction close and open conformation switch is regulated by either
calcium (Lurtz and Louis 2007)or post-translational regulation such as phosphorylation (Warn-Cramer
and Lau 2004).
The last but not the least type of cell-cell junction is desmosome. Desmosome exists mainly in
epithelial cells other than endothelial cells, but desmosome protein desmoplakin is expressed in cultured endothelial cells (Valiron, Chevrier et al. 1996). Desmoplakin interacts with cadherin or vimentin
to regulate endothelial cell intercellular junction. In epithelial cells, the function of desmosome is to sustain the cells against shearing force. Desmosome complex forms plaque structure on the membrane
across cells and the complex is constructed by a series of cadherin family proteins such as Desmoplakin,
Desmocollin and Plakoglobin. The complex attaches to intermediate filaments inside of the cells, such as
keratin (Bornslaeger, Corcoran et al. 1996).
Both epithelial cells and endothelial cells rely on the four types of cell junctions to interact or
communicate with adjacent counterpart cell, to maintain and protect epithelia and endothelia tissues
and to prohibit random diffuse. Besides the cell-cell interactions, epithelial and endothelial cells require
the interaction with the extracellular matrix to survive and to perform various physiological functions.
1.4.1.1

Cell-matrix interaction
Basement membranes are thin layers under epithelia or surrounding endothelia. Basement

membranes have fiber structure and are composed of various extracellular matrix proteins such as collagen, laminin and fibronectin. Basement membranes provide supports to epithelial and endothelial cell
layers. Integrin and hemidesmosome are the two major receptors for cell-matrix interaction.
Hemidesmosome shares the similar structure and components as the desmosome complex however,
hemidesmosome functions differently with desmosome. Desmosome functions to connect epithelial
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cells together while hemidesmosome is to attach epithelial cells to basement membranes or extracellular matrix. Hemidesmosome attaches to intermediate filament in the cells to regulate cellular functions
(Zhang and Labouesse 2010). The other protein family for epithelial and endothelial attachment to
basement membranes is the integrin. Integrins are heterodimeric transmembrane proteins, which regulate various types of cell functions such as cell adhesion, migration and proliferation through either inside-out or outside-in activation. Integrins are also involved in many pathological conditions such as angiogenesis. Since integrins are important molecules in my dissertation, I will discuss it in details.
1.4.2

Integrin structure
Integrins are membrane proteins with single alpha-helices transmembrane domain. Integrins

are heterodimers formed by α subunits and β subunits. More than 20 different heterodimeric integrins
are formed by 18 α subunits and 8 β subunits in mammals (Margadant, Monsuur et al. 2011). Extracellular domains of integrins are glycosylated and form functional domains to interact with ligands or other
proteins. Integrin family can be divided into two subgroups by their structures difference: with or without an extra von Willebrand factor type A domain (αA or αI domain). Integrins can also be divided into
four groups based on their ligands or binding partners: collagen-binding integrins; laminin-binding
integrins; RGD dependent integrins and Leukocyte integrins. Each integrin subunit contains a bunch of
specific domains. Integrin heterodimers are illustrated as a headpiece and ‘leg’ part (Springer 2002). Integrin ligand binding site is located in the headpiece.
1.4.2.1

Integrin conformation change
Integrins have two conformational structures: close and open conformation. In the close or

‘bent’ conformation, the headpiece of integrin heterodimers bends over to the ‘leg’ part. The ligand
binding site is facing to the cell membrane, which results in the low binding affinity of integrin heterodimers to their ligands (Humphries, McEwan et al. 2003). Extensive studies have been carried out to un-
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derstand the relationship between integrin conformation change and its function. Upon the binding of
integrin to its ligand, integrin undergoes dramatic conformational change in its extracellular domain.
This change makes integrins skewed towards clustering with adjacent integrin. The conformational
change in the extracellular domain of integrins also induces a structure change in integrin
transmembrane domain and intracellular domain (ICD), which separates integrin c-terminals of α and β
subunits. C-terminal separation of integrin α and β subunits leads to the assembly of focal adhesion
complex and activation of FAK and its further downstream signaling pathways (Askari, Buckley et al.
2009).
1.4.2.2

Integrin ligand
RGD-containing ligand is the largest protein family which binds integrins including αvβ3, α5β1,

αIIbβ3, and etc. This integrin subfamily recognizes a consensus binding sequence: three amino acids
RGD (R: Arginine, G: Glycine, D: Aspartic acid). Based on the analysis of the crystal structure, the binding
site for RGD-containing ligand locates at the interface of integrin α and β subunits (Xiong, Stehle et al.
2002). Lysine residue interacts with β-propeller domain in α subunit while aspartic acid binds to von
Willebrand factor A (vWF) domain in β subunit. Many extracellular matrix (ECM) components contain
RGD sequence including fibronectin and vitronectin. Certain ECM proteins do not have accessible RGD
sequences on the protein surface, but expose their cryptic RGD sequence to interact with RGD-specific
integrins after being denatured by temperature or cleavage by the matrix metalloproteinase
(Yamamoto, Yamato et al. 1995). For instance, Integrin α5β1 and αvβ3 are the typical RGD dependent
integrins. But collagen I does not bind to either integrin α5β1 or αvβ3 due to the absence of any solvent
accessible RGD sequence. However, after being partially denatured by increasing temperature or degraded by extracellular proteases (MMP-2 or MMP-9), collagen I unfolds and exposes its RGD sequence
to interact with both α5β1 and αvβ3 integrins (Taubenberger, Woodruff et al. 2010). This mechanism is
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related to cancer angiogenesis and metastasis (Eliceiri and Cheresh 1999). GRGDSP is a sequence from
fibronectin and used as an angiogenesis inhibitor as to compete with RGD-containing native ligands.
In addition, some non-ECM proteins containing RGD sequence were also reported to interact
with integrins. The human immunodeficiency virus (HIV-1) protein, transactivating factor (TAT) activates
FAK through integrin αvβ3 and promote angiogenesis (Urbinati, Mitola et al. 2005). TAT interaction with
integrin is inhibited by both RGD peptide competitive inhibitor and blocking antibody LM609, which indicates that the interaction is via RGD sequence in TAT protein. Another example is CD40 ligand or
CD40L. Soluble CD40 ligand was reported to bind to integrin α5β1 and induce signaling transduction by
activating MAPK and its downstream ERK1/2 in endothelial cells (Leveille, Bouillon et al. 2007). This interaction is through RGD sequence on the CD40L (Andre, Prasad et al. 2002).
Besides RGD sequence, KGD (Lysine-Glycine-Aspartic acid) is also recognized by integrins in certain cases. Integrin β3 is the major type of integrin for interacting with KGD, especially αIIbβ3. KGD plays
important role in disintegrin binding to integrin. Disintegrin is a family of proteins in viper venom.
Disintegrin inhibits platelet aggregation and causes hemorrhage through the interaction of KGD sequence with αIIbβ3 integrin (Lu, Lu et al. 2005).
A synergetic site might be important for integrin binding to RGD. RGD peptides are used for cancer therapy to target cancer angiogenesis. RGD peptide such as cilengitide a cyclic RGD pentapeptide has
been applied as an angiogenesis inhibitor. However, the affinity of RGD peptide is 1000 fold lower than
their natural ligand. One of the most important reason is that integrin ligand contains not only RGD sequence but also synergetic site. Pro–His–Ser–Arg–Asn (PHSRN) is a synergetic binding site in fibronectin
for integrin α5β1 and this synergy site facilitates HUVEC cell attachment and spreading in vitro
(Ochsenhirt, Kokkoli et al. 2006).
Other than RGD sequence, LDV is another major binding sequence for integrins. LDV mainly
binds to β2, β1 and β7 integrins (Humphries, Byron et al. 2006). LDV has other derivative sequences
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such as IDA or REDV (Mould and Humphries 1991). As mentioned earlier, a subgroup of integrins contain
α domain, α1β1, α2β1, α10β1 and α11β1. Those integrin binds to specific residues other than RGD and
LDV. GFOGER is the critical sequence on collagen to be recognized by αA-containing integrins. The glutamic acid residue in the recognition sequence is crucial to interact with the metal in the integrins
(Emsley, Knight et al. 2000).
1.4.2.3

Metal binding vs. Ligand binding
Magnesium and calcium metal ions are crucial to maintain integrin proper structure and ligand

binding activity. As described above, integrin can be divided into two subfamilies based on their structure similarity: αA integrins and non-αA integrins. αA integrins contain a von Willebrand factor type A
domain. αA is responsible for mediating integrins binding to their ligands and α domain contains an ion
binding site, named metal-ion-dependent adhesion site (MIDAS) (Michishita, Videm et al. 1993). MIDAS
coordinates one divalent cation, usually Magnesium and MIDAS domain accepts one interaction from an
acidic amino acid from integrin ligand (Lee, Rieu et al. 1995). MIDAS has even higher binding affinity for
Manganese (Li, Rieu et al. 1998). However, Manganese is not a physiological ion. Although structure different exists between αA-containing and α-lacking Integrins, integrins without αA domain shows similar
strategy for ligand binding. Integrin αvβ3 is an important αA-lacking integrin. αvβ3 contains an αA-like
domain or βA/βI domain (Fig 1-5)(Luo and Springer 2006). Aspartic acid in RGD tripeptide attaches to
the ion located at MIDAS site, while Arginine (R) residue interacts with a couple of negative charged residues at β propeller on αsubunit. MIDAS on integrin β subunit and β propeller domain from α subunit
forms the basic ligand binding pocket. Besides MIDAS at αA domain or A-like domain on integrin β subunit, other two metal binding sites locates adjacent to MIDAS: the ADMIDAS (adjacent to MIDAS) and
LIMBS (ligand-associated metal binding site). Those sites favor calcium ion and provide additional regulation on ligand binding (Valdramidou, Humphries et al. 2008). Tumor endothelial marker 8 (TEM8) is a
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transmembrane protein, which highly expresses in tumor endothelium.TEM8 also contains an MIDAS
site and this MIDAS was reported to be involved in binding to the anthrax toxin antigen (Ramey, Villareal
et al. 2010). The interaction of TEM8 and its ligand is much similar to the binding of integrin and RGD
peptide. It was reported that PKM2 also could bind to TEM8 in vitro (Duan, Hu et al. 2007). This interaction indicates the possibility that PKM2 also binds to MIDAS on the integrin.
Integrin α subunit also contains 5 Calcium binding sites. 4 of them are in beta propeller loop region and the other one is at ‘genu’ region, which acts as a ‘knee’ for integrin conformational change
(Arnaout, Goodman et al. 2007). Metal ions are required for integrin structure and integrin ligand binding. EDTA completely inhibits integrin function and detaches cells.
1.4.3

Integrin functions
Integrins transmit outside-in or inside-out signals astransmembrane proteins. The major physio-

logical function of integrins is involved in cell adhesion and migration. Integrins are the main receptors
for extracellular matrix proteins such as collagen, fibronectin and laminin. Binding of integrins with ECM
proteins anchors the cells to basement membrane. After binding to ECM components, integrin recruits
paxillin and talin to form focal adhesion complex in cytosol. Focal adhesion complex attaches to cytoskeleton: actin filament (Brakebusch and Fassler 2003). Ligand-bound integrins also activated Focal Adhesion Kinase (FAK). FAK phosphorylated and activated various downstream pathways, for example Src
and PI3K/Akt pathways, which were well-studied to regulate cell proliferation, survival and migration
(Yano, Mazaki et al. 2004; Caron-Lormier and Berry 2005).
1.4.3.1

Integrin activation
Integrins are activated via two different ways: inside-out and outside-in pathways. The inside-

out activation of integrin has been well studied. Without stimuli, integrins rest in the inactive (bent
form) and have low affinity to its ligand. Cytoplasmic tails of α and β integrin are close together and in-
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teract with each other. When the cells receive stimulation from growth factors such as VEGF or EGF,
cells initiate signal transduction. One important regulator, talin is activated by phosphorylation. The detailed mechanism of talin activation is not fully understood. Activated talin exposes its FERM domain
(Pearson, Reczek et al. 2000) and binds to integrin intracellular domain. Binding of talin to integrin cterminus induces a conformational change of cytoplasm domain and transmembrane domain of
integrins. This change leads to a further conformational change of integrin extracellular domain: integrin
ECD switch from bent form (low affinity to ligand) to extended form (high affinity to ligand). Inside-out
activated integrin facilitates cell to attach to ECM (Qin, Vinogradova et al. 2004). The conformational
change of bent and extended form is visualized by electron microscopy (Weisel, Nagaswami et al. 1992).
Outside-in activation is more straightforward. Ligands bind to integrin ECDs and cause integrins
conformational change, which leads to integrin activation. Ligand binding also induces integirn clustering
to enlarge integrin activation. Activated integrins (extended or open conformation) cluster together on
the cytoplasm membrane to form a patch-like structure. Integrin clustering provides stronger binding
capability of integrins to ECM by holding a bunch of integrins at one single spot. Those structures then
form focal adhesion (Kinashi 2005). Upon focal adhesion complex assembled, integrins regulate cell attachment and migration through this outside-in manner.
1.4.3.2

Integrin endocytosis and recycling activation

In order to attach to or migrate on ECM proteins or basement membrane, cells require assembly
and disassembly of focal adhesion complex rapidly. Therefore, integrins need to be transported from the
rear region to the migrative leading edge. This is achieved by integrin endocytosis and recycling. Integrin
endocytosis is initiated by binding to integrin ligand or synthetic peptide such as RGD peptide Cilengitide
(Reynolds, Hart et al. 2009). Growth factors could also induce integrin endocytosis and recycling. After
initiation, endocytotic integrins are delivered to endosomes and transported back to cytoplasm mem-
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brane for reuse (Bretscher 1996). Integrins retrieved from the rear of the moving cells is mediated by
Rab4 and Rab5; while integrin delivered to the frontier of the cell is mediated by Rab11 and Arf6
(Margadant, Monsuur et al. 2011).
1.4.3.3

Integrin regulates cell adhesion
Cell adhesion regulates various physiological events, such as embryonic development, cancer

metastasis, inflammation, homeostasis and wound healing (Edelman and Crossin 1991). Endothelial cells
and epithelial cells have to line on the extracellular matrix to form tissues. Integrin family members
show specificity to different ECM substrates. For example, integrin α5β1 has highest affinity to
fibronectin, αvβ3 has higher affinity to vitronectin and α1β1 and α2β1 mostly bind to collagens and
laminins. Upon the binding of integrins to their ECM, integrins convert from bent form to extended form
and cluster together. Integrin activation and clustering recruit a group of focal adhesion proteins such as
talin, paxillin and vinculin. Focal adhesion complex attaches to actin filaments to regulate cell attachment to ECM. Other than integrins, desmosome and other proteoglycans also provide cell-matrix adhesion. However, integrins are the most dominant and universal adhesion molecules. Cancer cells alter
integrin patterns to dysfunction cell adhesion and deregulate cell migration.
1.4.3.4

Integrin dictates cell migration and invasion
Migration is described as directional cell movement. This movement is generally divided into

several steps including (1) Lamellipodium extension at the leading edge; (2) detachment on the rear side
of moving cells; (3) make new contact at the front side; (4) cell contract to move forward. Integrins play
vital roles at both front and rear sides of moving cells. Integrin endocytosis and recycling is responsible
for redistribution of integrins. The intracellular domain of integrins contains a motif for clathrindependent endocytosis (Gawaz, Besta et al. 2001). After endocytosis, Rab GTPase family proteins such
as Rab11 and Rab4 mediates integrin trafficking. Integrin recycling is involved in two pathways: short-
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loop and long loop. Rab4 GTPase is involved in short-loop recycling and integrins enter early endosomes
and are rapidly transported to the plasma membrane. On the other hand, long-loop recycling is mediated by Rab11 small GTPase. Integrins are translocated to perinuclear recycling compartment (PNRC) first
and then transported back to plasma membrane (Caswell and Norman 2006).
It was also reported that integrin α4β1 regulates SPARC activity, which regulates extracellular
matrix remodeling (Gerson, Shearstone et al. 2012). MMP-2 and MMP-9 were commonly studied to
regulate cancer cell invasion by degrading ECM components. Both MMP-2 and MMP-9 were reported to
be modulated by integrin directly and indirectly (Chen, Wei et al. 2009; Morozevich, Kozlova et al. 2009).
Cancer cells frequently mutate integrin genes to facilitate cell migration.
1.4.3.5

Integrin signaling mediates cell proliferation and cell survival
In early 1990’s, Integrins were proved to be responsible for cell proliferation upon cell attach-

ment on the fibronectin-coated surface. The proliferation is associated to Mitogen-activated protein
kinase activation, ERK1 and ERK2 (Zhu and Assoian 1995). Various types of integrin expressions were
found to be associated with endothelial and cancer cell proliferation. The main mechanism is that Iigand
binding to integrins activates FAK and its downstream signaling pathway. Meanwhile, it was also reported that integrin α5β1 regulates epithelial cell proliferation through interaction with epidermal growth
factor receptor (Kuwada and Li 2000). This suggested an alternative pathway for integrins to regulate
cell proliferation. Another membrane-bound receptor, Urokinase-type plasminogen activator receptor
(uPAR) was reported to interact with intergrins to regulate cell proliferation (Ossowski and AguirreGhiso 2000).
In certain extracellular environment, integrins were shown to be able to promote cell survival or
induce cell apoptosis (Desgrosellier and Cheresh 2010) (Fig 1-6). Integrin activation caused the phosphorylation and activation of Focal Adhesion Kinase (FAK). FAK phosphorylation activates many cell sur-
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vival signaling pathways, such as PI3K-Akt, NF-κB and Bcl-2. Among them, Bcl-2 is the member of antiapoptotic Bcl family. Bcl-2 binds Bax or Bak in resting cells and BH-3 only proteins compete with Bcl-2 to
release Bax or Bak. Bax or Bak forms pores on the mitochondria membrane leading to the release of Cytochrome c to cytosol. It was reported that activation of integrin α5β1 and αvβ3 increased Bcl-2 on both
mRNA and protein level (Matter and Ruoslahti 2001). This increase is FAK-activation and Src-activation
dependent. Immobilized vitronectin (VN, an ECM component and secreted by cancer cells) conferred
resistance of cancer cells to drug treatments (Uhm, Dooley et al. 1999). This is due to the increase of
Bcl-2 and Bcl-XL induced by α5β1 and αvβ3 activation. Recently, PKM2 was also suggested to be related
to drug resistance (5-FU resistance) (Shin, Yoo et al. 2009). This might be explained by the fact that
PKM2 binds and activated integrins, and increased anti-apoptotic protein expression. Similar result was
reported that integrins prevents breast cancer cells from apoptosis by activating PI3K-Akt signaling
pathway (Aoudjit and Vuori 2001). It was also reported that integrin activates Scr/Akt pathway and mediates anti-cancer drug resistance in cancer cells (Kanda, Kawahara et al. 2013). Scatena and colleagues
had shown that NF-κB is responsible for integrin suppression of endothelial cell apoptosis induced by
integrin αvβ3 during angiogenesis (Scatena, Almeida et al. 1998).
Pyruvate Kinase M2 has been studied for decades on its role in cancer metabolism. Recently,
PKM2 is highlighted again for its new function: promotion gene transcription by acting as a protein kinase. Moreover, it is well known that PKM2 is released into the circulation of cancer patients. The PKM2
levels in patient circulation have been exploited as a diagnostic marker for many types of cancers. However, it is not known how the glycolytic enzyme is released into circulation, and whether the circulative
PKM2 has any physiological function(s) in tumor progression. In my dissertation, I demonstrated that
PKM2 in the blood circulation facilitates tumor growth by promoting tumor angiogenesis. My data have
shown that PKM2 promotes tumor angiogenesis by increasing endothelial cell proliferation, migration
and survival. These angiogenic responses are induced by the interaction of PKM2 with αvβ3 integrin.

25
PKM2 increased FAK phosphorylation and activated focal adhesion complex. I also found that PKM2 redistributed integrin to the leading edge of endothelial cells, which might be involved in endothelial cell
migration. In my dissertation, I also discussed PKM2 dimer/tetramer issue. Dimer PKM2, other than
tetrameric PKM2 possesses the activity in promoting tumor angiogenesis. I screened several PKM2
monoclonal antibodies, one of which has been proved to prevent PKM2 from binding to integrin and
repress PKM2-induced angiogenesis response. Our data suggested that PKM2 in blood circulation could
be used as a therapeutic target for cancer treatment. In addition, I found that PKM2 enhances drug resistance of cancer cells with high integrin αvβ3 expression. I also discussed a cooperative study on investigating a compound, RX-5902 which specifically interrupts the interaction of phosphorylated p68 RNA
helicase and β-catenin.
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1.5

Figures

Figure 1-1 PKM1 and PKM2 sequence alignment
‘+’ indicates similar charged residues. Blank indicated completely different residues. Human PKM1 and
PKM2 have 10 residues difference and 12 residues with similar charges.
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Figure 1-2 Dimeric and tetrameric PKM2 regulates glycolysis

PKM2 has two isoforms: dimer and tetramer. Tetrameric PKM2 (also termed as Tumor M2-PK) has high
affinity to its substrate PEP, while dimeric PKM2 has relatively low affinity. In cancer cells, oncoproteins
binding or modification leads to the conversion of tetramer PKM2 to dimer PKM2. Therefore, all intermediates above pyruvate kinase are accumulated and utilized for other macromolecules synthesis,
which facilitates cancer cell proliferation.
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Figure 1-3 Pyruvate kinase M2 structure
Human pyruvate kinase crystal structure was illustrated. Pyruvate kinase M1 and M2 difference was
shown in yellow and red.
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Figure 1-4 Angiogenesis balance
Angiogenesis balance is maintained by levels of angiogenesis activator and angiogenesis inhibitor. Impropriate amount of activator or inhibitor leads to dysfunction of angiogenesis and angiogenesis related
diseases.
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Figure 1-5 Integrin activation
a. Functional domain of integrin α and βchains
b. Activation of integrin with I-domain
c. Activation of integrin without I-domain
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Figure 1-6 Microenvironment influences cell fate via integrins
Integrin regulate cell survival signals upon binding to ECM. Integrin & ECM interaction activates PI3k-Akt
and NFκB signaling pathways and its downstream survival response. Unligated integrins induce cell
apoptosis though Caspase 8.
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2.1

Abstract
It is long known that pyruvate kinase isoform M2 (PKM2) is released into the circulation of can-

cer patients. The PKM2 levels in patient circulation have been used as a diagnostic marker for many
types of cancers. However, it is not known how the PKM2 is released to blood circulation, and whether
the circulating PKM2 has any physiological function(s) in tumor progression. In this report, we demonstrate that PKM2 in the blood circulation facilitates tumor growth by promoting tumor angiogenesis.
Our experiments show that PKM2 promotes tumor angiogenesis by increasing endothelial cell proliferation, migration, and cell-ECM adhesions. Only the dimeric PKM2 possesses the activity in promoting tumor angiogenesis, which is consistent with the observations that the PKM2 in circulation of cancer patients is a dimer form. Our results further show that PKM2 directly interacts with integrins αvβ3 and α5β1.
PKM2 promotes endothelial cell migration by activating the integrin signals.
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2.2

Introduction
An important molecular signature of tumor development is that a shift in expression of

isoenzymes of pyruvate kinases occurs to the tumors of almost all types. The tissue specific isoform (L, R,
or M1) disappears in many tissue types. In replacement, PKM2 is expressed in cancer cells [1-3]. In tumor cells, growth stimulations convert the pyruvate kinase active tetramer PKM2 to a pyruvate kinase
inactive dimer form [4]. It is believed that during tumor development the demands for biosyntheses,
especially syntheses of nucleotides and amino acids, are high. One main source of the carbon frame and
reducing power of NADPH for the biosynthesis comes from metabolites of glycolysis. Thus, the inactive
dimeric PKM2 actually provides a metabolic advantage to supply precursors for biosynthesis. Activation
of pyruvate kinase activity is actually unfavorable for tumor growth [5, 6]. Christofk, HR. and colleagues
demonstrated that PKM2 is important for cancer cell metabolism and tumor growth [7]. Interestingly, a
number of recent studies showed that PKM2 is functionally involved in multiple cellular processes in different subcellular locations, including metabolism control, transcription regulation, and chromatin package [8-12].
High serum levels of PKM2 have long been observed in cancer patients of many types, including
gastrointestinal cancer, pancreatic cancer, renal cell carcinoma (RCC), lung cancers, and ovarian cancer
[13-16]. Studies show that there is a strong correlation between the serum levels of PKM2 and tumor
progression. Thus, it is proposed that serum levels of PKM2 can be used as an important molecular
marker for cancer diagnosis/prognosis. PKM2 is a glycolytic enzyme. The forms and the mechanism of its
release into the circulation of cancer patients are not known. It is also not known whether the circulating PKM2 has any physiological function in tumor progression. In present study, we provide evidence to
show that the circulating PKM2 facilitates tumor growth by promoting angiogenesis. PKM2 promotes
tumor angiogenesis by increasing endothelial cell proliferation, migration, and cell-ECM adhesions.
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2.3
2.3.1

Results
PKM2 in blood circulation facilitates tumor growth
We sought to investigate the physiological function(s) of circulating PKM2 in tumor progression.

We first tested whether PKM2 was also released to the blood circulation in the xenograft model of human colon cancer cell SW620. After four week tumor growth in nude mice, blood samples from the mice
with or without tumor implantation were collected. PKM2 levels in the blood samples were analyzed by
immunoblot and ELISA of the serum. It was evident that the PKM2 levels in blood of the SW620 tumor
mice were very high. As a control, negligible PKM2 levels were detected in blood of mouse without tumor inoculation (Fig. 1A). We also examined the PKM2 levels in the cell culture medium of SW620 cells.
In consistent, we observed high levels of PKM2 in the medium (Fig. S1A). We questioned what would be
the effects if the PKM2 in the mouse blood circulation was neutralized using an antibody against PKM2.
We used an in-house developed rabbit polyclonal antibody raised against full length recombinant PKM2
(Ref to as PabPKM2). Antibody screening indicated specific recognition of PKM2 in the cell extracts (Fig.
S2A). The recognition of cellular PKM2 was completely abolished by the bacterially expressed PKM2 (Fig.
S2B). The antibody did not recognize any protein in serum of nude mouse (Fig. S2C). IgGs were purified
from the antiserum of the PabPKM2 (Ref to as IgGPK) by an affinity column of rPKM2 (Fig. S2D). The purified IgGPK or the IgGs purified from pre-immune serum by protein A/G beads (Ref to as IgGCon) was
i.p. injected into nude mice that carried SW620 xenograft tumor every two days for 8 days. The administered IgGPK was detectable in mouse serum (Fig. S1B). It was clear that the IgGPK inhibited the tumor
growth, while administration of the IgGCon did not exhibit any significant effects on the growth of the
same tumor (Fig. 1 B, C, and D). The results suggest that PKM2 in the blood circulation is critical important for the tumor growth.

36
We next tested whether addition of PKM2 to blood circulation would promote tumor growth.
We employed the bacterially expressed recombinant PKM2 (ref to as rPKM2) and its isoenzyme PKM1
(ref to as rPKM1) as a control. Since PKM2 is secreted from cancer cells, presumably, the protein should
be present in the extra-cellular space of tumors. Thus, the purified rPKM2 and rPKM1 were pre-mixed
with cancer cells at concentration of 2 µM. The mixtures were then s.c. implanted into nude mouse. The
purified recombinant proteins were also subsequently i.p. injected (5 mg/kg) to the tumor-bearing nude
mice every other days for 8 days. The first injection started 5 days post tumor inoculation. Clearly, the
SW620 tumors that were treated with the rPKM2 experienced over 2 folds higher growth rates compared to the tumors that were treated with the rPKM1 and buffer. The tumors treated with the rPKM1
and buffer had almost similar growth rates (Fig. 2 A, B, and C). Fructose-1,6-bisphosphate (FBP) is an
allosteric activator of PKM2 [17]. We therefore examined whether addition of FBP would affect the activity of the rPKM2 in promoting tumor growth. Apparently, there is a decrease in the activity of the
rPKM2 in promoting tumor growth with addition of FBP (Fig. 2 A, B, and C). To test whether the observed effects of rPKM2 was specific to the SW620 tumor, we employed another xenograft model, human prostate cancer PC-3 cells, by the same treatment schedule. PKM2 was detected in the cell culture
medium of PC-3 cells (Fig. S1A). Evidently, administration of the rPKM2 facilitated PC-3 tumor growth
(Fig. 3 A, B, and C).
2.3.2

PKM2 promotes angiogenesis
It is intriguing that cancer cells release PKM2 to the blood circulation and the circulating PKM2

promotes cancer growth. We questioned what the functional role of the circulating PKM2 is in promoting tumor growth. One possibility is that extracellular PKM2 promotes cancer cell proliferation. Tissue
section stains using an antibody against Ki-67 indeed indicated that the tumors treated with the IgGPK
had reduced proliferation rates, while the tumors treated with rPKM2 had higher proliferation rates (Fig.
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1E & 2 D&E). The representative H&E stains of SW620 tumor tissue sections are shown in figure S1C.
However, addition of the IgGPK, IgGCon, rPKM2, rPKM1, and rPKM2 + FBP into SW620 and PC-3 cell culture medium did not lead to any significant change in cell proliferation (Fig. 4 A&B). Thus, the tumor
growth promotion by the rPKM2 and inhibition by the IgGPK were unlikely due to their actions on cancer
cells. The other possibility is that the PKM2 in circulation promotes angiogenesis to facilitate tumor
growth. To test this conjecture, we carried out histology analyses with the tumor tissue sections using
antibody against mouse CD31, a marker for endothelial cells. It was clear that treatment of mouse with
the IgGPK dramatically reduced blood vessels in the SW620 tumor (Fig. 1 F&G). Reversely, treatment of
mouse with the rPKM2 led to substantial increases in blood vessels in both PC-3 and SW620 tumors. The
rPKM2 + FBP had reduced effects, while the rPKM1 had no significant effects (Fig. 2 F&G, Fig. 3 D, E, &F).
Our analyses strongly suggested that the PKM2 in blood circulation promotes angiogenesis.
To further verify the role of PKM2 in angiogenesis, we employed the in vitro tube formation assay using HUVEC cells. The rPKM2, rPKM2+FBP, rPKM1, and buffer alone were added to the culture medium of the cells. Formation of endothelial tubes was analyzed. The rPKM2 strongly promoted endothelial tube formation (Fig. 5 A&B). The time required for formation of the tubes was substantially shortened, and the tubes were maintained much longer time (data not shown). The rPKM2 + FBP had less
effects compared to that of the rPKM2. The rPKM1 had only marginal effects, while saline had no effects
(Fig. 5 A&B). We subsequently tested the effects of the PKM2 antibody on the tube formation by coculture the medium collected from SW620 cell cultures in which PKM2 was immunodepleted by the
IgGPK with HUVEC cells. Immunoblots indicated that PKM2 in SW620 cell culture medium was completely removed by the IgGPK (Fig. S3A). Clearly, the antibody depletion greatly reduced the endothelial tube
formation in the co-culture of SW620 medium with HUVEC cells (Fig. S3 B&C). These in vitro tests supported our notion that PKM2 promotes angiogenesis.

38
2.3.3

Dimer PKM2 promotes angiogenesis
It is believed that the PKM2 in the cancer patient blood circulation exists as a dimer [18, 19],

while the protein in cancer cells exists as a mixture of tetramer and dimer [17, 20] [8]. Thus, an interesting issue is whether the dimer and tetramer status of PKM2 have different effects in promoting tumor
growth. We first examined the tetramer and dimer status of the administered rPKM2/rPKM1 in the
mouse serum. Chromatography analyses followed by immunoblots indicated that the rPKM2 existed
mostly as dimer in the circulation, while the rPKM1 was mostly tetramer (Fig. 6A). Using an ELISA analysis, we estimated that the concentration of the i.p. injected rPKM2 and rPKM1 (at dose of 5 mg/kg) in
the mouse blood was around 400 – 800 nM 4 hours after the administration. We also analyzed the tetramer and dimer status of the rPKM2/rPKM1 in vitro. Chromatography profiles indicated that the
rPKM2 existed as a mixture of tetramer and dimer (with tetramer to dimer ratio at around 80% to 20%)
at concentration of 12 µM, while the rPKM1 was almost completely tetramer at the same concentration
(Fig. 6B). The purified proteins possessed pyruvate kinase activity (Fig. 6C). Interestingly, dilution of the
rPKM2 led to conversion of tetramer to dimer with the rPKM2 became almost completely dimer at
around 1 µM (Fig. 6 D&G). This concentration is very close to the concentration of the administered
rPKM2 in mouse blood. Most of the rPKM1 still existed as tetramer at this concentration (Fig. 6 F&G).
Addition of 3 mM FBP converted the rPKM2 to the tetramer, even at concentration as low as 1 µM (Fig.
6E). Consistently, a large portion of rPKM2 was tetramer in mouse blood circulation when the protein
was co-administered with 3 mM FBP (Fig. 6A). Clearly, the observed activity of FBP in facilitating the
conversion of the rPKM2 from dimer to tetramer is consistent with the results that addition of FBP to
the rPKM2 reduced the effects of the protein on promoting tumor growth (Fig. 2 A, B, and C, Fig. 3 A, B,
and C). Both support a conclusion that introduction of the dimeric PKM2 to blood circulation promoted
tumor angiogenesis. Can FBP also convert the circulating dimer PKM2 to a tetrmer therefore inhibit tumor angiogenesis? To answer this question, we collected the serum samples from the mice that had
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been implanted tumors. FBP was added to the serum samples. The PKM2 in the serum was analyzed by
the same chromatography procedure. Clearly, addition of FBP did not convert the circulating PKM2 to
tetramer (Fig. S4). The observation is consistent with previous report that FBP could not convert the nuclear dimer PKM2 to a tetramer [8].
2.3.4

PKM2 facilitates endothelial cell migration
How does circulating PKM2 promote tumor angiogenesis? To address this question, we analyzed

cell proliferation, migration, and adhesion of HUVEC cells. Addition of rPKM2, to the cell culture medium
led to a marginal increase in cell proliferation (Fig. 5C). It is unlikely this small effect would be the sole
factor that confers the in vivo effects on tumor growth. On the other hand, boyden chamber assays
showed that addition of the rPKM2 led to a strong increase in cell migration, and the effects were substantially reduced by addition of FBP. The rPKM1 had almost no effects (Fig. 5D). The increases in cell
migration were not observed with SW620 and PC-3 cells (Fig. S5A). We noted a strong attachment of
HUVEC cells to the culture plates with rPKM2 coating (Fig. 5E). In addition, the attachment of HUVEC
cells to the ECM coated plate was substantially strengthened by addition of SW620 cell culture medium,
while the enhancement was abolished by addition of the antibody PabPKM2 (Fig. S5B). We suspected
that the rPKM2 might affect endothelial cell adhesion to ECM. Indeed, the cell attachment assays
showed that the HUVEC cell adhesion to vitronectin and fibronectin, matrix molecules was strongly enhanced upon addition of the rPKM2 to the culture medium (Fig. 5F). The effects were not observed with
rPKM1. In consistent, we observed a strong effect on the HUVEC cell spreading by addition of rPKM2
into the cell culture medium, while this effect was not observed with rPKM1 (Fig. S5C). The effects of
PKM2 on cell adhesion to ECM and cell migration was not observed with epithelial cancer cells (Fig. S5
A&D), indicating that the effects were endothelial cell specific. Thus, we conclude that PKM2 promoting
angiogenesis by facilitating endothelial cell migration and cell adhesions to ECM.
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PKM2 enhanced the attachment of endothelial cells to ECM. We therefore examined whether
PKM2 interacts with integrins by Biacore using recombinant integrins αvβ3 and α5β1. PKM2 interacted
with both integrin pairs with stronger affinity for αvβ3 (Fig. 7A). We further confirmed the interaction by
an antibody blocking experiments. HUVEC cells were attached on microscopic slides with rPKM2 coating.
The cells were detached by addition of antibody against αvβ3 and the IgGPK (Fig. 7B). To verify whether
the PKM2 and integrin interaction had any functional relevance, we examined HUVEC cell migrations on
fibronetin and vitronectin in the presence of rPKM2 and rPKM1. Evidently, migrations of the cells on
vitronectin and fibronectin were significantly increased by addition of rPKM2 but not rPKM1. The increases in migration were diminished by addition of the PabPKM2 and the antibody against αvβ3 (Fig.
7C). Immunostaining of F-actin indicated that addition of rPKM2 led to an increased stress fiber of
actinfilament accompanied by increased accumulation of vinculin at the tips of stress fibers at early time
of ECM attachment (Fig. 7D). In consistent, a strong increase in activation of FAK was observed upon
addition of PKM2. The activation of FAK was diminished by the antibody IgGPK (Fig. 7E). Thus, our results indicate that PKM2 target integrins to promote angiogenesis.
2.4

Discussion
A very high percentage of cancer patients of different cancer types have elevated levels of PKM2

in their blood circulation [21]. We show that the circulative PKM2 plays a critical role in facilitating tumor growth by promoting tumor angiogenesis. An obvious question is why tumors release this glycolysis
enzyme to the circulation to promote angiogenesis. One plausible explanation is that dimeric PKM2 is a
sensor for the glycolysis status and glucose demands in cancer cells for high proliferation. It is demonstrated by many laboratories that PKM2 is converted to dimer in high proliferation cells with high glycolysis activity [20, 22]. Thus, it is possible that dimeric PKM2 is a signal that reflecting nutrition requirement, therefore a signaling for angiogenesis. Most recently, Luo, W. and co-workers reported that PKM2
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co-activates the transcription factor HIF1α [10]. It is conceivable that PKM2 may also be an important
molecular factor that response to hypoxia condition for angiogenesis stimulation. Interestingly, PKM2 is
the main pyruvate kinase isoform during fetus development. It is well known that angiogenesis is active
during organ development and maturation. Is PKM2 also secreted into blood circulation of fetus for
promoting angiogenesis?
Another open question is why PKM2 but not PKM1 in the circulation promotes tumor angiogenesis. PKM2 and PKM1 differ by only 23 amino acids resulted from alternative pre-mRNA splicing. These
two isoforms share almost identical structure. However, structural analyses revealed that the segment
with different amino acid sequence is mostly localized at the dimer-dimer interface [4]. Thus, it is conceivable that the dimer interface is engaged in interaction with the integrins, and consequently promotes angiogenesis. This notion is consistent with the results that the dimer PKM2 is effective in promoting angiogenesis, while tetramer is inactive. We previously demonstrated a PKM2 mutant R399E
that is a dimer and less active in puryvate kinase activity [8]. The R399E mutant is fully functional (slightly more active) in promoting HUVEC cell attachment to ECM (Fig. S6), suggesting that the pyruvate kinase activity is not required and the exposed dimer-dimer interface is required, which also supports the
notion that the dimer interface may be engaged in interaction with the target(s) consequently promotes
angiogenesis. Apparently, inhibition of tumor growth by the PKM2 antibody reveals a potential new anti-angiogenesis target for cancer patients with high circulative PKM2. One great advantage of targeting
PKM2 is that the levels of circulative PKM2 would be a prognosis marker to predict the possible outcomes.
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2.5
2.5.1

Materials and Methods
Reagents, cell lines, antibodies, and protein expression/purifications
Antibodies against β-actin, mouse CD31, Ki-67 were purchased from Cell Signaling, SantaCruz,

and Abcam respectively. Antibody against PKM2 was raised using recombinant PKM2 expressed/purified
from E. coli. as an antigen. IgGs were purified from the rabbit anti-serum over a protein G column.
Integrins αvβ3, α5β1 were purchased from R&D System, and were directly used without further treatment. Cell lines SW620 and PC-3 were purchased from ATCC, and HUVEC cells were purchased from Invitrogen. The cells were cultured by following the vendor’s instructions. The cDNAs that encode human
PKM2 and PKM1 were purchased from Adgenes. The cDNAs were subcloned into bacterial expression
vector pEG-32a. The recombinant proteins were purified from bacterial lysates by a two column procedure.
2.5.2

Mice xenografts and treatments
All animal experiments were carried out in accordance with the guidelines of IACUC of Georgia

State University. Nude mice were subcutaneously injected with 5 × 106 of SW620 or PC-3 cells. Tumor
formation and volumes were assessed every 2 days. Tumor volumes were measured by two perpendicular diameters of the tumors with the formula 4π/3 × (width/2)2 × (length/2). The tumor bearing mice
were subjected to the i.p. injections of appropriate agents once every other days for eight days. The
treatments started five days post tumor inoculations. The tumors were collected and weighed at the
end of the experiments. Tissue sections were prepared from harvested tumors, and stained using commercially available antibodies against Ki-67 or mouse CD31. Statistical analyses were done in comparison
to the control group with Student’s t test.
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2.5.3

Boyden chamber and cell proliferation assays
QCMTM 24-Well Fluorimetric Cell Migration Assay kit (ECM) was used to measure the migration

of different cells. The test cells were first treated under the different conditions (indicated in figure legends) in regular cell culture plates. The treated cells were re-suspended into optimum medium (without
serum) and seeded into the inner chamber of the migration assay kit. The culture medium with 10% FBS
was added to the outer chambers. After overnight incubation, medium in the inner chamber was removed and the cells attached to the outer bottom side were detached using the cell detachment buffer
(included in the kit). The detached cells were then lysed using the cell lysis buffer (included in the kit).
The amounts of the migrated cells were determined by measuring the fluorescence using λex=485nm
and λem=535nm.
For analyses of cell proliferation, a cell proliferation ELISA kit that measures BrdU incorporation
was used. Briefly, cells were incubated for appropriate time in the presence of 10 µM BrdU under different conditions (indicated in figures). The cells were fixed after incubation and washed 3 times. The fixed
cells were detected by anti-BrdU-POD antibody and secondary antibody. The nuclei incorporations of
BrdU were measured by chemiluminescence emission (Victor 3TM, PerkinElmer). Cell proliferation was
also measured by cell number counting. Cells were incubated for appropriate time under appropriate
conditions. Cell numbers was counted before and after the indicated time of culture by five independent
cell counting.
2.5.4

Endothelial tube formation and cell attachment assays
Endothelial tube formations were carried out with the endothelial tube kit. Briefly, HUVEC cells

were seed in culture plat coated with martigel. After 30 minutes incubations, agents, e.g. FBS, proteins,
or cancer cell culture medium, were added to the HUVEC. The cells were further cultured for additional
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16 hours. The formed endothelial tubes were analyzed under light microscope. For the tube formation
with supplement of SW620 culture medium, no FBS was added to the HUVEC cell culture.
For cell attachment, cells were cultured overnight under standard conditions. Next days, different cells (with appropriate cell numbers) were transferred to a new plate with wells that coated with
different proteins (indicated in the figures) with fresh medium with addition of appropriate agents in the
medium (indicated in the figures). The cells were further cultured for 2 hours and washed gently. The
attached cells were either directly counted or lysed. The cell lysates were then measured to determine
the amounts of attached cells.
2.5.5

Size-exclusion chromatography
Size exclusion chromatograph was performed with a Superdex 200 10/300GL column. The sam-

ples of mouse serum (2 – 8 mg/ml of total protein), the rPKM2 (~15 µM), the rPKM1 (~15 µM) were prepared in tris-HCl buffer with/without FBP. 100 µl of the sample was loaded into the column and eluted
with elution buffer (50 mM phosphate, 0.15M NaCl pH7.2). The fraction of 300 µl was collected, and 20
µl of each fraction was analyzed by immunoblot. The elution profiles were compared to that of a size
exclusion chromatograph calibration kits (GE Healthcare) under identical conditions. The elution profile
was plotted against LogMW according to vendor’s instructions.
2.5.6

Pyruvate kinase activity
Pyruvate kinase activity was analyzed by following the experimental procedure similar to that

was described by Christofk and colleagues [22].
2.5.7

Biacore binding analyses
The interactions of rPKM2 and rPKM1 with integrins were analyzed by Surface Plasmon Reso-

nance (Biacore). The purchased integrins α5β1 and αvβ3 was diluted in 50 mM acetate buffer to a concen-
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tration of 100 µg/ml. The integrins were immobilized on the CM5 chips to show response units (RU) of
1980 and 2030 for α5β1 and αvβ3 respectively. The first channel with full ethanol amine block was used
as negative control. The rPKM2 and rPKM1 were diluted to 100 µg/ml in the running buffer (10 mM
HEPES, 150 mM NaCl, 5 mM MgCl2, pH7.4). The flow rate of rPKM2/rPKM1 in running buffer was 20
µl/min and the binding time was 16 min. The dissociated time is 30 min. The Kds were obtained by the
fitting the binding data as 1:1 ratio of integrin/PKM binding.
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Figure 2-1 Antibody against PKM2 inhibits tumor growth.
(A) The levels of PKM2 in the serum of mouse blood collected from tumor bearing nude mouse (SW620)
and non-tumor nude mouse (Con) were examined by immunoblot of PKM2 (IB:PKM2). Coomassie stain
(CBS: M-Albumin) of serum albumin is a loading control. (Bottom) The PKM2 levels in serum of nude
mouse with/without SW620 tumor implantation and with/without i.p. administration of rPKM2 (48
hours after injection) were determined by sandwich ELISA using an in-house developed rabbit monoclonal antibody against PKM2 and a commercially available goat polyclonal antibody against PKM2. The
PKM2 concentration was presented as the range of high and low levels (ng/ml) in serum samples from
five mice per group tested.
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Figure 2-1B Growth curve of SW620 tumor.
Growth of SW620 tumor under the treatment of purified IgGs of IgGPK (IgGPK) or pre-immune serum
(IgGCon) was monitored by growth curve measuring tumor volumes every two days.
The *p values in (B) and (D) are calculated using unpaired two-tailed Student t-test. The error bars in (B)
are standard deviations from measurement of five mice.
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Figure 1C&D PKM2 antibody inhibits tumor growth.
(C) and (D) indicates the growth of SW620 tumor under the treatment of purified IgGs of IgGPK (IgGPK)
or pre-immune serum (IgGCon) was monitored by; (C) endpoint pictures and (D) endpoint weights of the
harvested tumors with 8 days treatment (treatment started 5 days post tumor inoculation).
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Figure 2-1E Ki-67 staining of SW620.
The top panel is representative images of immunostaining of tissue sections prepared from the harvested tumors using antibodies against Ki-67 (Red). The blue is DAPI stain of cell nucleus. The bottom panel
indicates the quantization of Ki-67 staining signals of the tissue sections. The standard deviations of the
mean values were measured from randomly selected 4 fields in randomly selected 3 sections from each
tumor.
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Figure 2-1F&G CD31 staining of SW620 tumors.
(F) is DAPI stain of cell nucleus. The proliferation index was percentage of the positive nucleus staining
by counting the nucleus number with ki-67 positive staining in randomly selected three fields in each
slide from randomly selected three slides from each tumor. (G) Quantitative analyses of vessel lengths,
densities, and branch points (manually counting) of the CD31 staining of the tumor tissue sections using
software imaging-J. The quantization was statistical mean values of randomly selected 4 fields in randomly selected 3 sections from each tumor.
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Figure 2-2 Recombinant PKM2 promotes SW620 tumor growth.
(A), (B), and (C) Growth of SW620 tumor under the treatment of different recombinant proteins (indicated) was monitored by; (A) growth curve by measuring tumor volumes every two days, (B) endpoint
pictures and (C) endpoint weights of the harvested tumors with 8 days treatment (treatment started 5
days post tumor inoculation). The *p values in (C) are calculated using unpaired two-tailed Student ttest. The error bars in (A) are standard deviations from measurement of five mice.
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Figure 2-2D Ki-67 staining of SW620 tumor administered by recombinant proteins.
Representative images of immunostaining of tissue sections prepared from the harvested tumors with
antibodies against Ki67 (Red). The blue color indicates nucleus staining by DAPI. Photos were taken by
Confocal Microscope.
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Figure 2-2E quantization of Ki-67 staining of SW620 tumor.
(E) indicates quantization of Ki-67 staining signals of the tissue sections. The proliferation index was percentage of the positive nucleus staining by counting the nucleus number with ki-67 positive staining in
randomly selected three fields in each slide and randomly selected three slides from each tumor. The
standard deviations of the mean values are from measurements of randomly selected 4 fields in randomly selected 3 sections from each tumor.
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Figure 2-2F CD31 staining of SW620 tumor treated with recombinant proteins.
(F) is representative images of immunostaining of tissue sections prepared from the harvested tumors
with antibodies against mouse CD31 (Green). The blue color is DAPI stain of cell nucleus. Photos were
taken by Confocal Microscope.
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Figure 2-2G Quantization of CD31 staining of SW620 tumors.
Quantitative analyses of vessel lengths, densities, and branch points (manually counting) of the CD31
staining of the tumor tissue sections using the software imaging-J. The quantization was statistical mean
values of randomly selected 4 fields in randomly selected 3 sections from each tumor.
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Figure 2-3 Recombinant PKM2 promotes PC-3 tumor growth.
(A), (B), and (C) Growth of PC-3 tumor under the treatment of different recombinant proteins (indicated,
one tumor in the rPKM1 treatment group did not grow) was monitored by; (A) growth curve by measuring tumor volumes every two days and the tumor volumes were calculated by formula; Tumor volume =
π/6 x (width) 2 x length, (B) endpoint pictures and (C) endpoint weights of the harvested tumors after 13
days growth with 8 days treatment. The *p values are calculated using unpaired two-tailed Student ttests.
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Figure 2-3D CD31 staining of PC-3 tumor treated with recombinant proteins.
Representative images of immunostaining of tissue sections prepared from the harvested tumors with
antibodies against mouse CD31 (Green). The blue color is DAPI stain of cell nucleus. Photos were taken
by Confocal Microscope.
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Figure 3E&F Quantization of CD31 staining of PC-3 tumor.
(E) & (F) Quantitative analyses of vessel densities (E) and branches (F) (by manually counting) of the
CD31 staining of the tumor tissue sections using the software imaging-J. The quantization was statistical
mean values of randomly selected 4 fields in randomly selected 2 sections from each tumor. The error
bars in (E) and (F) are standard deviations of the mean values from measurements of randomly selected
4 fields in randomly selected 2 sections from each tumor.
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Figure 2-4 PKM2 and anti-PKM2 antibody does not affect cell proliferation of SW620 and PC-3 cells.

(A) and (B) Cell proliferations of SW620 (filled bars) and PC-3 (open bar) cells in the presence of rPKM2,
rPKM2 + FBP, and rPKM1 (5 µg/ml) (A) or the antibody IgGPK (IgGPK) and the IgGCon (IgGCon) (B) were
analyzed by a commercial BrdU proliferation kit. The cell proliferations are presented as relative proliferation by defining the proliferation of buffer saline treated cells as 100. The error bars in (A) and (B) are
standard deviations from five repeating experiments.
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Figure 2-5 PKM2 affects endothelial tube formation, migration and attachment.
(A) Representative light microscopic images of endothelial tubers formed by HUVEC cells in the presence
of rPKM2, rPKM2 + FBP, and rPKM1, or (B) Quantitative analyses of the branch points in the formed
HUVEC tubes. The quantization was the mean average of branch point counts of randomly selected four
fields from each slide and with five repeating experiments (slides).
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Figure 2-5C&D PKM2 promotes endothelial cell proliferation and migration.
(C) & (D) Cell proliferation (C) and migration (D) of HUVEC cells in the presence of rPKM2, rPKM2 + FBP,
rPKM1, and buffer saline were analyzed by a commercial BrdU proliferation kit and boyden chamber
assay respectively. The cell proliferation and migration are presented as relative proliferation (C) or relative migration (D) by defining the proliferation of buffer saline treated cells as 100 and cell migration of
rPKM2 treated cell as 100.
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Figure 2-5E Endothelial cells bind to PKM2.
Cell attachment of HUVEC cells to cell culture plate on which rPKM2, rPKM1, or BSA was coated respectively.
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Figure 2-5F PKM2 enhances endothelial cells to bind to Extracellular Matrix.
Cell attachment of HUVEC cells to cell culture plate on which fibronectin (open bars) or vitronectin (filled
bars) was coated and the indicated proteins were added to the culture medium. The cell attachments
are presented as relative attachment by defining the cell attachment in the plate on which rPKM2 was
coated as 100 in (E) or buffer saline was added to the culture medium as 100 in (F). In (A), (B), (C), and
(D), buffer saline is a control. The error bars in (B), (C), (D), (E), and (F) represent standard deviations
from five repeating experiments.
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Figure 2-6 tetramer or dimer formation of PKM2 and PKM1.
(A) (Upper) Immunoblot analyses of the chromatography fractions of the mouse serum collected from
mice that were administered rPKM2, rPKM2 + FBP, and rPKM1 using the antibody PabPKM2. (Bottom)
The chromatography profiles of the standard molecular weight calibration kit.
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Figure 2-6B Recombinant PKM2 forms tetramer at high concentration.
Chromatography profiles of rPKM2 (Blue) and rPKM1 (Red) at concentration of 12 µM. Elution volumes
equivalent to tetramer and dimer are indicated by arrows.
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Figure 2-6C PKM2 has low enzymatic activity.
Pyruvate kinase activity of the rPKM2, rPKM2 + FBP, and rPKM1 (5 µg/ml) was analyzed by the method
described by Christofk and colleagues. The pyruvate kinase activity was expressed as relative pyruvate
kinase activity by define the activity in the rPKM1 as 100.
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Figure 6D, E, F and G rPKM2 forms dimer at low protein concentration
(D), (E), (F), and (G) The chromatography profiles of different concentrations (indicated) of rPKM2 (D),
rPKM2 + FBP (E), and rPKM1 (F), as well as 1 µM of rPKM2/rPKM1 (G). The dimer and tetramer ratios
(T/D ratio) in (B), (D), (E), and (F) were calculated by the areas under the dimer and tetramer peaks. In
(A), (B), (D), (E), (F), and (G) the y-axis is the absorbance of the elution at 280 nm. The numbers in the Xaxis are the elution volumes. The error bars in (C) are standard deviations from five repeating experiments.
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Figure 2-7 PKM2 interacts with integrins to activate integrin signaling.
(A) (Upper) the representative binding curves of binding of PKM2 to integrins αvβ3 and α5β1 that were
monitored by Biacore with integrins that were immobilized on the Biacore chip. (Bottom) The deduced
disassociation constants (kd) of PKM2 to integrin αvβ3 and α5β1 from the Biacore binding analyses.
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Figure 2-7B endothelial cell binding to PKM2 is inhibited by integrin αvβ3 antibody.
Cell attachment of HUVEC cells to microscopic chamber slides on which rPKM2 was coated and the indicated agents were added to the slides. LM609 is an antibody against integrin αvβ3. The cell attachments
are presented as relative attachment by defining the cell attachment in the slide on which the rabbit IgG
purified from pre-immune serum (IgGCon) was added to the culture medium as 100. The error bars in
(B) and (C) represent standard deviations from five repeating experiments.
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Figure 2-7C Integrin mediates PKM2-induced HUVEC migration.
Migration of HUVEC cells in the presence of rPKM2, rPKM2 + FBP, rPKM1, and buffer saline (Upper) and
with addition of antibodies against PKM2 (IgGPK) or integrin αvβ3 (Bottom) were analyzed by boyden
chamber assay. The ECM virtonectin (VN) or Fibronectin (FN) was always added to the migration assays.
The cell migrations are presented as relative migration by defining the cell migration of buffer saline
treated cells as 100.
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Figure 2-7D PKM2 promotes focal complex assembly and stress fiber forming.
Representative microscopic images of immune-staining of HUVEC cells with antibody against F-actin
(Red) and Vinculin (Green). The cells were seeded on microscopic chamber slides with ECM coating. The
indicated proteins (at 5 µM) were added to the slides. The cells were fixed 45 minutes after seeding on
the chamber slides and stained using the indicated antibody. The numbers indicate the percent of cells
have typical or similar staining pattern as showed in the images after analyses of randomly selected 4
view fields from each slide and three independent experiments.
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Figure 2-7E PKM2 activates FAK by tyrosine 397 phosphorylation.
Activation of FAK was analyzed by immunublot of cell extracts of HUVEC cells that were seeded on ECM
coated culture plate with addition of the indicated proteins (5 µM) for 60 minutes using antibody against
phosphorylated FAK (IB:p-FAK397). Immunoblot of extracts using antibody against FAK (IB: FAK) is a control indicate the cellular levels FAK and loading control.
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Figure 2-8 PKM2 was actively released or secreted to cell culture medium.
Left panel: PKM2 and β-actin were detected in SW620 whole cell lysate (SW620 Lysate), SW620 cell culture medium (SW620 CM) and controlled culture medium (Con) respectively. The data indicated that
PKM2 is actively released to the culture medium since β-actin was not present in the SW620 culture
medium.
Right panel: PKM2 were present in both colon cancer cell line SW620 and prostate cancer cell line PC-3.
Meanwhile, SW620 cells released 3-5 fold more PKM2 than PC-3.
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Figure 2-S1B administered PKM2 antibody in mouse blood serum.
Immunoblot indicates PKM2 antibody (IgGPK) can be detected in mice blood serum. SW620 tumor bearing mice were administered by IgGPK.
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Figure 2-S1C H&E staining or SW620 tumors.
Hematoxylin and eosin staining indicates the structure of SW620 tumors treated with Saline, rhPKM1,
rhPKM2 and rhPKM2+FBP respectively.
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Figure 2-S 1 specificity test of anti-PKM2 antibody.
Left panel (S2A): Single band was detected in H146 and H460 whole cell lysate by western blot. The band
located in around 60KDa Protein ladder band is PKM2. BSA was used as control.
Right panel (S2C): PKM2 antibody (IgGPK) only recognized PKM2 band in the blood serum of SW620
tumor bearing mice, but not the control mice. Control antibody (IgGCon) did not recongnized any
protein in the blood serum of control mice.
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Figure 2-S2B recombinant PKM2 competes with cellular PKM2 to bind to IgGPK.
Immunoblot indicates the recognition of cellular PKM2 was completely abolished by bacterially expressed recombinant PKM2.
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Figure 2-S2D PKM2 antibodies purification.
Anti-PKM2 antibody, IgGPK and normal rabbit IgG, IgGCon were purified by Protein A sepharose beads.
Purified antibodies were analyzed by SDS-PAGE.
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Figure 2-9 PKM2 secreted by SW620 cell promotes endothelial cell tube formation.
(A) PKM2 in SW620 culture medium was removed by anti-PKM2 antibody, IgGPK. Immunoblot has
shown that PKM2 level was significantly reduced after removal by IgGPK conjugated to Protein A
sepharose beads. IgGCon was taken as a control. IgG heavy chain was blotted as an internal loading control.
(B) Representatives of endothelial tube formation assay show that PKM2 removal from SW620 culture
medium significantly reduced tube formation compared to SW620 culture medium treated with IgGCon.
(C) Quantization of branch points in endothelial tube formation assay. The error bars in branch points
are standard deviations of the mean values from measurements of randomly selected four wells.
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Figure 2-10 FBP does not convert circulating PKM2 to tetramer.
Mice blood sera were analyzed chromatography and immunoblots. PKM2 mainly forms dimer with absence or presence of FBP.
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Figure 2-11 PKM2 does not affect SW620 and PC-3 cell migration.
Cell migration of SW620 (filled bars) and PC-3 (open bar) cells in the presence of rPKM2, rPKM2+FBP,
and rPKM1 were analyzed by Boyden chamber assay. The cell migration is presented as relative migration by defining the migration of buffer saline treated cells as 100. The error bars are standard deviations from three repeating experiments.
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Figure 2-S5B IgGPK abolishes PKM2 from cell medium induced cell attachment.
SW620 cell culture medium enhanced endothelial cells attaching to ECM coated surfaces and this attachment is abolished by anti-PKM2 antibody, IgGPK, but not by normal rabbit IgG, IgGCon. The cell attachments are presented as relative attachment by defining the cell attachment in the well in which the
control culture medium (ConCM) was added as 100. The error bars represent standard deviations from
five repeating experiments.
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Figure 2-S5C rhPKM2 enhanced endothelial cell spreading.
Top left, top right and bottom left panels illustrated endothelial spreading upon treatment of saline,
rhPKM1 and rhPKM2 respectively.
Bottom right panel: statistically analysis of percentage of spreading endothelial cells among all attached
cells. RhPKM2 treatment significantly increased numbers of spreading cells compared to rhPKM1 and
BSA control.
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Figure 2-S5D PKM2 does not affect SW620 and PKM2 adhesion to ECM.
SW620 cell attachment on ECM in the presence of rPKM2, rPKM2 + FBP, and rPKM1 were analyzed cell
binding assay. The cell attachments are presented as relative attachment by defining the cell attachment in the plate on which saline was added as 100. The error bars represent standard deviations from
five repeating experiments.
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Figure 2-12 PKM2 dimer is required for promoting endothelial cell attaching to ECM.
Endothelial cell attachment on ECM in the presence of rPKM2 or PKM2 R399E mutant was analyzed cell
binding assay. The cell attachments are presented as relative attachment by defining the cell attachment in the plate on which rPKM2 was added as 100. The error bars represent standard deviations from
three repeating experiments.
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3.1

Abstract
Pyruvate kinase isoform M2 (PKM2) is released into the circulation of cancer patients. The PKM2

levels in patient circulation are used as a diagnostic/prognostic marker for many types of cancers. We
previously demonstrated that PKM2 in blood circulation facilitates tumor growth by promoting tumor
angiogenesis. Here, we report that the circulative PKM2 mediates cancer cell drug resistance. Antibody
raised against PKM2 render cancer cells sensitive to chemotherapies. Our results demonstrate that
PKM2 mediates drug resistance by activating integrins αvβ3 signaling. Evidently, the extracellular PKM2
activates survival signal Akt via activation of the integrin signaling. Our study uncovers a novel molecular
mechanism by which cancers acquire drug resistance by secreting PKM2, revealing a potential target for
developing cancer treatment.
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3.2

Introduction
An important molecular signature of tumor development is that a shift in expression of

isoenzymes of pyruvate kinases occurs to the tumor of almost all types. The tissue specific isoform (L, R,
or M1) disappears. In replacement, PKM2 is expressed in cancer cells [1-3]. In tumor cells, growth stimulations convert the pyruvate kinase active tetramer PKM2 to a pyruvate kinase inactive dimer form [4]. It
is believed that during tumor development the demands for biosyntheses, especially syntheses of nucleotides and amino acids, are high. One main source of the carbon frame and reducing power of
NADPH for the biosynthesis comes from metabolites of glycolysis. Thus, the inactive dimeric PKM2 actually provides a metabolic advantage to supply precursors for biosynthesis. Activation of pyruvate kinase
activity is actually unfavorable for tumor growth [5, 6]. Christofk, HR. and colleagues demonstrated that
PKM2 is important for cancer cell metabolism and tumor growth [7]. Interestingly, a number of recent
studies showed that PKM2 is functionally involved in multiple cellular processes in different subcellular
locations, including metabolism control, transcription regulation, and chromatin package [8-12].
High serum levels of PKM2 have long been observed in cancer patients of many types, including
gastrointestinal cancer, pancreatic cancer, renal cell carcinoma (RCC), lung cancers, and ovarian cancer
[13-16]. Studies show that there is a strong correlation between the serum levels of PKM2 and tumor
progression. Thus, it is proposed that serum levels of PKM2 can be used as an important molecular
marker for cancer diagnosis/prognosis. How PKM2 is released into patient blood circulation was an intriguing question. Recent studies showing that cultured cancer cells actively secret PKM2 to the culture
medium suggesting that the circulative PKM2 may not be a result of nature turn-over of cancer cells,
rather it is an active mechanism by which cancer cells protect themselves. Several studies noted that the
levels of PKM2 in patient blood circulation correlate well with patient drug resistance to several anticancer drugs. It is not known whether and how the circulative PKM2 mediate cancer drug resistance.
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We previously demonstrated that the circulative PKM2 facilitated cancer growth by promoting
tumor angiogenesis. The extracellular PKM2 promoted angiogenesis by acting on integrin αvβ3. We
showed that PKM2 directly interacted with the integrin and activated the integrin signals. It is well
known that activation of integrin αvβ3 activates cell survival signals. Activation of integrin αvβ3 contributes a major mechanism for cancer cell drug resistance. In present study, we provide evidence to show
that extracellular PKM2 mediates cancer cell drug resistance. Antibody raised against PKM2 sensitizes
cancer cells to apoptosis induction by anticancer drugs. Extracellular PKM2 mediates cancer cell drug
resistance by activating integrins αvβ3 signaling and subsequent activation of survival signals. Our study
uncovers a novel molecular mechanism.
3.3

Results
Our previous studies showed that PKM2 in cancer patient blood circulation facilitated tumor

growth by promoting tumor angiogenesis. The extracellular PKM2 promotes tumor angiogenesis by activating integrin αvβ3 signals in angiogenic endothelial cells. Since it is well known that activation of integrin αvβ3 signaling constitutes a major mechanism by which cancer cells acquire apoptosis resistance, we
reasoned whether secretion of PKM2 constituted an important mechanism for cancer cells that express
integrin αvβ3 to develop drug resistance. To test our hypothesis, we carried out screening to select our
study system. We examined several cancer cell lines for integrin αvβ3 expression and PKM2 secretion.
Evidently, melanoma SK-MEL-28 cells have high levels of integrin αvβ3 expression and relative high level
of PKM2 secretion, while colon cancer SW620 cells do not express the integrin pair but has high levels of
PKM2 secretion. PC-3 cells do not have high levels of integrin αvβ3 expression nor PKM2 secretion (Fig.
1A). Based on the screening, we selected SK-MEL-28 and SW620 cells as our study cell lines. We examined whether the cells with high levels of integrin αvβ3 expression and high levels of PKM2 secretion
would be resistant to drug treatments. We used oxaliplatin as an example. Clearly, both SK-Mel-28 and
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SW620 cells were strongly resistant to the drug induced apoptosis, with SK-Mel-28 had stronger resistance (Fig. 1B). To verify whether the extracellular PKM2 levels play a role in the apoptosis resistance,
we first employed the rabbit monoclonal antibody against PKM2 (ABPK) that is known to block the
PKM2 and integrin αvβ3 interaction. The SK-Mel-28 and SW620 cells were treated with oxaliplatin in the
presence of ABPK or control rabbit IgG. It was clear that the SK-Mel-28 cells were more sensitive to the
drug induced apoptosis in the presence of ABPK. As a control, rabbit IgG did not have such effects, while
the antibody almost had no effects on the drug sensitivity of SW620 cells (Fig. 2A). To further test
whether PKM2 indeed mediates the drug resistance, we examined whether addition of the recombinant
PKM2 (rPKM2) into culture medium would increase the apoptosis resistance with the integrin αvβ3 expressing cells. SK-Mel-28 cells have high levels of integrin αvβ3 expression, while SW620 cells do not express integrin αvβ3. Treatment of SK-Mel-28 cells with rPKM2 strongly increased resistance to apoptosis
induced by oxaliplatin, as a control, rPKM1 did not have such effects. On the other hand, both rPKM2
and rPKM1 did not increase the apoptosis resistance with SW620 cells (Fig. 2B). The observations suggest PKM2 mediate cancer cell apoptosis resistance via integrins αvβ3. To prove that the effects of PKM2
on increasing cancer cell drug resistance act via integrin αvβ3, the integrins were exogenously expressed
in SW620 cells (Fig. 3A). The integrin expressing cells were treated by oxaliplatin in the presence and
absence of rPKM2 and in the presence of IgGPK or IgGCon. Clearly, cell apoptosis induced by the drug
became rPKM2-dependent (Fig. 3B). These experiments suggest that the secreted PKM2 mediates cancer cell apoptosis resistance via activation of integrin αvβ3.
Preceding experiments demonstrate that cancer cells secret PKM2 to feedback act on their cell
surface integrin molecules to promote survival. We next question whether the effects of the extracellular PKM2 would also be true in vivo with animal models of cancer. To this end, we employed xenograft
of SK-MEL-28 melanoma cells. As demonstrated early SK-MEL-28 cells express high levels of integrin
αvβ3. The cells also secret relative high levels of PKM2 to culture medium. We first examined whether
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PKM2 was secreted to blood circulation of xenograft mouse. The tumors were implanted. Blood samples
from tumor-bearing animals were collected. Analyses of serum samples indicated that PKM2 levels were
high (Fig. 4A). We then carried out the treatments with oxaliplatin, ABPK, and oxaliplatin + ABPK. As our
previous observations, ABPK alone had marginal effects in inhibition of tumor growth, likely due to inhibition of tumor angiogenesis, while oxaliplatin had almost no effects. Interestingly, combination of ABPK
and oxaliplatin had much strong effects in inhibiting tumor growth (two tumors regretted in size) (Fig. 4
B, C, D). The experiments indicate that PKM2 secreted by the SK-MEL-28 tumor plays a role in drug resistance.
We asked what the molecular mechanism by which extracellular PKM2 mediated cancer cells resistance to apoptosis induction was. We first examined whether the extracellular PKM2 activated the
integrin signaling. Thus, we analyzed the activation of FAK upon addition of rPKM2 to the culture medium of SK-MEL-28 cells. Immunoblot of S397 phosphorylated FAK in the cell extracts indicated that addition of rPKM2 into culture medium strongly activated FAK, and addition of rPKM1 could not lead to the
FAK activation. Addition of rPKM2 into culture medium of cells without integrin αvβ3 expression (SW620)
did not result in FAK activation (Fig. 5A). It is well established that activation of integrin αvβ3 signaling
consequently leads to several survival signal activations. Typical examples are activation of AKT and ERK
kinases. We therefore examined whether presence of extracellular PKM2 would lead to activation of
AKT and/or ERK inside of cells. We still employed SW620 and SK-MEL-28 cells. Addition of rPKM2 into
the culture medium of SK-MEL-28 cells led elevation of phosphorylated/activated AKT, while the effects
were not observed with SW620 cells (Fig. 5B). The results suggest that extracellular PKM2 mediates cancer cell apoptosis resistance by activation of AKT signaling pathway. To verify indeed AKT pathway mediated the effects of extracellular PKM2, we used a commercially available AKT inhibitor triciribine. Evidently, in the presence of AKT inhibitor, the effects of PKM2 in promoting SK-MEL-28 apoptosis resistance were abrogated (Fig. 6).
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3.4

Discussion
Cancer cells actively secret PKM2 into extracellular space and patient blood circulation. Meas-

urements of the secreted PKM2 have been suggested as an important marker for cancer diagnosis and
prognosis. Several studies have revealed that serum PKM2 levels have a close correlation with cancer
drug resistance. On the other hand, a number of studies revealed that knockdown of PKM2 expression
abrogate cancer cell apoptosis resistance. Expression of PKM2 in cancer cells is shown to be associated
with cell survival. All these studies suggested a functional role of intracellular/extracellular PKM2 in
promoting cancer cell survival. Consistently, our study demonstrated that extracellular PKM2 promotes
cancer cell apoptosis resistance, thus confer the cancer cells drug resistance. Apparently, sequestration
of the function of extracellular PKM2 in mediating cancer survival may represent a new target to develop anti-cancer treatment. Clearly, our experiments with PKM2 antibody treatment provided proof of
concept showing that antibody that neutralize the function of extracellular PKM2 sensitize cancer cells
to apoptosis induction. A very important potential advantage of application of the PKM2 antibody in
treatment is that the levels of circulative PKM2 would be a prognosis marker to predict the possible outcomes. Since secretion of PKM2 is relatively disease associated, it would also be expected that the effects of the PKM2 antibody would be more cancer specific. We tested the effects of PKM2 antibody and
rPKM2 in combination with oxaliplatin in this study. It will be interested to examine a number of other
anti-cancer drugs to see whether the PKM2 antibody have effects to enhance the apoptosis induction by
other anti-cancer drugs.
Our experiments showed that the effects of PKM2 and the PKM2 antibody are integrin αvβ3 pair
expression dependent. The extracellular PKM2 mediates apoptosis resistance by activation of integrin
αvβ3 signaling, subsequently activation of Akt survival signal. It is well known established that cancer
cells very frequently express this pair of integrin, and activation of integrin αvβ3 signaling is one of major
mechanisms by which cancer cells promote survival under various stress conditions. Integrin activation
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involves the engagement of the integrin receptor with the specific type of ECM molecule, which signaling the attachment of cancer cells to ECM. Apparently, PKM2 does not belong to any ECM families, the
extracellular PKM2 more acts like a soluble molecule. It is intriguing how the extracellular PKM2 is able
to activate the integrin signaling. Answers to this question will certainly require a comprehensive understanding the interaction between PKM2 and the integrin αvβ3, including binding site and binding mode.
Another interesting issue is how the PKM2, a glycolytic enzyme, secreted to extracellular space,
and whether cancer cells are the only cell types that secret PKM2. An inhibition of conventional exocytosis process did not prevent secretion of PKM2 to extracellular space, while a number of studies indicated that PKM2 exist in the exosome of several different cell types. These observations suggest that
PKM2 may be secreted by non-canonical pathways that response to the stress conditions, such as hypoxia and apoptosis induction agent treatment. We observed that hypoxia conditions promote the
PKM2 secretion (data not shown), which support this speculation.
3.5
3.5.1

Materials and Methods
Cells, reagents, and antibodies
Human melanoma cells SK-MEL-28 and colon cancer cells SW620 were from ATCC, and were cul-

tured by following vendor’s instruction. Oxaliplatin, MTT formazan, and triciribine were purchased from
Sigma-Aldrich and Millipore respectively. Antibodies against Akt, phospho-Akt, Erk 1/2, phospho-Er 1/2,
FAK, phosphor-FAK, integrin αv, integrin β3, and GAPDH were purchased from Cell Signaling and Abcam.
Rabbit monoclonal antibody against PKM2 was generated by Epitomic-Abcam.

102
3.5.2

Plasmids for integrins and transient transfection
The cDNA encoded integrin αv and β3 were purchased from Addgen and cloned into pEF1 and

pcDNA3.1 vectors for integrin overexpression in mammalian cells. The DNAs were verified by DNA
autosequencing.
SW620 cells were seeded 60 mm cell culture dishes and cells were transfected at 60-70% confluence. Briefly, 3 µg of each integrin αv and β3 plasmids and 10 µL Lipofectamine 2000 was mixed in
100 µL Opti-MEM at room temperature for 20min. Then Opti-MEM containing plasmid and
Lipofectamine 2000 were added to SW620 cell culture. The cells were transfected for 24 hours and then
trypsinized and reseeded into 96 well plates for future analyses.
3.5.3

Cell viability and TUNEL assays
After cells were treated, 20 µL of 5mg/mL MTT reagent was added to each well of 96 well plates.

Cells were continuously cultured for 2-4 hours. Culture medium containing MTT reagent was removed
and cells were rinsed with PBS twice. 100 µL DMSO was added to each well to dissolve MTT crystals and
then absorbance was measure at 570nm using spectrophotometer.
SK-MEL-28 cells were seeded on glass coverslips in 6 well plates. After treatment, culture medium was discarded and cells were washed with TUNEL equilibration buffer (from Biotium) for 5min. 1 µL
TdT enzyme diluted to 50 µL TUNEL reaction buffer was added on to each coverslip. The coverlips were
incubated at 37°C for 60min, followed by twice washes with TPBS (0.1% Triton X-100 in PBS). Coverslips
were mounted with anti-fade mounting medium containing DAPI for further fluorescence microscopy
analysis (excitation/emission: 593/614nm).
3.5.4

Mice xenografts and treatments
All animal experiments were carried out in accordance with the guidelines of IACUC of Georgia

State University. Nude mice were subcutaneously injected with 5 × 106 of SK-MEL-28 cells. Tumor for-
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mation and volumes were assessed every 2 days. Tumor volumes were measured by two perpendicular
diameters of the tumors with the formula 4π/3 × (width/2)2 × (length/2). The tumor bearing mice were
subjected to the i.p. injections of appropriate agents at appropriate time intervals. The treatments
started five days post tumor inoculations. The tumors were collected and weighed at the end of the experiments. Statistical analyses were done in comparison to the control group with Student’s t test.
3.6
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Figure 3-1 integrin expression and PKM2 secretion in SK-MEL-28 and SW620 cells.
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α
Integrin

(Left panel) Expression of integrins αvβ3 in indicated cancer cells were examined by immunoblot of cell

GAPDH
GAPDH

extracts using antibodies against integrin αv (IB: integrin α) and integrin β3 (IB: integrin β). (Right panel)
The levels of PKM2 in medium (CM) of the indicated cancer cells were analyzed by immunoblot of PKM2
(IB: PKM2). Immunoblot of GAPDH (IB: Actin) in whole sell lysate is loading controls.
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Figure 3-1B Cell viabilities of SW620 and SK-MEL-28 treated by oxaliplatin.
Cell viabilities of SK-MEL-28 (Upper) and SW620 (Bottom) cells under the indicated concentration of
oxaliplatin treatments were measured by MTT assays. The viabilities were expressed as percent of viability by defining the cells treated with buffer as 100%.
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Figure 3-2 Effects of extracellular PKM2 on the cell viability and apoptosis.
Cell viability of SK-Mel-28 and SW620 cells under treatments of oxaliplatin (20 µM) and in the presence
of antibody against PKM2 (OXA+IgGPK) or control rabbit IgG (OXA+IgGCon). The viabilities were expressed as percent of viability by defining the cells treated with buffer as 100%.
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Figure 3-2B Effects of extracellular PKM2 on the cell viability.
Cell viability of SK-Mel-28 and SW620 cells under treatments of oxaliplatin (20 µM) and in the presence
of either rPKM2 (OXA + hrPKM2) or rPKM1 (OXA+ hrPKM1), were measured by MTT assays. The viabilities were expressed as percent of viability by defining the cells treated with buffer as 100%.
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Figure 3-2C PKM2 antibody induces oxaliplatin sensitivity of SK-MEL-28 cell sensitivity.
(Upper) Apoptosis of SW620 cells under the indicated treatments was measured by TUNEL assays. The
cell apoptosis is presented as % cell apoptosis by defining the apoptosis of buffer treated cells as 1%.
(Bottom) Representative cell images of the TUNEL assays. Red is Terminal Transferase (TdT) stains. Blue
is DAPI stains.
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Figure 3-3 Apoptosis resistance mediated by extracellular PKM2 is integrin αvβ3 dependent.
Exogenous expression of integrin αv and integrin β3 in SW620 cells were analyzed by immunoblot of the
cell extracts using antibodies against the integrins (IB: integrin αv, IB: integrin β3). Immunoblot of
GAPDH (IB: GAPDH) is a loading control.
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Figure 3-3B Apoptosis resistance mediated by extracellular PKM2 is integrins αvβ3 dependent.
Cell viability of SW620 cells with transient transfection of integrins αvβ3 or empty vector under treatments of oxaliplatin (20 µM) and in the presence of rhPKM1, rhPKM2, IgGCon and IgGPK; indicated
agents were measured by MTT assays. The viabilities were expressed as percent of viability by defining
the cells treated with buffer as 100%.
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Figure 3-4 The effects of antibody against PKM2 on tumor drug treatment.
The levels of PKM2 in the serum of mouse blood collected from tumor bearing nude mouse (SK-MEL-28)
and non-tumor nude mouse (Con) were examined by immunoblot of PKM2 (IB: PKM2). Coomassie stain
(CBS: M-Albumin) of serum albumin is a loading control.
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Figure 3-4 Effects of antibody against PKM2 on tumor drug treatment.
Growth of SK-MEL-28 tumor under the indicated treatments (Buffer, oxaliplatin – OXA, the antibody
IgGPK – IgGPK, oxaliplatin plus IgGPK – OXA + IgGPK) was monitored by (C) endpoint pictures and (D)
endpoint weights of the harvested tumors with 10 days treatment (treatment started 5 days post tumor
inoculation). The p values were calculated by One-way ANOVAs analysis of variance.

115

SK-MEL-28

SW620

NT PKM2 PKM1 NT PKM2 PKM1
IB:

FAK

p-FAK 397
Figure 3-5 Extracellular PKM2 activates FAK via integrin αvβ3.
Activation of FAK in SK-MEL-28 and SW620 cells was analyzed by immunoblot of the cell extracts using
antibody against S-397 phosphorylated FAK (IB: p-FAK). The cells were treated by rPKM2 (PKM2), rPKM1
(PKM1), and buffer saline (NT). Immunoblot analyses of cellular FAK (IB: FAK) is a loading control indicating total cellular levels of FAK.
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Figure 3-5B Extracellular PKM2 activates Akt.
Activation of ERK1/2 and Akt in SK-Mel-28 and SW620 cells was analyzed by immunoblot of the cell extracts using antibodies against phosphorylated ERK1/2 (IB: p-ERK1/2) and phosphorylated Akt (IB:p-Akt).
The cells were treated by rPKM2 by indicated times. Immunoblot analyses of cellular ERK1/2 (IB:
ERK1/2) and Akt (IB: Akt) are loading controls indicating total cellular levels of ERK1/2 and Akt.
Immunoblot of GAPDH (IB: GAPDH) is a loading control.
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Figure 3-6 AKT inhibitor abolishes PKM2 induced oxaliplatin resistance.
Cell viability of SK-Mel-28 cells under treatments of oxaliplatin (20 µM) and in the presence of
Triciribine, rPKM2 or Triciribine+rPKM2. The viabilities were expressed as percent of viability by defining
the cells treated with buffer as 100%.
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4.1

Abstract
We previously reported synthesis of 1-[(5 or 6-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-

(hetero)arylpiperazine derivatives, and demonstrated that 1-(3,5-dimethoxyphenyl)-4-[(6-fluoro-2methoxyquinoxalin-3-yl)aminocarbonyl] piperazine (ref to as RX-5902). The synthesized compound exhibited strong activity in inhibition of the growth of human cancer cells with IC50 at around 20 nM [1]. In
present study, we show that RX-5902 interacts with p68 RNA helicase leading to disruption of the interaction of the Y593 phosphorylated p68 with β-catenin. Furthermore, treatment of cancer cells with RX5902 results in downregulation of genes that are known to be regulated by the phosphor-p68 and βcatenin interaction. Thus, our study indicates that interaction with p68 and/or phsopho-p68 may, at
least partially, contribute to the anti-cancer activity of our compound RX-5902.
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4.2

Introduction
A series of novel quinoxalinyl-piperazine compounds were synthesized and their effects in anti-

proliferation and apoptosis were examined [1, 2]. Among them, one representative compound (Ref to as
RX-5902) demonstrated very potent activities in inhibition of cancer cell growth and apoptosis induction,
with IC50 around 20 nM [1]. Pharmacokinetic analyses of this compound showed also optimal PK properties in rats [2]. These previous studies hold a strong promise for RX-5902 to be an orally available anticancer agent.
A number of heterocyclic N-substituted piperazine derivatives and other piperazine derivatives
are long known to have anti-viral activities and for treatment of nervous system disorders. Several anticancer compounds containing a quinoxaline ring have been reported as well [3-14]. Although there is a
report suggesting unsubstituted quinoxaline compounds containing piperazine exhibit microtubuleinhibiting activity [15, 16]. The molecular mechanism and cellular targets of anticancer activities are not
studied well and should be explored.
In previous studies, we have demonstrated that treatment of cancer cells with our synthesized
quinoxalinyl-piperazine derivative RX-5902 led to down-regulation of cellular levels of Bcl-2 and cell cycle arrest at G2/M phases to induce the cell death [1]. However, the molecular target(s) in the cells by
which RX-5902 exerts its effects leading to down-regulation of Bcl-2 and cell cycle arresting is not clear
yet.
The nuclear p68 RNA helicase belongs to prototypical DEAD box family. A number of studies
showed that the protein is involved in cancer progression and cell proliferation/survival. Experiments
from our laboratory demonstrate that p68 is phosphorylated at multiple amino acid residues.
Phosphorylations of p68 at tyrosine closely correlate with cancer progression. Specifically, phosphorylation of p68 at Y593 mediates the effects of growth factors in promoting epithelial-mysenchymaltransition (EMT). The phosphor-p68 also plays a critical role in up-regulating expression of snail 1, a gene
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product plays important role in EMT. These studies suggest that phosphor-p68 may have very important
function in tumor development and cancer progression and metastasis. Thus, the phosphor-p68 may
constitute an important target for development of anti-cancer therapies.
We report here that our synthesized compound RX-5902 interacts with p68 and/or phsopho-p68.
The interaction results in abrogation of the interaction between phsopho-p68 and β-catenin and inhibits
the β-catenin dependent ATPase activity of phsopho-p68 with no effects on p68 RNA-dependent ATPase
activity. Furthermore, cancer cells treated by the compound RX-5902 experienced down-regulation of
several proliferation-associated genes that are known to be regulated by p68-β-catenin interaction. Our
studies indicate that interaction between RX-5902 and p68 and/or phsopho-p68 may, at least partially,
contribute to the anti-tumor activity of the compound.
4.3

Results and discussion
We previously reported the synthesis of a series of quinoxalinyl-piperazine derivatives and eval-

uation the anti-cancer activities of the synthesized compounds. We asked what would be the cellular
target(s) of these compounds for their activities in inhibiting cell proliferation and inducing cell apoptosis. We employed the well established target identification method, called drug affinity responsive target stability (DARTS) method [17], to find target proteins that would interact with the compound RX5902 in which cells were treated with various concentration of RX-5902 (0, 0.1, 1, and 10 µM) and then
cell lysates were collected followed by treatment of thermolysin. The samples were run on SDS/PAGE
gel and stained with Coomassie blue staining solution. After comparison with control, the bands only
detected from thermolysin treated samples were excised and identified by protein mass spectrometry
sequencing. Several candidate proteins were found and they are verified by western blotting. From this
experiment, it was found that p68 degradation by thermolysin was protected in the RX-5902 treated
sample but not the control sample (Fig. 1), indicating that RX-5902 may interact p68 RNA helicase to ex-
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ert its effects in inducing cancer cell apoptosis. P68 RNA helicase is a prototypical member of DEAD box
family of RNA helicase. It was well documented that p68 RNA helicase expression and posttranslational
modifications play an important role in cancer progression and metastasis [18, 19]. Particularly,
phosphorylations of p68 have been shown to associate with cancer progression. Phosphorylation of p68
at Y593 facilitates cancer metastasis via promoting EMT [20]. Furthermore, phosphorylation of p68 at
Thr and Tyr residues confer cell apoptosis and survival via interaction with several important apoptosis
and proliferation regulators. Thus, we speculated that RX-5902 may target p68 and/or phospho-p68 to
exert its activity in inhibiting proliferation and/or inducing apoptosis.
Originally, p68 protein was shown to be an RNA-dependent ATPase and a helicase capable of
unwinding RNA [21]. As a helicase, p68 binds to both double- and single- stranded RNA, with greater
affinity to double-stranded RNA. Binding to RNA induces ATPase activity of p68 and results in unwinding
of RNA in both the 5’ to 3’ and 3’ to 5’ direction. Along with its helicase activity, p68 possesses an RNA
annealing activity and can catalyze the rearrangement of secondary structures in RNA. Using RNA as a
substrate, p68 possesses a variety of activities including ribosome biogenesis which requires rRNA remodeling, RNA splicing activity and processing of microRNA [22]. It has been postulated that the main
oncogenic functions of p68 are independent of their activity on RNA as a true RNA helicase. To determine the effects of the interaction of RX-5902 with p68 RNA helicase on the ATPase activity, we measured the ATPase activity of recombinant p68 in the presence of RX-5902 with addition of yeast total
RNAs. Evidently, RX-5902 was shown not to affect RNA-dependent ATPase activity of p68 (Fig. 2A).
It was demonstrated that interaction with β-catenin and microtubule also stimulates its ATPase
activity. We therefore reasoned whether interaction with RX-5902 would affect its β-catenin dependent
ATPase activity. To this end, recombinant His-p68 was first treated by RNase cocktail to remove any potential RNA contaminations. The treated His-p68 was phosphorylated by c-Abl kinase. The phosphorylated p68 was then mixed with RX-5902 and a commercially available recombinant β-catenin and then
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ATPase activity was the measured. It was evident that the β-catenin dependent ATPase activity of phosphor-p68 was largely diminished in the presence of RX-5902 (Fig. 2B) with IC50 61 nM, indicating that
RX-5902 potentially disrupted phospho-p68/β-catenin interaction.
Phosphorylation of p68 at Y593 confers cancer cells for proliferation and survival. It was demonstrated that these important functions of the phospho-p68 was mediated by interacting with β-catenin
in cancer cells. We therefore sought to detect the effects of RX-5902 on p68/ β-catenin interaction. We
carried out co-immunoprecipitation experiments with cell extracts prepared from the cells that were
treated or untreated by RX-5902 using antibody against p68 or antibody against β-catenin. The
immunoprecipitates were analyzed by immunoblot. Clearly, co-precipitation of p68 with β-catenin was
largely reduced upon the treatment by the compound RX-5902 (Fig. 3A). The reduction in p68/ βcatenin co-immunoprecipitation was confirmed by using both anti-p68 and anti-β-catenin as IP antibody. This result is consistent with the observation that RX-5902 strongly inhibited the β-catenin dependent ATPase activity of phosphor-p68 as shown in Fig 2B. (Please add more explanation on Fig 3,
especially 3B).
Since RX-5902 disrupted p68 and/or phosphor-p68 and β-catenin interaction, we therefore
questioned whether treatment of cells with the compound RX-5902 would affect the regulatory effects
of p68 (and/or phosphor-p68)/β-catenin interaction in regulating several growth associated gene expression. It was reported that phosphor-p68 and β-catenin interaction plays a role in expression of cyclin
D1 and c-myc, and also affects activation of c-jun MAP kinase activation. Thus, we analyzed expression
of cyclin D1 and c-myc expression, as well as phosphorylation of c-jun in cells that were treated by RX5902. We used MDA-MB-231 and SK-MEL-28 cells here as we found that the compound was more effective in apoptosis induction these two cell lines. We also used a normal fetal lung fibroblast cell line (WI38) as control. It was evident that RX-5902 treatment led to decrease in expression of both cyclin D1 and
c-myc and decrease in c-jun phosphorylation in MDA-MB-231 and SK-MEL-28 cells, while the treatment
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did not resulted in any significant change in cyclin D1/c-myc expressions and c-jun phosphorylation in
WI-38 cells (Fig. 4). The results clearly suggested that the effects of the phosphor-p68 and β-catenin interaction on expression of several proliferation and survival related genes were suppressed by the compound RX-5902.
We have developed several novel quinoxalinyl-piperazine derivative compounds and demonstrated high potency of anti-cancer activities in vitro. In present study, we provide evidence that one
representative compound RX-5902 interacting with p68 (and/or phosphor-p68) RNA helicase. Our study
revealed that RX-5902 interacted with p68 to disrupt the interaction of the phosphor-p68 with βcatenin, which consequently affected the functional role of this critical protein-protein interaction in
regulating the expression of several important proliferation and survival associated genes. Although, our
study may not pinpoint to the target of the anti-cancer activity of RX-5902 to the phosphor-p68/βcatenin interaction, our results demonstrated that p68/β-catenin interaction, at least, constitute partially
Due to important biological functions of many protein-protein interactions (PPI) in almost all
physiological and pathological processes, development of molecules that would disrupt these disease
causative PPIs has emerged as an important approach to develop therapeutics for many diseases. One
potential advantage of targeting specific disease related PPI is that the targeting can achieve highly disease specific effects. Phosphorylation of p68 at tyrosine residues has been shown to be closely associated with cancer progression and metastasis. Interaction between the phosphorylated p68 and β-catenin
plays a role in cancer cell proliferation and survival. This interaction does not exist in normal cells and in
normal physiological processes. Thus, this PPI should be an excellent target for develop cancer therapies. Certainly, our study sets an example for further development of molecules that would be effectively in disrupting the phosphor-p68/β-catenin interaction. How does RX-5902 interact with p68 is an open
question. Our results showed that the compound did not affect the RNA dependent ATPase activity, but
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affected the β-catenin dependent ATPase activity of phosphor-p68, indicating that RX-5902 likely interact with p68 (and/or phosphor-p68) at C-terminal. This is also consistent with previous observations that
translational modifications at the C-terminal of p68 mediate pro-growth and anti-apoptosis functions of
this RNA helicase. Thus, it would be interested to test whether the compound also interfere with the
functional role(s) of other C-terminal modifications of p68 RNA helicase.
4.4
4.4.1

Materials and Methods
Cell Culture and antibodies
SW620, MDA-MB-231, SK-MEL-28, WM266, and WI-38 cells were obtained from ATCC (Manas-

sas, VA, USA) and were cultured according to vendor’s instruction. Antibodies against p68 were raised
against bacterially expressed His-tagged C-terminal domain (amino acid 437-614) of human p68 (Invitrogen, Carlsbad, CA, USA, Auburn University Hybridoma Facility). Antibodies against β-actin, phosphotyrosine (p-tyr-100), β-catenin, cyclin D1, p-c-jun, c-myc, were purchased from Santa Cruz, BD Bioscience, and Roche Applied Science respectively. Recombinant β-catenin was purchased from abcam and
used without further treatment.
Compound RX-5902 was dissolved in DMSO to prepare a stock solution of 2 mM. The stock solution was stored at -20°C and diluted with medium to prepare working concentrations. The cDNA of p68
ORF was subcloned into pHM6 vector (Roche) at HindIII site to get HA-tagged p68 expression vector. The
various p68 single and double threonine mutants (threonine replaced by alanine) were generated by
Quick-Change site-directed mutagenesis kit (Stratagene) and the mutations were confirmed by DNA sequencing. P38α cDNA (Origene) was subcloned into p3XFLAG-myc-CMV™-24 Expression Vector (Sigma).
A number of mutations to get the constitutively active form of p38 were done using the reference [39].
All DNA transfections were performed using fugene HD (Roche) and lipofectamine 2000 (Invitrogen)
while siRNA transfections were done with lipofectamine RNAimax (Invitrogen). The duplex siRNA against
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p68 was purchased from Dharmacon and the sequence was as follows: siRNA oligonucleotides against
p68 (sense: GCAAGUAGCUGCUGAAUAUUU; antisense: 50-PAUAUUCAGCAGCUACUUGCUU). Cells were
transfected with the indicated plasmids 24 hrs after p68 siRNA knockdown and treated with the drug
after further 24 hrs. The cells were then harvested for nuclear extract preparation using a kit from Active
motif.
4.4.2

Protein Expression & Purification and in vitro phosphorylation
The procedure used to express and purify p68 is similar to the procedure reported previously.

P68 ORF cloned and various mutants cloned into expression vector pET-30a+ using the restriction sites
BamHI/HindIII and transformed into E.coli BL21-CodonPlus bacteria (Stratagene) were used to express
protein. The bacteria were subcultured in fresh LB broth till OD reached between 0.5 to 0.8 units at
600nm and then subsequently induced with 0.5mM IPTG for 18 hrs at 16°C. The cells were harvested,
washed with 1 x PBS buffer, pelleted and stored at -80°C. The cells were then disrupted by one freezethaw cycle at -80°C, resuspended in lysis buffer (50mM Tris-HCl pH 8.0, 300mM NaCl, 1mM DTT, 10mM
PMSF, 10% glycerol) and subjected to lysozyme (0.5mg/ml) digestion. DTT and PMSF were also added at
1mM final concentration. The cells were further subjected to ultrasonication and pelleted. After centrifugation, the expressed protein was found to be precipitated in the bacterial inclusion bodies (IB). The IB
were dissolved in denaturing buffer containing 8M urea, 50mM Tris-HCl pH 8.0, 250mM NaCl and 0.2%
Triton-100. The lysate was passed through Ni-NTA column for purification of recombinant protein by
affinity separation and the column was washed with the denaturing wash buffer (8M urea, 50mM TrisHCl pH 8.0, 250mM NaCl, 0.2% Triton-100 and 20mM imidazole pH 8.0). The protein was finally eluted
with elution buffer containing 250mM Imidazole, 8M urea, 50mM Tris-HCl pH 8.0, 250mM NaCl, 0.2%
Triton-100, 0.5mM DTT and 10% glycerol. The eluted protein solution was refolded using stepwise dialysis procedure (8M→ 6M→ 4M→ 2M→ 0M) to remove urea using refolding buffer (200 mM arginine,
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50mM Tris-HCl pH 8.0, 250mM NaCl, 0.2% Triton-100, 0.5mM DTT and 10% glycerol) and preserved in
further 15 to 20% glycerol.
Phosphorylation of recombinant His-p68 by v-Abl was carried out by the procedure similar to
our previous description. Briefly, the recombinant p68 RNA helicase was first dephosphorylated by protein tyrosine phosphatase 1B (PTP1B, Calbiochem). Approximately 5 µg of protein was incubated with 4
units of the phosphatase in manufacture suggested buffer conditions in total volume of 50 µl at 30°C for
90 minutes. The reactions were either directly used for ATPase assays/western blots or used for rephosphorylation. Protein phosphatase inhibitor set vanadium was added to the above
dephosphorylation reactions. Protein kinase, v-Abl kinase, was added to the reaction mixture. ATP was
added to a final concentration of 2 mM. The phosphorylation reactions were further incubated at 30°C
for 90 minutes. The re-phosphorylated proteins were re-purified by Ni-NTA column.
4.4.3

Identification of RX-5902 binding proteins by DARTS method
MDA-MB-231 cells were plated onto 6 well plates and treated with RX-5902 at various concen-

trations (0, 0.1, 1 and 10 µM) for one hour and cells were lysed with p-MER buffer containing protease/phosphatase inhibitors on ice. Cell lysates were treated with thermolysin (1:15 ratio) for 10 min at
RT and stopped the reaction with adding 0.5 M EDTA solution. The reaction mixtures were loaded and
separated onto 10% SDS-PAGE gel and visualized by Coomassie staining. The bands were picked and
sliced out for the Mass spectroscopy analysis. After identifying several candidate proteins from mass
spectrometry sequencing analysis, we confirmed the protein which may interact with RX-5902 by western blot analysis.
4.4.4

ATPase Assay
ATPase activities were determined by measuring the released inorganic phosphate during ATP

hydrolysis using a direct colorimetric assay. The method is based on the change in absorbance (A623nm)
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of malachitegreen-molybdenum complex in the presence and absence of inorganic phosphate. A typical
ATPase assay was carried out in 50 µl reaction volumes, containing 20 mM Tris-HCl pH = 7.5, 200 mM
NaCl, 1 mM MgCl2, 5 mM DTT, ~1-2 µg of appropriate substrate, 4 mM ATP, and 10 µl of helicase. The
ATPase reactions were incubated at 37oC for 30 minutes. After incubation, 1 ml of malachitegreenmolybdenum reagent was added to the reaction mixture, and reactions were further incubated at room
temperature for exactly 5 minutes. The absorbance (A) at 630nm was then measured. The concentrations of inorganic phosphate were determined by matching the A630nm in a standard curve of A630nm
vs. known phosphate concentrations.
Cell viability of indicated cells was measured using MTT (3-[4,5-dimethylthiazol-2-yl]-2,5diphenyl tetrazolium bromide) (Sigma). 4000 Cells were seeded per well of 96 well plate 24 hrs before
knockdown and transfection of p68 and the mutants. Subsequently, 24 hrs after transfection, the cells
were treated with oxaliplatin for 24 hrs. Next day, reconstituted MTT reagent was added in an amount
equal to 10% of the culture medium volume and the cells were incubated at 37°C for a further 4 hrs. The
formazan crystals were dissolved by adding MTT solubilization solution. Cell viability was measured
spectrophotometrically by reading the absorbance at a wavelength of 570 nm.
Cells plated on 6 well plates were treated with indicated drugs. The activity of caspase-3 was
measured using caspase-3/CPP32 colorimetric assay kit (Biovision Research products). Briefly, after
apoptosis induction, the cells were resuspended in Cell Lysis Buffer for 10 mins and centrifuged. 50 μg of
proteins were diluted in Cell Lysis Buffer to which 2 x reaction buffer and 4 mM DEVD-pNA substrate
were added and incubated at 37°C. The samples were read at 405 nm using a microtiter plate reader.
Alternatively, apoptosis was measured using FITC Annexin V Apoptosis Detection Kit (BD Biosciences).
Briefly, the cells were washed twice with cold 1 x PBS after treatment and resuspended in 1 x Annexin
Binding Buffer at a final concentration of 1 x 106 cells/ml. To 1 x 105 cells (100 μl) in a 5ml FACS tube, 5 μl
of FITC Annexin V and 5 μl of PI were added, gently vortexed and incubated at room temperature for 15
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mins in the dark. Finally, 400μl of 1 x Annexin Binding Buffer was added and the samples were analyzed
by flow cytometry within 1hr.
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Figure 4-1 RX-5902 interacts with p68 RNA helicase.

MDA-MB-231 cells were treated with RX5902 at various concentrations (0, 0.1, 1, and 10 µM) for an
hour and cell lysates were collected followed by treatment of thermolysin for 10 min. The reaction mixtures were loaded and separated onto SDS-PAGE gel and probed with anti-p68 antibody.
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Figure 4-2 Effects of RX-5902 on ATPase activity of p68:
ATPase activity of p68 was measured in the presence of 2 µg yeast total RNA, ATP, and recombinant p68
RNA helicase, in the presence or absence of RX-5902 at the indicated concentrations. The ATPase activity is presented as µmol of released inorganic phosphate from ATP hydrolysis. (B) ATPase activity was
measured in the presence of 1 µg β-catenin, 2 mM ATP, and 1 µg of recombinant phospho-p68 RNA helicase, in the presence or absence of indicated concentrations of RX-5902. The ATPase activity is presented as percentage of inhibition by defining the ATPase activity of phospho-p68 without RX-5902 as zero
percent inhibition and 100% in the presence of 200 µM of RX-5902. The ATPase activity is defined as µM
of released inorganic phosphate from ATP hydrolysis.
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Figure 4-3 RX-5902 abrogates the p68 and β-catenin interaction.
(A) Interaction of p68 with β-catenin in cell lysate of SW620 (left) and WM266 (right) cells were probed
by co-immunoprecipitation using antibody against β-catenin (IP: β-catenin) as pull-down antibody. The
co-immunoprecipitates were analyzed by immunoblot using antibody against p68 (IB: p68). Immunoblot
of β-catenin in the co-immunoprecipitates (IB: β-catenin) are loading controls indicating the amounts of
β-catenin pulled-down by the co-immunoprecipitation. (B) Interaction of p68 with β-catenin in cell lysate of cells that derived from patient with metastatic colorectal adenocarcinoma or malignant melanoma cells were probed by co-immunoprecipitation using antibody against β-catenin (IP: β-catenin) as
pull-down antibody. The co-immunoprecipitates were analyzed by immunoblot using antibody against
p68 (IB: p68). The cells were treated (+) /untreated (-) by 2 µM of RX-5902 for 24 hours before preparation of cell lysates.
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Figure 4-4 Effects of RX-5902 on expression downstream genes of p68 – β-catenin.
Phosphorylation of p68 RNA helicase was analyzed by western blot of cell extracts of indicated cells using an antibody against Y593 phosphor-p68 (IB: P-Tyr-p68). Expression and activation of multiple genes,
cyclin D1, C-myc, and c-Jun, that are regulated by p68-β-catein interaction were analyzed by
immunoblot using antibodies against indicated proteins (IB:cyclin D1, IB:c-p-jun, and IB:c-myc). The cells
were treated by indicated concentrations of RX-5902. Immunoblots of total p68 (IB: p68) in the cell lysates indicate the cellular levels of p68. Immunoblot of β-actin (IB:actin) is a load control.
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CHAPTER 5
5.1

CONCLUSION AND DISCUSSION

PKM2 is a multi-functional protein
Pyruvate kinase has been studied for decades in cell metabolism. Non-proliferative cells or differen-

tiated tissues produce energy to support common cellular functions by oxidative phosphorylation. Glucose is metabolized to pyruvate and further oxidized to CO2 and generate great amount of ATP. The metabolism is different in highly proliferative cells and cancer cells. Tissues with high proliferation rate produce huge amounts of lactate or ethanol at low oxygen concentration. Cancer cells produce lactate and
ethanol even with oxygen supply. This is Warburg effect. It has been reported that altered glycolysis dictates Warburg effect. Pyruvate kinase M2 expression (PKM2) is regulated by HIF1 (Selak, Armour et al.
2005) and c-Myc (David, Chen et al. 2010). PKM2 functions differently to PKM1 due to its low enzymatic
activity, which results in the accumulation of metabolic intermediates at the last step of glycolysis.
Those intermediates are required for cancer cells rapid cell division. Pyruvate Kinase is one of the key
enzymes for cancer cells to manipulate metabolism.
Furthermore, PKM2 has recently been highlighted for its gene transcription activity. Dr. Gao from
our lab has reported that PKM2 regulates MEK5 gene transcription by phosphorylating transcription factor STAT3. PKM2 functions as a novel protein kinase and phosphorylates STAT3 at Y705 residue (Gao,
Wang et al. 2012; Gao, Wang et al. 2013). Earlier studies also reported that PKM2 interacts with transcription factor Oct-4 and enhances Oct-4 activated gene transcription (Lee, Kim et al. 2008). Dr. Zhimin
Lu’s group and our unpublished data both indicated that PKM2 regulates gene transcription by phosphorylating histone and switches on cancer promoting genes.
In order to regulate gene transcription, PKM2 translocates into nucleus to interact with transcription
factor directly. Glycolysis occurs in the cytosol and PKM2 was reported to translocate to nucleus in different studies. PKM2 K399E mutation (K399E mutation promotes PKM2 formation of dimer confor-
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mation) increases the nuclear presence of PKM2 to regulate MEK5 gene transcription (Gao, Wang et al.
2012). ERK2 is phosphorylated by EGFR and ERK2 activation phosphorylates PKM2 at Serine 37 and further exposes NLS in PKM2. PKM2 is imported to nucleus by interacting with importin α5 (Yang, Zheng et
al. 2012). PKM2 nuclear localization provides the prerequisite for PKM2 in regulating gene transcription.
PKM2 was also reported to localize in extracellular spaces. PKM2 was detected in patients’ blood serum or other body fluids in many types of cancers. Commercially available sandwich ELISA kit for serum
or feces PKM2 is currently used in diagnose of colorectal, gastric, lung, breast and pancreatic cancers
(Goonetilleke, Mason et al. 2007; Kumar, Tapuria et al. 2007). Fecal PKM2 was also considered as a predictor for bowel inflammation diseases (Day, Judd et al. 2012). PKM2 released from cancer cells was
firstly considered to be due to the high turnover rate of cancer cells. However, recent studies indicated
that PKM2 might be involved in physiological or pathological processes: PKM2 is actively secreted from
cultured cancer cell (Wu, Chen et al. 2008) and secreted PKM2 correlates with 5-FU (5-ﬂuorouracil) resistance (Shin, Yoo et al. 2009). Another study indicated that PKM2 interacts with TEM8 (Tumor endothelial cell marker 8) in vitro (Duan, Hu et al. 2007). All the studies above suggested potential physiological or pathological roles of extracellular PKM2.
5.2

PKM2 regulates tumor growth in vivo by promoting angiogenesis
Since PKM2 is secreted to the cell culture medium, we then studied physiological or pathological

relevance of circulating PKM2 in mice model. Serum PKM2 concentration was dramatically increased in
mice with SW620 tumors comparing to the mice without tumors. SW620 tumor bearing mice were then
administered with either anti-PKM2 antibody, IgGPK or control antibody, IgGCon. Our result indicated
that the neutralization of PKM2 by antibody in mice blood led to decreased tumor sizes. It suggested
that the existence of PKM2 secreted by cancer cells promotes tumor growth in vivo. Numerous studies
have reported that PKM2 serves as a diagnostic biomarker for various types of cancers. Our study sug-
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gested that neutralization of PKM2 in circulation by anti-PKM2 antibody could also be a promising therapeutic strategy for cancer.
In order to further confirm that PKM2 is involved in tumor growth in vivo, I administered recombinant human PKM2 (rhPKM2) to mice with SW620 tumor. Mice tumor size and weight measurements have shown that rhPKM2 promoted SW620 tumor growth compared with recombinant human
PKM1 (rhPKM1) and saline control. Therefore, I have confirmed that PKM2 concentration is highly related to SW620 tumorigenesis in nude mice model. PKM2, but not PKM1 promoted tumor growth. This is
either due to the 23 amino acids difference in amino acid sequences or due to the structural difference
regarding to dimer and tetramer conformations. I am going to discuss this issue in the late section.
Is the effect of PKM2 on tumor growth a universal mechanism or is it tumor type specific? To
address this question, mice model with s.c. prostate cancer PC-3 tumor was employed. This result indicated that PKM2 also promoted PC-3 tumor growth. However it seems that PKM2 has a stronger effect
in promoting tumor growth in SW620 tumor than that in PC-3 tumor. This is likely due to that VEGF (vascular endothelial growth factor) is a dominant angiogenesis regulator in promoting PC3 tumor growth.
Though SW620 and PC3 tumors are both highly vascularized (Gardner, Kelly et al. 2012), VEGF singling is
essential in PC-3 tumor angiogenesis (Schulman, Davis et al. 1987) and inhibition of VEGFR kinase activity completely eliminated PC-3 tumor angiogenesis but only partially inhibited SW620 tumor angiogenesis. This implies that PKM2 might play more crucial role in less VEGF dependent tumor such as SW620
(Dev, Dornsife et al. 2004). This data also suggested that PKM2 could also serve as a complementary target for treating VEGF-dependent cancers. We are going to test it by administering either Avastin along
or Avastin with anti-PKM2 antibody in PC3 tumor bearing mice. Avastin (Bevacizumab) is a FDA approved anti-cancer therapeutic drug for blocking VEGF.
By finishing animal experiments, we drew a conclusion that PKM2 regulates tumor growth in vivo and this regulation is involved in a common mechanism in different types of cancers. We then stud-
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ied how PKM2 regulates tumor growth. Our original hypothesis is that PKM2 promotes tumor growth
directly. We firstly analyzed SW620 frozen tumor sections. Ki67 staining has shown a relatively higher
proliferation rate of SW620 cancer treated with rhPKM2 compared to saline group. Then, we applied
rhPKM2 and anti-PKM2 antibody to cultured SW620 cells and tested cell proliferation. However, our
results indicated that rhPKM2 did not significantly promote SW620 and PC-3 cell proliferation in vitro.
Therefore, we concluded that PKM2 does not promote cancer cells growth directly. We then modified
our hypothesis to test whether rhPKM2 affects tumor angiogenesis and further facilitates tumor growth.
CD31 immunofluorescence staining result suggested a potential role of PKM2 in angiogenesis. Mice administered with rhPKM2 have substantially higher MVD (Microvessel Density) and vessel length. Mice
contain less MVD and vessel length in IgGPK treated group than those in IgGCon treated group. CD31
staining has also shown that PKM2 promoted tumor angiogenesis in PC-3 tumor model. In conclusion,
our data implied that PKM2 facilitates tumor growth by promoting tumor angiogenesis in vivo.
5.3

PKM2 promotes endothelial tube formation
We have discussed that PKM2 is involved in tumor angiogenesis in nude mice model. In order to

establish a direct relationship of PKM2 on angiogenesis, we performed in vitro angiogenesis assay. The
endothelial cell tube formation assay result indicated that PKM2 does promote human umbilical vein
endothelial cell angiogenesis in vitro. We also tested tube formation assay on another endothelial cell
line: HMEC, Human Microvascular Endothelial Cell, generously gifted by Dr. Yuan Liu from out department. RhPKM2 significantly increases numbers of branch points and stabilizes tube structure of HMEC at
both high (2µM) and low (0.5µM) concentration. Then we also demonstrated that PKM2 secreted by
cancer cells promotes endothelial cell tube formation. In conclusion, PKM2 promotes angiogenesis in
vivo and in vitro. However, angiogenesis is a complicated process which is involved in endothelial cell
proliferation, migration and survival.
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5.4

PKM2 promotes endothelial cell proliferation, migration and survival
Angiogenesis is a complicated process, which includes endothelial cell migration, survival and prolif-

eration. Therefore, we first tested HUVEC cell proliferation and migration of HUVEC cells in vitro. Our
result indicated that rhPKM2 increased HUVECs cell proliferation up to 40% comparing to saline control
and rhPKM1. We also tested whether PKM2 has effects on endothelial cell adhesion on extracellular matrix proteins. Endothelial cells attach to ECM such as collagen, laminin and fibronectin in physiological
conditions. Therefore, we are interested in whether PKM2 promotes or inhibits endothelial cells binding
to ECM proteins. The data have shown that rhPKM2 facilitates HUVECs attach to ECM proteins, such as
fibronectin and vitronectin. However, if HUVECs were incubated for 2 hour or longer after preincubation with rhPKM2, no significant difference was observed in this situation. This suggests an earlyphase angiogenic role of PKM2. We think that rhPKM2 either shortens the time period for HUVECs attachment or rhPKM2 promotes HUVECs spreading and facilitating endothelial cells attach to ECM
strongly. After all, this phenomenon illustrated that rhPKM2 activates and stabilizes focal adhesion complexes. This can also be interpreted as that PKM2 physiological or pathological role might be promoting
endothelial cell migration and proliferation, not adhesion. We thereafter tested whether HUVECs
spreads on the surface of coated collagen upon treatment of PKM2. The data have shown that HUVECs
treated with rhPKM2 possessed higher percentage of spreading cells than those treated with either
rhPKM1 or BSA.
Endothelial cell migration is one of the most important contributors to angiogenesis. In order to
demonstrate whether PKM2 regulates HUVEC migration, we employed Boyden Chamber assay to test
HUVEC cell migration. We tested endothelial cell migration with two different methods. Firstly, rhPKM2,
rhPKM1 or saline were incorporated to the cell culture medium in the upper chambers along with
HUVECs while cells were seeded. This result verified that existence of rhPKM2 in the culture medium
significantly promoted HUVECs migration. Interestingly, we also observed that PKM2 possesses some
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characteristic of ‘chemoattractants’, inducing endothelial cell to migrate towards PKM2. In order to test
this specific aim, rhPKM2, rhPKM1 or saline was mixed with medium in the bottom chambers of Boyden
Chamber. Migrated HUVECs are greater in numbers in PKM2 loaded chamber than PKM1 or BSA loaded
chambers. This strongly implied a novel concept that PKM2 secreted by the cancer cells could induce
endothelial cell to migrate towards cancer cells. This is consider to be crucial that cancer cells communicate with surrounding cells such as vascular endothelial cells or fibroblast cells in pathological cancer
scenarios. Further studies are needed to test this hypothesis.
Previously, I have discussed my result that PKM2 promotes endothelial cells to form more vascular
tubes (branch points). I also observed that endothelial vascular tubes only last 24-48 hours on Matrigel
in saline treated group, but the tubes sustain to 72 hours or even longer when treated with PKM2. This
suggests that PKM2 might enhance endothelial cell survival. Endothelial cell survival ability is an essential factor in early angiogenesis (Chavakis and Dimmeler 2002). At the early stage of angiogenesis, endothelial cells is devoid of the protection from extracellular matrix and surrounding smooth muscles as the
matured blood vessels have. PKM2 could activate endothelial cell survival signaling pathway and protect
endothelial cell from apoptosis.
Based on our results from the BrdU incorporation, ECM attachment assay and Boyden chamber assays, we have successfully demonstrated that PKM2 is sufficient to facilitate endothelial cell proliferation, migration and survival.
5.5

PKM2 interacts with Integrin family proteins
As we had found that PKM2 promotes endothelial cell proliferation, migration and survival, the next

question we asked is how PKM2 regulates proliferation, migration and survival. In order to address this
question, we tested whether PKM2 directly interacts with endothelial cells and what is the binding partner for PKM2 on the endothelial cell membrane.
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Our direct binding assay revealed that endothelial cells bind to rhPKM2, but not to rhPKM1 and BSA.
The binding activity of endothelial cells to PKM2 was able to be blocked by anti-integrin αvβ3 antibody
LM609, antibody 23C6 and anti-PKM2 antibody IgGPK, but not by other two integrin H-2 and Q20 antibodies. It is known that LM609 and 23C6 bind to ligand binding region of integrin αvβ3, but H-2 and Q20
do not. Thus, the blocking assay suggested that PKM2 binds to the region close to the active site of integrin αvβ3. Our speculation was also confirmed by competitive binding assay with RGD peptide,
Cilengitide. Cilengitide is small cyclic peptide with a sequence of RGDfV and it specifically inhibits RGD
dependent integrin binding to their ligands. HUVECs binding to PKM2 can be strongly inhibited by
Cilengitide. Therefore, we concluded that PKM2 interacts with endothelial cells through binding to integrin and this interaction is involved in integrin ligand binding site.
In order to further investigate the binding receptors for PKM2, we utilized SPR (Surface Plasmon
Resonance or Biacore) assay. CM5 chip was coated with Integrin αvβ3, α5β1 and α1β1 to three different
channels. Purified recombinant protein rhPKM1, rhPKM2 and BSA were flowed though the chip. The
normalized curves indicated that PKM2 binds to integrin αvβ3 and α5β1, but not integrin α1β1 (binding
to αvβ3 is stronger than that to α5β1). This is consistent with our antibody and peptide blocking assay
which I have described above. Biacore results also implied that rhPKM2 has higher affinity to integrin
than rhPKM1 or BSA does. This data provided strong evidence that PKM2 binds to integrin in vitro. Integrin family is a well-studied transmembrane receptor family which regulates cell adhesion and migration. After integrins bind to their ligands in extracellular matrix, integrins are activated by either conformational change (affinity) or integrin clustering (avidity).
Since PKM2 and integrin interaction is blocked by RGD peptide and αvβ3 integrin is a RGD dependent integrin, we speculated that PKM2 binds integrins through RGD sequence. RGD sequence is an amino acid sequence, Arg-Gly-Asp, which binds von Willebrand factor A domain on integrin β3 subunit.
Therefore, we started to search putative RGD on PKM2 protein sequence. We found one RGD sequence
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in PKM2, but this RGD sequence (294-296) is partially buried inside from analysis of PKM2 crystal structure. However, this RGD sequence still could be the binding region for integrins even it is not completely
assessable. It has been reported that proteins such as collagen and thrombin expose their RGD binding
sites after the cleavage by extracellular matrix proteases, MMP-2 or MMP-9 (Papaconstantinou, Carrell
et al. 2005). More importantly, PKM2 might undergo conformational change while converting from tetramers to dimers. RGD site is likely to be exposed during this conformational change. It is still possible
that PKM2 binds integrins through other sequences than RGD. Numerous studies have reported that
proteins containing no canonical RGD sequence bind to RGD dependent integrins. CCN1 (CYR1) is one
example. It binds integrins via a sequence NCKHQCTCIDGAVGCIPLCP (Chen, Leu et al. 2004), which does
not contain any RGD. It is also reported that RGD synergy binding site PHSRN sequence is able to activate fibronectin binding to RGD-dependent integrin αvβ3 and stimulate angiogenesis (Zeng, Yao et al.
2009). Within these 5 residues, Serine and Arginine are the most conservative residues and both mutations completely abolished the binding affinity of PHSRN peptide to integrins. Meanwhile, Serine mutated to Threonine or Tyrosine residue maintained the binding activity over 80% (Hattori, Hozumi et al.
2009). Interestingly, PKM2 contains a sequence similar to PHSRN: AVTRN, which could be another potential binding sequence to integrins. We are currently testing the integrin binding site on PKM2.
Duan et al has reported that PKM2 might interact with TEM8 (Tumor Endothelial Marker 8). To test
whether PKM2 interacts with TEM8, we expressed recombinant GST-TEM8 extracellular domain (ECD)
and performed GST pull-down assay. We did observe weak binding of PKM2 to TEM8 ECD. We also
overexpressed full length TEM8 in HEK 293 cells, which is reported to have basal expression level of
TEM8, but overexpression of TEM8 in HEK did not significantly enhance HEK cells binding to PKM2.
However it is noticed that TEM8 has structural similarity with integrins on their ligand binding site. The
MIDAS (metal ion-dependent adhesion site) motif in vWA domain in TEM8 is very similar to the I domain
in integrin β subunit. Magnesium is actively involved in the binding which is also supported by our exper-
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iment result: EDTA completely inhibits endothelial cell to attach to immobilized PKM2. This evidence
suggests the possibility that PKM2 could bind to vWA (I domain) located in integrins and TEM8. We did
not exclude that possibility that PKM2 could also interact with TEM8 in certain cells or circumstances.
We are going to isolate tumor endothelial cells to test whether PKM2 could regulate tumor endothelium
through TEM8 or not. We will further investigate PKM2 interacting proteins on the cell membrane in our
future studies by co-immunoprecipitating membrane proteins abstract and identifying candidate proteins by 2-D electrophoresis and mass spectrum.
5.6

How does PKM2 bind to integrins and activate integrins
Evidently, we speculated that PKM2 binds to the ligand binding site in integrin αvβ3. This is sup-

ported by the evidence that the interaction of integrin and PKM2 can be inhibited by RGD peptide or
LM609, an antibody binding to integrin αvβ3 ligand binding region. Further studies need to be done on
the detailed binding sequences. Several strategies can be employed: 1. Crystallography. Cocrystallization of PKM2 and integrin complex is the most straight-forward method. If PKM2 and integrins
are co-crystallized, we are able to identify the binding site locating on both PKM2 and integrins by structure analysis. However, certain technical difficulties have to be considered. Integrins are too large in size
to be expressed in bacteria. Mammalian expression of integrins is also hampered by low expression level
and inhomogeneous glycosylation. Crystallization condition needs to be explored as well. 2. Protein
cross-linking assay. After PKM2 forms complex with integrin αvβ3, chemical reagents can be employed
to covalently cross-link the protein complex. Cross-linked proteins are further digested with trypsin and
analyzed by LC-MS. Selection of cross-linker and optimizations of cross-linking parameters are most important for this method. 3. Electron microscopy. Conformational changes of integrins (close or open
form) can be visualized and differentiated by electron microscopy. Therefore, we are able to identify
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binding regions approximately and then carry out mutagenesis assay to further locate the binding sequences.
If it mimics the ligand binding, then PKM2 might induce the separation of c-terminus of α and β
subunits. If PKM2 does not bind to the ligand binding site, we need to further test how integrins respond
to PKM2 binding.
5.7

PKM2 binds integrins and activates integrin signaling pathways and cellular responses
I have described above that PKM2 binds to recombinant integrins and endogenous integrins on the

cytoplasm membrane of endothelial cells. We also demonstrated that PKM2 facilitates endothelial cell
adhesion, proliferation and migration. Therefore, we next tried to establish the linkage between protein
interaction and cellular responses. It is well known that immobilized extracellular matrix proteins bind
and activate integrins. Activated integrins initiate downstream pathways via FAK phosphorylation or ILK
phosphorylation. In my study, I am interested in whether PKM2 also activates integrin signaling. Western blot result showed that PKM2 induces FAK tyrosine 397 phosphorylation, which is an early event of
FAK activation. FAK activation is reversed by PKM2 antibody and LM609 the αvβ3 integrin specific antibody. This indicated that PKM2 and integrin interaction is required for FAK phosphorylation. FAK inhibitor I14 inhibited PKM2 induced FAK activation and blocked PKM2 induced cell adhesion. All the evidences suggested that integrins are the main receptors for PKM2 on endothelial cell membrane. We further
tested whether PKM2 is able to facilitate focal adhesion complex assembly. The data have shown that
integrin αvβ3 started clustering at the leading edge of HUVEC upon the treatment of PKM2 compared
with BSA and PKM1. We also demonstrated that PKM2 promotes vinculin recruiting to focal adhesion
complex and enhances actin stress fiber formation. Actin stress fiber formation and vinculin recruitment
both are the downstream events of FAK activation during cell migration and adhesion. In conclusion, we
have shown that PKM2 activates integrin αvβ3 and its intracellular signaling pathways.
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The classical role of integrins is to mediate attachment to ECM (extracellular matrix, immobilized ligand) or migration on ECM. Many studies have revealed that soluble ligands binding to the active site of
integrins inhibit cell adhesion and migration. In my dissertation, PKM2 is a soluble protein in culture medium or cancer patient blood. It is interesting why PKM2 promotes endothelial cells adhesion and migration instead of inhibition. A number of other studies have shown that soluble proteins are also able to
activate integrin and its downstream signaling pathway, such as TAT protein in HIV virus, CD40L, CD97
(Wang, Ward et al. 2005) and fibronectin. Cilengitide, a designed integrin inhibitor was originally considered to repress angiogenesis by inhibiting integrin, but was proved to activate integrins and potentially
promote angiogenesis instead (Alghisi, Ponsonnet et al. 2009).
How do soluble proteins induce endothelial cell adhesion or migration and further angiogenesis? We
are trying to understand how soluble proteins induce endothelial cell adhesion and migration. Firstly,
cell adhesion and migration is a complicated process in human body during physiological and pathological situation. Plenty of studies have reported that certain types of integrin overexpression results in deregulation of cell adhesion and migration (Margadant, Raymond et al. 2009). Integrin α1β1, α2β1 and
α3β1 mainly mediate cell adhesion to extracellular matrix; while αvβ3 is responsible for cell migration.
In the adult tissues, almost all cell types except the cells in blood vessels or lymphatic vessels attach to
extracellular matrix. Therefore, blocking of integrin α1β1 and α2β1 to their ligands causes cell adhesion
defects. However, inhibition of αvβ3 does not necessarily inhibit endothelial cell adhesion (Rainero,
Caswell et al. 2012). Secondly, cell migration is a dynamic process. One of the explanations could be that
soluble PKM2 from cancer cells drives endothelial cells to migrate towards cancer cell through integrin
recycling. This mechanism was studied on osteopontin and Cilengitide cases. Both proteins in soluble
forms induce cell migration through activating Rab dependent pathway (Caswell, Chan et al. 2008). At
the leading edge of endothelial cells, integrins are activated; while integrins dissociate at the rear of the
migrating cells. Soluble proteins might promote integrin recycling process to facilitate cell migration
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(Huveneers, Truong et al. 2008). Thirdly, whether soluble proteins or ligands are able to inhibit αvβ3 is
dependent on the binding affinity and soluble protein concentration. Cyclic RGD peptide, Cilengitide is
able to inhibit angiogenesis at high concentration. At low concentration, Cilengitide tends to promote
endothelial cell migration and angiogenesis (Reynolds, Hart et al. 2009). In summary, soluble PKM2 activates FAK in endothelial cells and induces integrin αvβ3 redistribution to the leading edges in endothelial cells.
5.8

PKM2 dimeric and tetrameric forms
PKM2 has two conformational structures in the cells: dimer and tetramer formations. Tetramers

have higher affinity to PKM2 substrate PEP and higher enzymatic activity, however, dimeric PKM2 has
relatively lower enzymatic activity. We found a very interesting fact which had not been addressed by
other studies before. We revealed that recombinant PKM2 mainly forms tetrameric conformation in solution at a concentration of 8-15µM. However, upon the dilution, PKM2 converts from tetramers to dimers at lower concentration, 1 µM. Unlike rhPKM2, rhPKM1 has tetrameric formation at both low and
high concentration. We also observed FBP induces PKM2 to form tetrameric forms, which was consistent with many other studies (Merrins, Van Dyke et al. 2013). This implicates that PKM2, PKL and PKR
have a relatively loose interaction between their dimer-dimer association interfaces. This conformation
might be evolutionally apt to functional modulation in the cells for rapid cell proliferation. We have verified that recombinant PKM2 is dimer at low concentration and we are also interested in how PKM2 is
converted to dimer in the cell. Many groups have reported that tumor PKM2 in patient blood serum exists as dimers. Dr. Jing Chen’s group at Emory University and Dr. Zhimin Lu’s group at UT Anderson both
reported that modification (such as phosphorylation) to PKM2 stabilizes dimer PKM2. Tetrameric PKM2
is assembled in the glycolytic enzyme complex and vulnerable to dissociation to dimers. After converting
into dimeric PKM2, dimeric PKM2 dissociates from enzymatic complex and phosphorylated by FGFR to
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stabilize its dimer formation. In our study, we speculated that it is the dimer PKM2 that interacts with
integrin and exerts angiogenesis functions.
The next question we answered in our study is which PKM2 conformation interacts with integrins,
dimer or tetramer. In order to test this, we employed Pyruvate kinase synergetic co-activator FBP. FBP
association decreased the binding activity of PKM2 to endothelial cells. Biacore result also confirmed
that FBP weakened PKM2 binding to integrins in vitro. Since FBP represses the interaction of PKM2 and
integrin, we reasonably think that FBP might affect endothelial cell angiogenic responses induced by
PKM2. Therefore we further demonstrated that FBP impaired endothelial cell adhesion and migration
induced by PKM2. In vivo, tumor sizes were significantly smaller in the group treated with rhPKM2 than
the one treated with Saline or rhPKM1. As we expected, FBP decreased tumor size (comparing the p value of rhPKM2+FBP with saline group). However, p value is not significantly different between groups
treated with rhPKM2 alone and rhPKM2 with FBP. It could be explained by two reasons: 1) FBP easily
dissociates from PKM2/FBP complex and is excreted by kidney or absorbed by tissues in vivo; 2) PKM2
could be modified or bind to other proteins after injected to mice and cannot efficiently bind FBP anymore. We analyzed mice blood serum by western blot on mice blood serum after gel filtration chromatography. RhPKM1 and rhPKM2 in mice blood circulation maintain as tetrameric and dimeric formation
respectively. RhPKM2 with FBP partially converts dimeric PKM2 to tetramers, which indicated that FBP
induces PKM2 tetrameric conformation but is not able to completely convert PKM2 to tetramers.
5.9

PKM2 secretion mechanism
First of all, I have examined the secretion of PKM2 in vitro and in vivo. PKM2 was detected by

western blot in the culture medium from eight types of cancer cell lines. An interesting observation is
that primary cancer cell lines release higher levels of PKM2 than their metastatic counterparts do respectively within each cancer cell line pair. This result is consistent with the founding on the relationship
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between metastasis and angiogenesis which has been acknowledged for decades. Angiogenesis of metastatic tumor is repressed in vivo. Metastatic cells secrete less PKM2 and assist metastatic tumor to
keep the minimum angiogenesis level (Kirsch, Schackert et al. 2004). But primary solid tumors, on the
contrary, require more angiogenesis for nutrition transportation. Meanwhile, we also realized that Melanoma cell pairs had the highest level of PKM2 in the culture medium, followed by colon and lung cancer cell pairs, while breast cancer pairs had a comparatively low level of PKM2. These results are entirely
supported by early reports. In early 1980s, Chaudhury et al. reported that melanoma cells produce higher angiogenic activity than breast cancer cells in rabbit cornea model (Chaudhury, Lerner et al. 1980).
It has been well-studied that the hypoxia condition in solid tumors promotes tumor angiogenesis (Pugh and Ratcliffe 2003). To elucidate this question, I measured PKM2 concentration in culture medium during hypoxia comparing with nomaxia. The data indicated that CoCl2 up-regulated PKM2 secretion to medium. CoCl2 is reported to induce the expression of HIF1α and to mimic hypoxia condition
(Lum, Bui et al. 2007).This result suggested that hypoxia plays an important role in PKM secretion. We
also examined serum PKM2 level in mice blood with or without tumor inoculation. Mice with subcutaneous SW620 tumor contain more PKM2 in blood than mice without tumors. This is consistent with
many clinical reports that PKM2 was detected in patients’ blood serum with various types of cancers.
It remains mysterious how PKM2 is secreted to the extracellular spaces. PKM2 were reported to
be present in exosomes or microvesicles and tumor cells have elevated vesicles secretion (Wubbolts,
Leckie et al. 2003; Park, Tan et al. 2010). Exosome and microvesicles are small extracellular vesicles released by many cell types including cancer cells. (Steiner, Angot et al. 2011). We speculated that PKM2
secretion is related to those vesicles from cancer cells. Our data supported that DMA dramatically inhibits PKM2 secretion into the cell culture medium of WM115 cells. DMA is an amiloride homologue which
has been reported to specifically inhibit exosome and microvesicles release. But classic exocytosis pathway inhibitors such as BFA (Brefeldin A) and Exo1 do not inhibit PKM2 secretion. This indicated that
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PKM2 secretion is related to exosome and microvesicle release or PKM2 is included in those vesicles.
The detailed mechanism needs to be further studied.
5.10 PKM2 is involved in cancer cell drug resistance
We have tested proliferation and migration of SW620 and PC3 cells upon PKM2 treatment. The data
have shown that PKM2 did not promote SW620 and PC3 cell proliferation and migration significantly
compared to HUVEC cells. It seems that PKM2 only recognizes endothelial cells. Therefore, we tested
whether PKM2 functions on endothelial cells exclusively. Since we have demonstrated that PKM2 promoted endothelial cells through integrins, we examined integrin αv and β3 subunits expression in
SW620, SW480, PC3 and SK-MEL-28 cell lines. It has shown that expression level of integrin αv and β3 is
dramatically higher in SK-MEL-28 than in SW620 and PC3. We also tested the downstream pathways of
integrin and the data have shown that PKM2 phosphorylated Akt. This result led us to speculate that
PKM2 enhances SK-MEL-28 cell against apoptosis. Integrins are known to protect cancer cell from apoptosis. Integrin binding to ECM activates FAK signaling pathways leading to the activation of Erk or Akt
pathway. Akt is the key factor in survival pathways to protect cells from apoptosis. Moreover, we treated SK-MEL-28 and SW620 cells with anti-cancer drug, oxaliplatin. We also applied recombinant PKM2 or
PKM2 antibody (IgGPK) along with oxaliplatin. MTT assay and TUNEL assay both have indicated that
PKM2 protected SK-MEL-28 cells from apoptosis induced by oxaliplatin and PKM2 antibody, on the contrary, enhanced SK-MEL-28 apoptosis. However, either PKM2 or PKM2 antibody does not have significant effects on SW620 cell. Based on this result, we tested whether integrins play a crucial role on the
anti-apoptosis effect of PKM2. We overexpressed integrin αv and β3 subunits in SW620 cell and then
tested PKM2 anti-apoptosis activity in SW620 wild type (SW620WT) and SW620 αv and β3 transfected
(SW620AB) cells. The data has shown that PKM2 protected SW620AB cells from oxaliplatin induced
apoptosis, but not SW620WT cells. PKM2 was also reported be involved in another cancer drug 5-FU
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induced resistance. 5-FU resistant cell line has more PKM2 secretion in the culture medium comparing
with 5-FU non-resistant cell line (Shin, Yoo et al. 2009). In summary, PKM2 also binds cancer cells
through integrins and enhances cancer cell drug resistance.
In my dissertation, I have successfully demonstrated that PKM2 secreted by cancer cell promotes
endothelial proliferation, migration and survival. PKM2 has been proved to facilitate angiogenesis in
vitro and in vivo. The mechanism is that PKM2 recognizes and binds to integrin αvβ3 on endothelial cells
and this interaction of PKM2 with integrin phosphorylates Focal Adhesion Kinase and induces integrin
αvβ3 to redistribute to the leading edge of endothelial cells. Endothelial cell activation and endothelial
angiogenesis is able to be blocked by PKM2 antibody. Therefore, this indicates that PKM2 can be exploited as a potential therapeutic target for cancers. Anti-PKM2 antibody could serve as a combination
treatment with existing drugs to certain types of cancers.
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CHAPTER 6
6.1
6.1.1

METHODOLOGY

Molecular techniques
Polymerase Chain Reaction (PCR)
PCR technique was used to amplify PKM2 and other mutant DNA plasmids. The reaction system

includes the following materials: 1ul of template DNA (50ng/µl), 5ul dNTPs (final concentration 0.2mM),
5ul 10X KOD HOT START DNA polymerase buffer, 2ul MgSO4 (final concentration 1mM), 5µl primer mixture (forward and reverse primers at final concentration 1uM), 1µl KOD HOTSTART DNA polymerase
(1U/µl) and H2O. After all the components were mixed, a brief spin-down was performed and PCR tubes
are placed into eppendorf Mastercycler. The PCR procedure for amplifying the whole plasmid was: 2min
95°C; 30 sec 95°C, 30 sec 56°C, 10min 72°C, 30 cycles; 15min 72°C; the PCR procedure for amplifying
gene fragment is: 2min 95°C; 30sec 95°C, 30sec 56°C, 2min 72°C, 30 cycles; 8min 72°C The PCR results
were analyzed by 0.8 %-1.5 % agarose gel electrophoresis.
6.1.2

Agarose gel electrophoresis
PCR fragments were analyzed by Agarose gel electrophoresis. 0.8 % agarose gel was made by

adding 0.4g agarose to 50mL 1XTBE buffer. Gel mixture was boiling 1.5min by microwave to completely
dissolve agarose. After cooling down, 2µl Ethidium Bromide was added into gel mixture and gel mixture
was poured to gel casting tray to solidify the gel. PCR samples were mixed with 1 X Loading dye and
loaded to the wells. 6µl of 1K plus DNA ladder was loaded to a separate well. Agarose gel was run at the
voltage of 100V for 1hour. Agarose gel was visualized by UVP biospectrum 410 imaging system.
6.1.3

PCR gel extraction
Qiagen gel extraction kit was utilized to purify PCR product. Buffer Q was mixed with PCR prod-

uct with the ratio of 3:1. The mixture applied to the columns provided in the kit. Columns were centri-
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fuged for 1min at 13,000 rpm in the bench-top eppendorf centrifuge. The mixture centrifuged down was
returned to the column and another centrifuge was performed. The flow-through was discarded and
750 µl Buffer PE was added to the column. After centrifuge 1min at 13,000 rpm, the flow-through was
discarded. 40-50 µl de-ionized water was added to the column and the elution was collected to a new
1.5ml eppendorf tube. De-ionized water can be heated to 60-70°C if necessary.
Gel extraction was carried out with the similar protocol. PCR product was separated by agarose
gel. Targeted DNA fragments were cut off by blades and the gel is weighted on the scale. Buffer Q was
mixed with gel fragments with the ratio of 3:1 to 5:1. If the PCR fragments are larger than 5K bp, Isopropanol was added into the gel/Buffer Q mixture. The mixture was placed in the hotplate at 60-70°C for 10
minutes and vortexed twice while heating. The rest procedure is the same as mentioned above in PCR
fragments extraction procedure.
6.1.4

Restriction Digestion
In order to construct foreign DNA expression plasmid, PCR fragments and empty vectors need to

be digested with the same restriction endonucleases. Those restriction endonucleases are generated by
bacteria originally to protest bacteria from attacking of phage. Restriction endonucleases specifically
recognize unique sequences in PCR products and vectors as well, and cleave DNA sequence. Briefly, DNA
substrates, enzyme and reaction buffer were mixed together and the mixture was incubated in 37°C for
1 hour to 2 hours. The restriction digestion product can be analyzed by agarose gel electrophoresis or
purified by gel extraction kit.
6.1.5

PCR products phosphorylation
Some PCR products require phosphate group in 5’ end in order to be ligated. T4 polynucleotide

kinase (T4 PNK) was used transfer γ-phosphate from ATP to 5’-OH group of double stranded DNA. Phosphorylated PCR products can be used for DNA ligation to form circular plasmids. The reaction mixture
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contained: PCR product 5 µl (100ng/µl), 10 X T4 PNK reaction buffer A 2μl, ATP (10mM) 2μl, T4 PNK 1μl
(1Unit) and 10μl nuclease-free water. After mixed and spin down, the reaction was incubated at 37°C for
1 hour. The reaction was quenched at 75°C for 10min.
6.1.6

DNA ligation
After PNK treatment, PCR products were treated T4 DNA ligase to form a phosphodiester bond

between 5’ phosphate and 3’ hydroxyl termini. DNA ligation reaction can be used to circularize linear
RCP products or insert a gene into a vector. T4 DNA ligase can be used for both blunt end and sticky end.
Reaction mixture contains: linear DNA (after PNK treatment) 10μl, T4 DNA ligase buffer 2μl, T4 DNA ligase 1μl, nuclease-free water 7μl. The reaction was incubated at room temperature for 1 hour.
6.1.7

Transformation
Self-circularized by DNA T4 DNA ligase was transformed to E coli competent cells. The strains

used in this study are BL21 (DE3), BL21 (DE3) plys and Tuner (DE3). Competent cells were originally
stored in -80°C. Prior to transformation, competent cells were incubated on ice for 5min. Then ligation
products were added into 50μl competent cell and mixed by gentle finger tapping. After incubation for
10min on ice, competent cells were placed at 42°C on heat block for 90 sec. The competent cells were
then kept on ice again for another 2min and 950µl warm LB medium was added to competent cells. After 60mins, 100μl LB containing competent cells was spread onto LB agar plates by bacteria spreader. LB
agar plates were placed in the 37°C incubator for overnight.
6.1.8

Plasmid miniprep
After transformation, single colony was picked up to fresh LB medium with Kanamycin at the

concentration of 1μl/ml and cultured at 37°C for overnight 250rpm in bacteria shaker. QIAprep spin
miniprep kit was applied to extract plasmids from E. coli. 3ml bacteria overnight culture was centrifuged
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for 2min at 12,000g and supernatant was removed by vacuum. The bacteria pellets were re-suspended
by 250 μl Buffer A containing RNase A. After completely vortexed, bacteria cells were broken down by
250 μl Buffer B (containing SDS and NaOH). Then 250μl of neutralization buffer or Buffer N was added.
The bacterial proteins were denatured and precipitated out by centrifuge at 12,000g for 10min. The supernatant containing DNA was applied to Qiagen miniprep column. The miniprep column was washed
twice with 75-80% ethanol buffer, Buffer PE and was dried in room temperature for 2min. Finally, DNA
on the column was eluted out by nuclease-free deionized water. DNA extracted can be applied to
agarose gel electrophoresis for analysis.
6.1.9

Recombinant protein expression
After plasmid verification by DNA sequencing, PKM2 or other mutants were cultured in 10mL LB

medium at 37°C, 250rpm for overnight. The second day, 10 ml bacterial culture was transferred to a 1L
fresh LB medium containing 1mM Kanamycin. And the 1L LB Broth was subjected to culture at 37°C
250rpm until OD600 reaches 0.3. 1L bacterial culture was cooled down in 4°C and then 0.2mM Isopropyl
β-D-1-thiogalactopyranoside (IPTG) was added to the culture. The bacteria were continuously cultured
for 16°C 150rpm for 18 hour for recombinant protein expression. The bacteria were collected by centrifuge at 4°C, 6000rpm for 15min. A portion of bacterial pellets were suspended with DI water and mixed
with 2 x SDS loading buffer.
6.1.10 Recombinant protein purification
Bacteria pellets were suspended and lysed by 20mL lysis buffer containing 50mM Tris-HCl pH
7.5, 50mM NaCl, 10mM Imidazole and protease inhibitor cocktail. The bacteria suspension was kept on
ice for 10min and bacteria were broken down by French Press. Then sonication was applied to the bacteria lysate for 1min with 10sec pause in every 10sec. The bacteria lysate was centrifuged at 4°C,
15,000g for 30min. Since recombinant proteins contain 6 X histag, the supernatant was applied to Ni-
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NTA on (Fast Protein Liquid Chromatography) FPLC. 6X histag proteins bind to nickel-chelated column
and high concentration of imidazole. Briefly, recombinant PKM2 was loaded to the Ni-NTA column at the
concentration of 20mM imidazole. Then imidazole concentration was increased to 250-300mM to elute
recombinant PKM2. Elution was dialyzed against the buffer containing 50mM Tris HCl pH 7.5, 50mM KCl,
15% glycerol and 1μM β-mercaptoethanol (2ME) at 4°C for overnight. Recombinant protein solution
concentration was measured by Bio-rad Bradford assay.
6.1.11 Protein concentration measurement
Bio-rad Bradford assay was used to measure protein concentration. Bio-rad Bradford solution
was mixed with water with a ratio 1:4. 1ml was added into cuvettes to measure OD595 by spectrophotometer. To establish the standard curve, 0μg, 2μg, 4μg, 6μg, 8μg and 10μg BSA was added to separate
cuvettes and OD595 was measured. Recombinant protein and control buffer were added to cuvettes to
measure OD595.
6.1.12 Gel filtration
Gel filtration was utilized to analyze PKM2 dimer/tetramer ratio. Firstly, we established the
standard curve by loading high molecular weight gel filtration calibration kit. This calibration kit contains
five proteins with molecular weight from 44,000 Dalton to 669,000 Dalton: Ovalbumin, Conalbumin,
Aldolase, Ferritin and Thyroglobin. The kit also includes Blue Dextran 2000. Standard curve is set up by
taking log Molecular weight as X-axis and Kav as Y-axis. Kav is calculated by equation (Ve-Vo)/(Vc-Vo). Vo is
column void volume. The elution volume for Blue Dextran 2000, a protein with molecular weight
2000Kd, is taken as Vo. Ve is determined by the elution volume of all the proteins in the calibration kit
respectively. Vc=r2 x π x l, r is the radius of the column and l is the length of the column. After linear fitting, excel generated an equation to represent the standard curve. Superdex 200 was used for analysis
in this experiment. Briefly, Blue Dextran 2000 was firstly applied to the column to determine Vo. Then
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proteins in the calibration kit were dissolved and mixed as the concentration of 3-5 mg/ml of each protein (with the exception of Ferritin, 0.3 mg/ml). The mixture was applied to superdex 200. Then recombinant PKM1 and PKM2 were diluted to 1μM and 8μM respectively. 200μL of each protein sample was
loaded to the column. The equilibration buffer used in this experiment is 50mM Tris pH 7.5 and 50mM
KCl.
6.1.13 Pyruvate kinase enzymatic activity assy
Pyruvate kinase enzymatic activity was measure by pyruvate kinase activity assay kit from
Biovision. Pyruvate kinase catalyzes PEP and ADP to produce ATP and pyruvate. This reaction is coupling
with pyruvate oxidase reaction. Pyruvate generated by pyruvate kinase is oxidized by pyruvate oxidase
to produce color at wavelength 570nm. Standard curve was prepared before measuring samples. Firstly,
pyruvate standard in the kit was diluted 100 folds with Assay Buffer. 0, 2, 4, 6, 8, 10μl was added to each
with each well in 96 well plate and Assay buffer was added to make the total sample volume to be 50 μl.
Then another 50μl of reaction mixture was added to each well. Reaction mixture contains: Assay buffer,
substrate mix, enzyme mix and OxiRed Probe. Secondly, the samples were diluted and added to 96 well
plate (50 µl each well) separately. 50μl reaction mixture was mixed with the samples. The plate was read
by Enspire plate reader in GSU core facility at wavelength 570nm every 5min for 20min at room temperature. Every standard point and sample was measured in triplet.
6.1.14 SDS-PAGE
SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis, is for analyzing or separating proteins based on molecular weight. Polyacrylamide gel generally has two layers: bottom layer is
separating gel and upper layer is stacking gel. Separating gel is made by mixing the following materials:
for 10% gel, 5.95ml DI water, 3.75ml 1.5M Tris-HCl pH 8.8, 150μl 10% SDS, 5ml Acrylamide/Bisacrylamide (29:1), 150μl 10% Ammonium persulfate and 6μl TEMED. Total volume is 15ml. Stacking gel
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is made by: 6.8ml DI water, 1.25ml 1M Tris-HCl pH 6.8, 100μl 10% SDS, 100 µl 10% Ammonium
persulfate, 1.7ml Acrylamide/Bis-acrylamide (29:1) and 10µl TEMED. Total volume is 10ml. The comb
was inserted to the upper stacking gel to generate loading wells. After becoming solidified, gels were
placed in the gel running cassettes, which was filled with gel running buffer (containing 25mM Tris,
192mM Glycine and 0.1% SDS) on both positive and negative ends. All the samples were mixed with 5X
SDS loading buffer (50 mM Tris-HCl pH6.8, 2% SDS, 10% Glycerol, 1% β-Mercaptoethanol, 0.02%
Bromophenol Blue and 12.5 mM EDTA). Then 20-30μl samples were loaded to each well and gels were
ran at constant voltage of 50-120V for 2 hours.
6.1.15 Coomassie brilliant blue staining
After SDS-PAGE, protein bands can be visualized by Coomassie Brilliant Blue staining. The gel
was removed from gel running plates by gel lifter and washed with DI water twice. Then the gel was
stained in Coomassie blue staining buffer for 30min-60min. After washed twice with DI water, the gel
was destained with destaining buffer till the target protein bands can be visualized clearly. Coomassie
blue staining buffer contains 0.1% Coomassie Brilliant Blue, 20% Methanol, and 10% Acetic acid, and
dissolved in DI water. Destaining buffer contains: 20% Methanol and 10% Acetic acid, and dissolved in DI
water.
6.1.16 Gelcode gel staining
This staining method is to stain proteins with low concentration or for proteins subjected to
Mass Spectrum. The gel is removed by the gel lifter mentioned above and washed twice with DI water.
The gel was then stained with 20ml Gelcode staining buffer for minimum 60min at room temperature.
The gel was destained by DI water instead of destaining buffer. The bands were able to be visualized
under UV 256nm by UVP biospectrum 410 imaging system in our lab.
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6.1.17 Protein phosphorylation assay of pyrvuate kinase
To test the protein kinase activity, western blot assay was utilized. Reaction mixture contains:
PKM2 (BSA or PKM1), 5mM PEP, 2mM DTT, and substrates such as STATs or Vitronectin. The reaction
was kept in room temperature for 2 hours or 4°C for overnight. The reaction was quenched by adding
SDS loading buffer. Reaction products were applied to SDS-PAGE and western blot. Anti-phosphoserine,
phosphotheonine and phosphotyrosine primary antibodies were used to blot the membrane.
6.1.18 Western blot
Western blot was used to specifically detect the existence of contain proteins. Protein sample or cell
lysates were separated by SDS-PAGE. After SDS gel was lifted, the gel, filter paper, the sponges and
nitrocellular membrane were soaked in the transfer buffer for 10min. Transfer buffer was made by
25mM Tris, 192mM Glycine, 10% methanol and DI water. Then the gel, filter paper, the sponges and
nitrocellulose membrane were placed together to form a sandwich structure. The gel has to face the
negative side and membrane faced to positive side. The sandwich structure was inserted to the transfer
cassette and the cassette was placed into the transfer chamber filled with transfer buffer. The transferred membrane was staining with Ponceau S. Prestained protein ladder on the membrane was labeled. The membrane was washed twice with TBST (1xTBS containing 0.05% Tween) to wash off the
Ponceau. Then the membrane was incubated with blocking buffer (5% BSA dissolved in 1XTBS) for 1
hour at room temperature. After brief wash, the membrane was incubated with primary antibody diluted with blocking buffer for overnight at 4°C or 2 hours at room temperature. Then the membrane
washed three times with 1xTBS (each time 5min) and incubated with HRP-conjugated goat-anti-mouse
or goat-anti-rabbit for 1 hour at room temperature. The membrane was washed three times with 1xTBS
(each time 5-10min). Pierce chemiluminescent substrates (supersignal western pico substrate) was add-
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ed to the membrane. After two minutes, the membrane was exposed to X-ray film for indicated time
and the film was development by X-ray film developer in GSU core facility.
6.1.19 Antibody generation
Recombinant human PKM2 (rhPKM2) was purified after Ni-NTA and gel filtration describe
above. rhPKM2 (1mg/ml) was mixed with either complete Freund’s adjuvant or incomplete Freund’s
adjuvant at a ratio of 1:1. Complete and incomplete Freund’s adjuvants were used to boost the rabbit
immune system. PKM2 and adjuvants were mixed completely to form a stable emulsion and 1ml of the
mixture was injected under the skin of New Zealand Rabbits. After the inoculation injection and three
follow-up boost injections (6-8 weeks in total), rabbit blood was collected and serum was separated by
centrifugation at 2500 rpm for 20min. The anti-PKM2 serum can be applied to western blot to analysis
the antibody titer and efficacy.
6.1.20 Antibody purification
Polyclonal antibody was purified from rabbit serum by Protein A sepharose 4B fast flow (GE life
science). In general, anti-PKM2 rabbit serum was centrifuged or filtered to remove the junks. Antiserum
was mixed with equilibrium buffer (20mM sodium phosphate pH 7.5) with a ratio of 1:1 and then mixed
with Protein A sepharose 4B resin beads for 1 -2 hours at room temperature. The beads were washed
twice with equilibrium buffer. Then IgG was eluted out from beads by elution buffer containing 0.1 M
glycine-HCl pH 2.7. The elution fractions were neutralized by 1.0 M Tris-HCl pH 9.0. SDS-PAGE was applied to analyze the purification results. The fractions containing IgG were combined and desalted by
desalt column. In the meantime, pre-bleeding rabbit serum was also used to purify control antibody
with the same procedure described above.
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6.1.21 PKM2 specific antibody purification
The method mentioned above is to purify total rabbit IgG from rabbit serum. PKM2 specific antibody only takes 10-20% of total IgG. We wanted to exclude the possibility that those non-specific antibodies do not affect PKM2 function. Therefore we carried out this assay to specifically purify PKM2specific antibodies from total rabbit IgG. The method we used to conjugated rhPKM2 to CNBR-activated
Sepharose 4B. Briefly, CNBR-activated Sepharose 4B was washed at low pH (pH 3) to remove additives.
1g CNBR lyophilized powder gives roughly 3.5 ml final volume. RhPKM2 was dissolved in the coupling
buffer (0.1 M NaCO3 pH 8.3 and 0.5 M NaCl). Mix rhPKM2 with CNBR-activated Sepharose 4B at room
temperature for 1 hour or at 4°C for overnight. Sepharose 4B beads were washed with coupling buffer
for 3 times and blocked with blocking buffer containing 0.1 M Tris-HCl pH 8.0 for 2 hours. Then
Sepharose 4B beads were washed for 3 times with each buffer. Buffer1 is made by 0.1 M acetic acid /
sodium acetate, pH 4.0 containing 0.5 M NaCl; Buffer 2: 0.1 M Tris-HCl, pH 8 containing 0.5 M NaCl. After rhPKM2 was successfully conjugated to Sepharose beads, purified rabbit IgG from rabbit serum were
incubated with rhPKM2-Sepharose at 4°C for 2 hours. Unbound proteins were washed away with PBS.
Then PKM2 specific antibodies were eluted out from beads by elution buffer containing 0.1 M glycineHCl pH 2.7. The elution fractions were neutralized by 1.0 M Tris-HCl pH 9.0. SDS-PAGE and western blot
were applied to analyze the purification results.
6.1.22 PKM2 purification from cell culture medium
Polyclonal anti-PKM2 antibody was incubated with Protein A sepharose (GE lifesciences) beads
for 1-2 hours at room temperature (Protein A sepharose binding capacity is 5mg/ml). The sepharose
beads were washed with PBS to remove unbound protein and then were washed twice with 0.1 M sodium borate, pH 9. The beading binding antibody was incubated in sodium borate buffer containing 20mM
DMP (dimethyl pimelimidate, from Sigma) for 30min in room temperature. Repeat this step once. The
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beads were incubated with buffer containing 50mM glycine pH 2.5 to quench the DMP activity for
30min. Finally, the beads were washed twice with PBS. After Protein A sepharose beads were successfully conjugated with polyclonal anti-PKM2 antibody, conditional culture medium from SW620 cancer cell
line was subjected to be incubated with conjugated Protein A sepharose. The beads then were washed
twice with PBS and eluted by 50mM glycine pH 2.5. 1M Tris-HCl pH 9.0 was added to the elution to neutralize pH. Purified exogenous PKM2 underwent dialysis to reduce salt concentration.
By using the same method, normal rabbit IgG was also purified by Protein A sepharose beads.
The elution was collected and neutralized by future experiment.
6.2
6.2.1

Cellular techniques
Mammalian Cell culture
Human umbilical vascular endothelial cell (HUVEC) and cancer cell lines were cultured in 75cm2

culture flasks containing 20-30 ml designated culture medium. The flasks were placed in the culture incubator in a condition of 37°C, 5% CO2/95% air and 95% humidity. Culture medium for cancer cell lines
was commonly supplemented with 5-10% Fetal Bovine Serum (FBS) to provide growth factors needed.
Culture medium for HUVEC cell is supplemented with low serum growth supplement (LSGS). While cultured cells reached 95% confluence, cells were digested and split into new flasks.
6.2.2

Subculture
Firstly, the culture medium was discarded by pipetting or vacuuming. Cells were then briefly

washed with 0.05% (w/v) Trypsin and 0.53 mM EDTA solution to remove all traces of serum in the flasks.
2mL of this Trypsin-EDTA solution was added to the flask for 5-10min. Cell culture flasks can be observed
under microscope to determine the digestion time. After cells detached from the flasks, 8mL culture
medium containing 10% FBS was added to the quench Trypsin. Trypsin-EDTA can be removed by centrif-
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ugation at 800 rpm for 5min at room temperature. Cells were suspended with culture medium containing 10% FBS following centrifugation and cells were split to new flasks with a ratio of 1:3 to 1:5.
6.2.3

Cell storage
Cultured cells need to be stored for future use. Cells were trypsinized following the method

mentioned above. After neutralization and centrifugation, cells were suspended with culture medium
supplemented with 10% DMSO and 10% FBS. The cell suspension was transferred to Cryovials and
Cryovials were placed into freezing container containing filled with isopropyl alcohol. Freezing container
was stored at -80 for overnight and then Cryovials were transferred to liquid nitrogen for long term
storage.
6.2.4

Cell lysis preparation
Culture medium was evacuated by vacuum and cells were washed twice with PBS containing so-

dium orthovanadate. After removing PBS, 1mL fresh PBS was added to culture flasks and cells were detached by cell lifters. Cells were transferred to eppendorf tube and centrifuged at 3000 rpm for 5min at
4°C. Cell pellets were suspended with 500-1000µl cold 1X RIPA buffer containing Protease inhibitor cocktail 1 and Protease inhibitor cocktail 2. The cell suspension was incubated for 1 hour at 4°C on a rotator
and centrifuged at 13,200 rpm for 10 min at 4°C. The supernatant was collected and stored at -80°C for
further immunoprecipitation or western blot analysis.
6.2.5

Immunoprecipitation
Wash protein A/G beads twice with PBS. Mix polyclonal rabbit serum (purified antibody) or

normal rabbit IgG with protein A/G beads at 4C for 1hour. Protein A/G beads were washed three times
with PBS to remove unbound antibody and other unspecific proteins. Cell lysates were thawd and mixed
with antibody bound protein A/G beads. The mixture was incubated at 4°C on a rotator for 2-4 hours.
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The supernatant was discarded and the beads were washed for three times with PBS. Finally, discard all
supernatant and add 60µl of SDS-loading dye to the beads. The beads were boiled for 5mins and then
the sample was ready for SDS-PAGE.
6.2.6

DNA precipitation
After mini- or midi- preparation, add 2 volume of cold 100% ethanol and 1/10 volume of 3M so-

dium acetate (NaAc), pH 5.2 to one volume of DNA solution. The whole mixture was placed at -20°C for
from 1 hour to overnight. Thereafter, the solution was centrifuged at 13,000 rpm for 10min at 4°C in a
bench-top eppendorf centrifuge. The supernatant was discarded and the pellet was washed with 70%
ethanol. The pellet was centrifuged again at 13,000 rpm for 10min at 4°C. Remove the ethanol and airdry the pellet or by vacuum. DNA pellet was re-suspended with Tris-HCl buffer pH 8.0.
6.2.7

Cell transfection
Cells were seeded in 6-well culture plates to 60-80% confluence. 2μg DNA plasmids and 3μl

Lipofectamine 2000 were diluted into 50μl Opti-MEM respectively for 5 min. Mix Opti-MEM containing
plasmids and Lipofectamine together and incubate at room temperature for 10 min. Total 100μl OptiMEM was added to cell culture medium in 6-well plates. Cells were continuously cultured for 48-72
hours for further testing.
6.2.8

Immunofluorescence
When the cells grew to 80-90% confluence, the cells were trypsinized and seeded in a 4 well

chamber slides (1x104 per well). After cultured overnight, cells were washed with non-FBS medium and
treated with rPKM2 and BSA respectively for 1-2 hours at 37C. Thereafter, culture medium was discarded and the cells were fixed with 200mL 4% formaldehyde in PBS for 5-10 min at room temperature. After fixation, cells were washed twice with PBS. Cells were incubated with 0.5% Triton X-100 in PBS for 10
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min to penetrate cell membrane, followed by blocking with 5% BSA in PBST (0.05% Tween 20 in PBS).
Cells were treated with primary antibody diluted in blocking buffer at 4°C overnight. On the second day,
cells were washed 3 times with PBST and stained with fluorescence-conjugated secondary antibody at
room temperature for one hour. This and following steps should be conducted in a humid light-tight
box. After washed 3 times, Prolong Gold anti-fade reagent with DAPI was added to slides, followed by
covering the slides with coverslips. The stained slides were dried for overnight and sealed with nail
polish for long time storage.
6.2.9

Cell attachment assay
Extracellular matrix proteins such as vitronectin or fibronectin were coated to 96 well ELISA

plates at 4 °C for overnight or recombinant pyruvate kinase proteins were coated at room temperature
for 2 hours. The plates were washed twice with PBS and blocked with 5% BSA diluted in PBS at room
temperature for 1 hour. Endothelial cells were cultured in a 75 cm2 flasks to 80% confluence and were
detached by 10mM HEPES buffer pH 7.4 containing 20mM EDTA and seeded to the ECM or recombinant
proteins coated ELISA plates. 2 x 104 endothelial cells were added to each well and plates were incubated at 37 °C incubator for 30-60 min. After removing the unbound cells with PBS by wash, attaching cells
were fixed with 3.7% formaldehyde solution at room temperature for 10 min and then stained with
0.1% crystal violet for 15min. Crystal violet out of the cells were washed away by PBS for 3 times. After
complete air dry, crystal violet was dissolved with 50-100 μL extraction buffer solution. The extraction
buffer is made of 0.1 M sodium citrate, 50% ethanol and 50% H2O. Transfer 50 μl extraction buffer solution to a new well and measure OD590. This experiment has been done three times independently.
6.2.10 Cell migration assay
Endothelial cells were seeded in 75 cm2 flask and cultured at 37 °C to 70-80% confluence. Cells
were washed with serum-free medium and detached with 10 mM HEPES buffer pH 7.4 containing 20mM
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EDTA, and neutralized by 3.5mM CaCl2 and 3.5mM MgCl2. Cell suspension was centrifuged at 800g for
5min and washed twice with serum-free medium or HBSS. Endothelial cells were then seeded onto the
upper chamber of Boyden chamber. 5x104 cells per well in 100 µl serum-free medium. Add 400 µl medium with FBS or with recombinant PKM2 proteins or control proteins to the lower chamber. Boyden
chambers were incubated at 37 °C for 12-24 hours with 5% CO2. The cells was fixed with 3.7% formaldehyde at room temperature for 10 min and washed twice with PBS, followed by staining the cells with
0.1% crystal violet for 15min. The cells on the membrane of the lower chamber were removed by cotton
swabs. After air dry, crystal violet was dissolved by extraction buffer for 5min (100 μl each well). Transfer 50μl of the extracted solution and measure OD at 590 nm. Each sample was done by 3 parallel
transwells and each experiment was repeated for 3 times independently.
6.2.11 Cell proliferation assay
Cell proliferation is assessed by BrdU incorporation assay. Briefly, cells were seeded into 96 well
plates (2500-100000 cells per well) and were incubated with recombinant proteins respectively at 37°C
for certain period (from 24-72 hours). Culture medium was changed to fresh medium containing 1:1000
diluted BrdU (100μL each well). Place the plates back to the incubator for another 4-12 hours based on
the cell growth rate. After removal of the culture medium, cells were fixed at room temperature for 30
min with fixing/denaturing solution, followed by 3 times wash; cells were incubated with primary antibody for 1 hour. Cells were incubated with HRP-conjugated secondary antibody for 30 min after another
3 times wash. Remove secondary antibody, wash plates 3 times with washing buffer and add TMB substrates solution. Add stop solution after incubating with substrates for 30 min and measure absorbance
at 450nm. Each sample was done by 5 parallel wells and each experiment was repeated for 3 times independently.
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6.2.12 Culture medium collection
Cancer cell lines were cultured in full FBS medium to 50-60% confluence in 75 cm2 flasks. The
cells were washed twice with non-FBS medium and fresh non-FBS medium was added. After 12 hour
culturing, cell culture medium was collected and suspended cells were removed by filtering. The culture
medium can be used for western and immunoprecipitation.
6.2.13 Tumor cell preparation for animal experiment
Prostate cancer cell line PC-3 and colon cancer cell line SW620 were cultured in 37 °C incubator.
Upon the injection day, cells were trypsinzed by trypsin-EDTA and neutralized by Full FBS medium. After
centrifuge at 800g, cells were washed with non-FBS medium. Then cells were washed 2-3 times with
HBSS. The cell pellet was responded with HBSS to a concentration of 2x107 cells per 1mL and places on
ice. Equal volume of Matrigel from BD Bioscience was mixed with cell suspension. The cell suspension
was left on ice for mice subcutaneous injection.
6.3
6.3.1

Animal experiments
Nude mice tumor model
The mice using is 4-6 week old Nu/Nu male mice from Harlan. Nude mice were housed in animal

facility at Georgia State University. One week later, 50-100 µl tumor cells were mixed with BD Matrigel
and injected on the back flank of nude mice under anesthesia. After tumor inoculation, mice were administered with recombinant proteins intraperitoneally three doses every week. Three days after tumor
implantation, tumor sized was by measured by length and wild. The tumor volume was calculated by
formula: V=π/6 x L (Length) x W2 (width). 15-20 days after inoculation, nude mice were euthanized by
CO2 and tumors or tissues were collected. The tumors were measured and weighted, followed by being
embedded in OCT reagent and frozen at -80°C for further sectioning.
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6.3.2

Breast Cancer Orthotopic model
Mouse breast cancer cell line 4T1 was maintained in DMEM at 37°C incubator. Cells were

trypsinized and collected by centrifuge. 4T1 cells were then washed three times with HBSS and concentrate to 1 million cells per 1ml. Female Bal b/c mice were purchased from Harlan and separated randomly to each cage. Mice were shaved and injected 20-30 µl to the fat pat on the left under anesthesia. IP
injection, tumor measurement and euthanasia were conducted by following the same protocol as the
nude mice model. The only difference is the tumor volume calculation. Tumor area volume is calculated
by Width x Length. This reason we were calculating tumor area instead of tumor volume is because the
fat pat tumor is much flatter.
6.3.3

Frozen tissue sectioning
The mice tissues and tumors were embedded in OCT and stored at -80°C. Before sectioning, tis-

sues and tumors were placed in -20°C for 10min. This may prevent sample cracking while sectioning. The
section machine is Cyrostat. Tissues were sectioned at a range 8-12µm and placed on the positively
charged slides. Allow sections to air dry on the slides for 1-2hour. Before fixation and staining, OTC was
washed away by Ethanol. The tissue area was circulated by Dako pen to maintain the solutions or antibodies at the tissue area.
6.3.4

Matrigel plug assay
Prepare the samples: rPKM2 or saline solution was mixed with high concentration Matrigel with

growth factor reduced. The mixture was kept on ice. Transfer the Matrigel/protein mixture to a syringe.
Nude mice were anesthetized and injected with 300µl of the Matrigel with protein on the back of the
mice. Ten days after Matrigel implantation, mice were euthanized and Matrigel plugs were harvested.
Take pictures on the Matrigel plug to record the peripheral angiogenesis. 10µg of the plug was cut and
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submitted for hemoglobin measurement. And the rest of the gel plug was frozen in OCT for tissue sectioning.
6.4

Statistics
All the in vitro data were analyzed by one-tailed, unpaired student t test. All the in vivo data were

performed by pairing nude mice and Balb/c mice after tumor implantation and before treatment. Mice
were paired based on the tumor size. If the tumor size were similar, mice were further paired by mice
weight. Mice tumor sizes were compared in the pairs before and after treatment. Nude mice experiment results have shown significance with one-tailed, unpaired student t test (p value is lower than
0.05); while orthotopic 4T-1 model didn’t show significance with one-tailed, unpaired student t test.
Therefore, we tried one-tailed, paired student t test. P values is lower than 0.05. Since we paired the
animals while treated, it is reasonable to analyze the data by pared t test.
6.5

Materials

Chemicals
(IPTG) Isopropyl β-D-1-thiogalactopyranoside

Sigma Aldrich

100% Ethanol, 200 Proof

VWR International

2-ME (β-Mercaptoethanol)

Sigma Aldrich

37% Formaldehyde in H2O

Sigma Aldrich

Acetic Acid

VWR international

Acrylamide-Bisacrylamide 40% (w/v 29:1)

VWR international

ADP (Adenosine 5’-diphosphate sodium salt)

Sigma Aldrich

Agar powder

Sigma Aldrich

Agarose

Sigma Aldrich

Ammonium Persulfate (APS)

Sigma Aldrich

Ampicillin

Sigma Aldrich

ATP (Adenosine 5’-triphosphate disodium salt)

Sigma Aldrich
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Autoradiography film

Fisher Scientific

Boric acid

Sigma Aldrich

Brij L23 Solution

Sigma Aldrich

Bromophenol Blue

EMD

Calcium Chloride

Sigma Aldrich

Calf Bovine Serum

Invitrogen Life technologies

Cell culture media

Cellgro

CNBr-activated Sepharose 4B

GE Healthcare Lifesciences

Complete Freud’s Adjuvant

Sigma Aldrich

Coomassie blue

Sigma Aldrich

Crystal Violet

Sigma Aldrich

Dimethyl Sulfoxide

Sigma Aldrich

DMP (Dimethyl pimelimidate dihydrochloride)

Sigma Aldrich

Drabkin’s reagent

Sigma Aldrich

DTT (Dithiothreitol)

Sigma Aldrich

ECL Western Blot substrate

Thermo Fisher Scientific

EDTA (Ethylenediaminetetraacetic disodium)

Sigma Aldrich

Ethanol

VWR international

Ethidium Bromide

Sigma Aldrich

FAK Inhibitor 14

Millipore

Fetal Bovine Serum

Invitrogen Life technologies

G418 Disulfate Salt

Sigma Aldrich

Gel code staining buffer

Fisher Scientific

Glutathione

Sigma Aldrich

Glutathione sepharose 4B

GE Healthcare Lifesciences

Glycerol

VWR international

Glycine

VWR international

H2O proteomics grade

Sigma Aldrich

HBSS (Hank’s Balanced Salt Solution)

Invitrogen Life technologies

HEPES

Sigma Aldrich

171
High Concentration Matrigel, phenol red-free

BD Biosciences

HiTrap Q column

GE Healthcare Lifesciences

Hydrochloric Acid

VWR international

Hydrocortisone

Sigma Aldrich

Igepal (NP-40)

Sigma Aldrich

Imidazole

Sigma Aldrich

Incomplete Freud’s Adjuvant

Sigma Aldrich

Isopropyl Alcohol

VWR international

Kanamycin

Sigma Aldrich

Lipofectamine 2000 Transfection Reagent

Life Technologies

Low Melting point Agarose

Sigma Aldrich

LSGS (Low serum growth supplement)

Invitrogen Life technologies

Magnesium Chloride

Sigma Aldrich

Magnesium Chloride 6H2O

Sigma Aldrich

Matrigel Basement Membrane Matrix

BD Biosciences

Matrigel, phenol red-free, growth factor reduced

BD Biosciences

Methanol

VWR international

Nail polish

Fisher Scientific

Ni-NTA agarose

Qiagen

OCT

Fisher Scientific

Oxalate

Sigma Aldrich

PCR Master Mix

Promega

Penicillin-Streptomycin solution

Cellgro

PEP(Phosphoenolpyruvic acid monopotassium salt)

Sigma Aldrich

Phosphatase inhibitor cocktail I

Sigma Aldrich

Phosphatase inhibitor cocktail II

Sigma Aldrich

PMSF (Phenylmethylsulfonyl FLuoride)

Sigma Aldrich

Ponceau

Sigma Aldrich

Potassium Chloride

Sigma Aldrich

Potassium phosphate monobasic

Sigma Aldrich
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Prolong gold anti-fade reagent with DAPI

Invitrogen Life technologies

Protease inhibitor cocktail

Sigma Aldrich

Protein A agarose

GE Healthcare Lifesciences

Protein G agaose

Millipore

Rhodamin Phalloidin

Cytoskeleton

RIPA buffer 10X

Millipore

Sodium Acetate

Sigma Aldrich

Sodium Azide

Sigma Aldrich

Sodium Chloride

VWR International

Sodium Dodecyl Sulfate

Sigma Aldrich

Sodium Hydroxide

Sigma Aldrich

Sodium Orthovanadate

Sigma Aldrich

Sodium phosphate dibasic

Sigma Aldrich

Sodium Pyruvate

Cellgro

Supdex 200

GE Healthcare Lifesciences

TEMED

Sigma Aldrich

TEMED (N,N,N’,N’-TetramethylEthylenediamine)

Sigma Aldrich

Tris base

Fisher Scientific

Triton X-100

Sigma Aldrich

Tryptone

BD Bioscience

Tween-20

Sigma Aldrich

Urea

Sigma Aldrich

Western Blot Stripping Buffer

Thermo Scientific

Yeast Extract

BD Bioscience

Nitrocellulose Membranes

Thermo Scientific

0.25% Trypsin-EDTA

Cellgro

FBP (Fructose 1,6-bisphosphate)

Sigma Aldrich

Acrylamide-Bisacrylamide 40% (w/v 37.5:1)

VWR international

Kits and disposables
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1.5ml eppendorf tube,15ml, 50ml conical tube

VWR International

10ml Bacteria cell tube

VWR International

20µl, 200µl and 1000µl pipette tips

VWR International

24-well transwell insert, 8.0 µm

BD Falcon

96-well ELISA plates

Thermo Scientific

Bio-Rad Protein Assay

Bio-Rad Laboratories

C18 ZipTip Pipette Tips

Millipore

Cell culture flasks and plates

Thermo Scientific

FuGENE HD transfection kit

Promega

Nuclear Extraction Kit

Active Motif

PCR tubes

VWR International

QIAGEN Plasmid Midi kit

Qiagen Inc.

QIAprep Spin Miniprep Kit

Qiagen Inc.

QIAquick Gel Extraction Kit

Qiagen Inc.

Virapower Lentiviral Expression System

Invitrogen Life Technologies

Biacore CM5 chip

BIACORE

DAKO Delimiting pen

DAKO

Laboratory Equipment
Hemocytometer

Hausser Scientific

Allegra 6R Benchtop Centrifuge

Beckman Coulter

C25 Incubated Floor Shaker

New Brunswick Scientific

Class II Biosafety Cabinet

Labconco

EC3 BioImaging System

UVP

UV-1700 Spectrophotometer

Shimadzu North America

AKTA fplc

GE Healthcare Lifesciences

BiaCore 3000

BIACore

MALDI TOF 4800 PLUS

Applied Biosystems

Enspire Plate Reader

Perkin Elmer

Film Processor

Kodak
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French Presure Cell Press

SLM/Aminco

Sonifier 450

Branson

Zeiss 510 Laser Scanning Microscope

Zeiss

CO2 incubator

Thermo Scientific

-80°C freezer

Fisher Scientifics

Proteins, peptides and antibodies
22% v/v Bovine Serum Albumin

Sera Care Lifesciences

Anti-Actin antibody
Anti-FAK antibody

Millipore

Anti-Histag antibody
Anti-human GAPDH antibody

Millipore

Anti-human Integrin α5/β1 antibody (JBS5)

Santa Cruz biotechnology, inc.

Anti-human Integrin αV antibody (H-2)

Santa Cruz biotechnology, inc.

Anti-human Integrin αV antibody (Q-20)

Santa Cruz biotechnology, inc.

Anti-human Integrin αV/β3 antibody (23C6)

Santa Cruz biotechnology, inc.

Anti-human Integrin αV/β3 antibody (LM609)

Millipore

Anti-human TEM8 antibody

IMGENEX

Anti-Ki67 antibody

Millpore

Anti-mouse CD31 antibody FITC-labeled
Anti-phospho-FAK (Tyr397) antibody

Millipore

Anti-Vinculin antibody
Bovine Serum Albumin standard

Sigma Aldrich

Collagen I from Rat tail

BD Bioscience

DNase

Promega

Gel Filtration Calibration Kit (Low molecular weight)

GE Healthcare Lifesciences

HA antibody (mouse monoclonal)

Roche Applied Science

HRP-conjugated goat-anti-mouse antibody

Thermo Scientific

HRP-conjugated goat-anti-mouse antibody

Thermo Scientific

Normal rabbit IgG

Cell Signaling Technology
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PDGF-BB

Pepro Tech

Pfu DNA polymerase

Promega

PKM2 (rabbit polyclonal)

Lab generated

p-Tyr-100 antibody (mouse monoclonal)

Cell Signaling Technology

p-Tyr-20 antibody (mouse monoclonal)

Santa Cruz biotechnology, inc.

Pyruvate kinase antibody (both M1 and M2)

Lab generated

Rabbit muscle Pyruvate Kinase (M1 type)

Sigma Aldrich

Recombinant human Fibronectin

R&D systems

Recombinant human Integrin α1β1

R&D systems

Recombinant human Integrin α5β1

R&D systems

Recombinant human Integrin αvβ3

R&D systems

Recombinant human VEGF

Millipore

Recombinant human vitronectin

R&D systems

Restriction enzymes

Fermentas

RNase A

Thermo Scientific

T4 DNA ligase

Fermentas

Thrombin from bovine plasma

Sigma Aldrich

TNK (T4 Polynucleoide Kinase)

Fermentas

Trypsin proteomics grade

Sigma Aldrich

Plasmids, bacteria stains, cell lines and animals
pHM6 mammalian expression vector

Roche Applied Science

pLenti6/V5-D-TOPO

Invitrogen Life Technologies

pLenti6/V5-DEST

Invitrogen Life Technologies

PET30a
PGEX 2TK

GE Lifesciences

Human Pyruvate kinase M2 gene
Human Pyruvate kinase M1 gene
Tumor endothelial marker 8 gene
Colon cancer cell line SW620

ATCC
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Colon cancer cell line SW480

ATCC

Human Umbilical Vein Endothelial cell line

Invitrogen Life Technologies

Microvascular endothelial cell line

Provided by Dr. Yuan Liu, Georgia State University

HEK 293 human embryonic kidney cell cline

ATCC

H460 human lung cancer cell line

ATCC

H146 human lung cancer cell line

ATCC

WM115 human melanoma cancer cell line

ATCC

WM266 human melanoma cancer cell line

ATCC

PC3 human prostate cancer cell line

ATCC

4T1 mouse breast cancer cell line

ATCC

NM2C5 human breast cancer cell line

ATCC

M4A4 human breast cancer cell line

ATCC

Nuce mice

Harlan

Bal b/c mice

Harlan

BL21 (DE3)
Tuner (DE3)
JM109
pcNDA3.1+
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